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For Synthetic Biology to reach its potential, it necessitates foundational knowledge of 
the organisms that can be engineered. The remarkable influence our microbiome has 
on our health status has made it a focus of attention for engineering possibilities aiming 
at its modulation. As the field of the human microbiome expands, it necessitates access 
to high-quality nucleic acid samples which are truly representative of the community 
of bacteria under study. Formalin-fixed, paraffin-embedded (FFPE) samples represent 
the most comprehensive collections of patient materials in hospital pathology 
archives. However, for this sample to become reliably accessible for microbiome 
studies, the effects of FFPE processing on bacteria must be considered.  
Any sample processing method should be based upon specific study aims, target 
organisms and sample types. It is only through a holistic understanding of FFPE-
induced changes to the bacterial cellular structure and its DNA content, that a reliable 
method can be developed It is hypothesised here that with a sample-prep workflow 
considering the effects of FFPE on bacterial cells, their DNA content and the overall 
contamination introduced, a reliable and reproducible analysis of the microbiome of 
FFPE samples could be achieved. As such, the overall aim of this thesis was to 
characterise FFPE induced changes to the bacterial cell walls/membranes and their 
DNA content, and with this information, to propose strategies for purifying and 
repairing DNA suitable for microbiome analysis, while also characterising the 
common contaminants found in samples processed in this manner. 
  
To achieve this, an appropriate FFPE bacterial study model was first developed. With 
this in place, a thorough characterisation of the state of bacterial FFPE DNA was 
performed and strategies to reduce this damage assessed. Finally, to develop an 
appropriate method for bacterial DNA extraction from FFPE samples (unavailable at 
the time of writing), the state of the bacterial cell wall/membrane was assessed and 




Chapter 2 Describes methods for creating a mock bacterial FFPE block (Protoblock) 
that serves as a standard for FFPE samples. The Protoblock is a cell matrix which can 
be populated with cell types and numbers as desired, so as to resemble those of the 
FFPE tissue specimens. Its accuracy for representing bacterial load and cell 
architecture was validated by microscopy. With this model, the performance of the 
human gold-standard FFPE kit for microbiome analysis of FFPE samples was 
evaluated and found unsuitable for microbiome research. Additionally, the Protoblock 
permitted the characterisation of bacterial FFPE DNA, where it was found to be highly 
fragmented (  length = 143 bp), a poor PCR template (with a log-fold loss of 
amplifiable 200 bp fragments) and featured significant sequence alterations. Finally, 
this model also permitted the characterisation of contaminants originating from the 
FFPE process, the most common being Xanthomonadaceae, Pseudomonadaceae and 
Clostridiaceae. 
Chapter 3 Makes a thorough investigation of the state of bacterial FFPE DNA in 
terms of PCR readability, formalin crosslinking, and the presence of sequence 
artefacts. Here, bacterial FFPE DNA was found to be highly fragmented, with a 
significant inverse correlation between fragment size and PCR recovery and a log-fold 
reduction between the recovery of 200 bp and 500 bp fragments. It was also evident 
that 95-97% of DNA present in these samples was crosslinked and that the most 
evident sequence artefacts were those derived from oxidative damage. Two strategies 
to reduce this damage were investigated. (1) An optimised decrosslinking procedure 
(10 oC lower than current methods) significantly reduced sequence artefacts generated 
by high-heat incubation. (2) The in vitro reconstitution of the Base Excision Repair 
pathway targeting oxidative DNA damage, using FPG and Endo VIII DNA 
glycosylases. Samples treated with both strategies showed a 3X increase in fragment 
length and a significant reduction in sequence chimeras and SNPs, leading to a 





Chapter 4 Investigates the state of the bacterial cell wall/envelope and mammalian 
membrane to assess the state of their permeabilisation in FFPE samples. In this 
chapter, mammalian and Gram-negative bacterial cells were found to be impermeable 
to molecules with dimensions of 3-5 nm. A host depletion strategy was devised using 
a combination of Saponin and DNAse (Benzonase). It was also found that FFPE 
bacterial cells require a lysis strategy, and the use of a mix of bacterial-lytic enzymes 
was found to provide a uniform cross-taxa bacterial lysis. The integration of different 
treatments was achieved using 0.2 µm CA filtering columns between treatments. The 
collection of methods developed were tested by 16S rRNA gene sequence analysis of 
protoblocks, murine FFPE faeces and human breast tumour samples. The collection 
of methods provided an overall increase in recovery of 16S PCR amplicons, a higher 
uniformity in bacterial lysis, and a higher bacterial to host DNA ratio in high biomass 
models. However, these improvements were obscured for low biomass samples, where 
contaminants dominated the sequencing reads.   
 
It is concluded from this work that to unlock the potential of FFPE specimens for the 
microbiome field, a full dedicated workflow, comprising not only sample-prep, but 
also QC, 16S PCR and 16S sequencing, needs to be in place. This workflow should 
be directed by a robust QC system. In addition, a database for known FFPE derived 
common contaminants is essential to inform future strategies for the biological 
removal of contaminants from these samples.   
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1. Synthetic Biology in the driving seat of the Bioeconomy 
Synthetic biology is revolutionising the biotech industry and is increasingly applied in 
previously unthought-of markets. We discuss the importance of this industry to the 
bioeconomy and two of its key factors: the synthetic biology approach to R&D, and 
the unique nature of the field's carefully designed, stakeholder-inclusive, community-
directed evolution. 
Synthetic Biology R&D: Revolutionising Biotechnology 
Synthetic biology is a young field that emerged from the convergence of biosciences, 
information technology and engineering. Since its coinage, synthetic biology has 
evolved as an umbrella term, defined by a conceptual framework, aiming at the 
rational design of biological systems to attain useful products. This is sought through 
the integration of engineering principles at the core of the R&D cycle and replacing 
ad hoc and serendipitous practices characteristic of traditional biotechnology. This 
results in a more reliable and robust industry, compatible with automation and 
scalability, while also upgrading its capabilities to carbon-neutral, simplified 
production systems, with a wider scope of products [1]. 
Synthetic biology has become a global enterprise, expanding to over 40 countries, with 
almost 700 organizations conducting synthetic biology research, funded by over 530 
funding agencies [2]. The promising breakthroughs and disruptive technological 
advances delivered by synthetic biology are evidence of the support placed by 
governments and funding bodies, who also fostered programmes that facilitate routes 
to market and the creation of a thriving heterogeneous community [3]. As a 
consequence, the scope of the biotech industry and its market has been revolutionised 
to a scale that required a new dimensional definition - ‘The Bioeconomy’  [4]. 
Here, we adopt the OECD Bioeconomy definition - the share of the economy delivered 
by biotechnology - although other definitions also include activities transforming bio-
resources. Nowadays the Bioeconomy is included in economic roadmaps of many 
nations and regions, where synthetic biology is a key technology, enabler of the global 
transition to a bio-based economy. This transition is proposed as the ultimate solution 
18 
 
to sustainably fulfil the current and future food, health and energy demands of a 
growing global population, where already scarce natural resources are challenged by 
constrains of climate change [4]. 
Turning synthetic biology into a Global Enterprise (Figure 1) 
Promising projects emerging in the mid-2000’s encouraged the launch of major EU 
and US federal initiatives. Among them, in 2006, the NSF funded $40 million to 
initiate the SynBERC (Synthetic Biology Engineering Research Centre), a multi-
institutional research centre fast-tracking the commercialisation of synthetic biology 
products, and since then, the NSF has allocated almost $140 million to synthetic 
biology research [5]. The same year, after a presidential mandate to develop a biofuel 
economy, the US Department of Energy (DOE) announced a $1bn investment in a 
multi-institutional consortium to progress each stage of biofuel production (from basic 
research and enabling technologies, to crops and microbes) with more than $400 
million allocated to synthetic biology related research i.  
The US government has invested approximately $500 million–$1bn in synthetic 
biology research since 2005, with a marked 200% increase in 2010, the year when the 
US Defence Advanced Research Projects Agency (DARPA) launched the precursors 
of its Living Foundries - ATCG and 1000 molecules programs ii  - levering 
bioengineering capabilities to manufacturing platforms. The NIH has funded more 
than $50 million during 2005-2010 and $20 million 2014-2019 the Genomes-to-
Natural Products program [3].   
Meanwhile in the EU, a gross figure of €450 million in synthetic biology funding was 
reported from 2004-2013 iii. The UK began funding synthetic biology activities in 
2007, and since then has become the world’s second-most active nation in synthetic 
biology activities and the European leader, investing over £300 million in synthetic 
biology activities. Unlike the US, UK synthetic biology programmes have been 
developed under a unified strategy, as detailed in its roadmap, focusing on developing 
a robust research community with strong links to industry. In 2016, the UK developed 
a new Strategic Plan: ‘BioDesign for the BioEconomy’, aiming at higher impact for 
their synthetic biology market [1]. Overall, centres performing synthetic biology 
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activities have been reported in 17 countries in Europe. On the other side of the world, 
China published its synthetic biology roadmap in 2010, allocating 260 million Yuan 
($36 million) per annum [5]. In 2016, the Human Genome Project write-up was 
launched with an initial budget of $100 million, sourced from private and public 
organisations worldwide. However, its total cost is expected to exceed $3bn [6].   
 
 
Figure 1. Initiatives driving synthetic biology expansion and its adoption as an 
industrial technological platform 
Synthetic biology fosters disruptive technological advances (Figure 2) 
DNA Sequencing – As an outcome of the thousand-dollar genome project, next-
generation sequencing (NGS) and third-generation sequencing platforms were 
conceived. These revolutionary technologies have increased productivity more than 
500-fold, changing the sequencing economics and seeding an industry that since 2007 
has outpaced Moore’s Law, yielding a 10,000-fold price decrease for a human genome 
relative to the cost in 2004 iv. 
DNA Synthesis and Assembly – Over the past decade, traditional de novo DNA 
synthesis methods have been significantly improved, but the introduction of novel 
microchip-based DNA synthesis strategies has represented a truly disruptive 
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technology in this industry, as it enables miniaturised, in-parallel and automated 
production, increasing throughput and efficiency, and increasing productivity more 
than 700-fold. These advances have facilitated the synthesis of gene-size DNA 
fragments and prompted a 104-106 decrease in price for oligonucleotide, and a 100-
fold decrease for gene, synthesis. Assembly of longer DNA constructs (>2 Kb) is now 
possible through novel high fidelity in vitro enzymatic assembly methods that are also 
inexpensive and suitable for automated systems[7]. 
Genomic Engineering – The advent of the CRISPR/Cas9 as a genome editing 
technology in 2013 marked the beginning of a new genome-engineering era. Since its 
publication in 2013, it has proven effective in a multitude of organisms, including 
humans. Its superior efficacy and precision, coupled with its simplicity and low cost 
(< $100), has revolutionised the genomic engineering arena, enabling its widespread 
adoption in research and industry, by both trained scientists and amateurs v.   
Mathematical modelling – elementary tool for the rational design of robust and 
complex synthetic biology systems. It enables abstraction and increases the speed and 
reliability of building synthetic biological devices and systems, by reducing the 
amount of time-consuming, expensive and unpredictable wet-lab experiments. By 
increasing the reliance of a project in in silico models, it accelerates innovation and 
reduces costs [8, 9]. 
 
Figure 2. Scientific breakthroughs, advances in enabling technologies, and 
milestones that have built synthetic biology as a discipline 
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Is There Really A Biotech Revolution? The Markets Say Yes 
Current reports estimate that biotech contributed $324bn to the US bioeconomy by 
2012 (more than 2% of US GDP), with an annual 10% growth over the last decade 
[10]. The EU has estimated a value of €2 trillion – although including activities beyond 
biotech vi. Similarly, the UK has estimated its bioeconomy to be £150bn, predicting a 
growth of £40bn over the next decade vii.  
Biotech’s expansion has also been perceived in the public and private markets, with 
the longest and largest expansion in biotech history beginning in 2009 and peaking in 
2015. Since 2013, more than 224 companies launched to the public market with Initial 
Public Offerings (IPOs) that created a market value of $95bn. This unprecedented 
period has defined the longest, more prolific IPO window (period with more than four 
IPO per month) in biotech history [11]. In 2015, Biotech companies raised an 
unprecedented $71bn, with 58% ($41.3bn) corresponding to innovation capital (raised 
by companies with <$500 million in revenues), featuring a record-high $11.8bn in 
venture capital funds (30%), and also record-high $3.5bn early-stage funding (235 
series A and seed funding) [12]. Moreover, despite the market’s contraction entered 
in 2016 (typical of the biotech market cyclic behaviour), the IPO window remained 
open, featuring a high proportion of early-stage companies, who raised 30% in 
valuations prior to investment viii. Similarly, venture funding to biotech remained 
strong, with US VC firms investing $7bn (well above the $4.2bn historic average), 
while average start-up investment doubled from $7.5 to $15 million per deal ix. 
Overall, despite the markets’ volatility, the biotech industry has kept a steady 
expansion, and the NASDAQ biotech index is still performing 160% of five years ago. 
The industry is providing a rich pipeline of products, with high capitalisation of its 
players (high valuations), higher flow of funds in the equity market (more IPO’s than 
any other industry sector) and a larger participation of earlier-stage players, all of 




Shaping the Bioeconomy:  Synthetic biology influence on the biotech 
market and the bioeconomy 
Despite its youth, synthetic biology already has a significant market participation, 
valued at $2.7bn in 2013, $3.9bn in 2016, growing at a Compound Annual Growth 
Rate (CAGR) of 24.4%, and expected to reach $11.4bn by 2021 [13]. However 
significant, this valuation is conservative, since its contributions are not confined to 
any readily-measured biotech industry segment, but benefit the overall industry. 
Synthetic biology has expanded the biotech industry by enabling its integration in 
other industries (e.g. Tech industry - DNA data archives x, Nano-motors and molecular 
machines xi); attracting new players through easy-to-use and inexpensive tools (Amino 
Labs xii, Bento Labs xiii) and enabling novel and sophisticated production systems and 
products. Overall, synthetic biology is an innovation platform driving the bioeconomy 
expansion, whose contributions go beyond research, and include the development of 
social and community-based initiatives facilitating its acceptance and integration by 
industry, society, governments and markets [1, 4, 5].  
1. Accelerating the R&D cycle: The initiatives supporting SynBio prioritised the 
advancement of enabling technologies. Some of which have advanced the scope of 
numerous research areas in industry and academia, rendering a potential economic 
impact of between $700bn and $1.6 trillion per year by 2025 [14]. Beyond these 
technological advancements, synthetic biology transformed conventional R&D cycles 
(figure 3) in the biotech industry by integrating to its core, the following approaches 
that improve reliability, speed and costs: (1) in silico modelling (through abstraction) 
that reduce trial-and-error approaches. (2) Public repositories of standardised genetic 
components, enabling sharing of parts that can be reused and optimised for different 
purposes [8, 15]. (3) Decoupling R&D projects from manufacture (such as DNA 
synthesis), where research efforts and scaled manufacturing can be performed 
simultaneously by different entities xiv. (4) Automation and scaling xv. This framework 
advances innovation by providing a common language and infrastructure encouraging 
collaboration, enabling in-parallel work, and reducing the dependence on highly 
trained specialists and expensive and time-consuming lab work xvi.  
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2. Fostering investment & entrepreneurship: By adopting this framework, biotech 
projects have become more reliable and feasible endeavours, which are more attractive 
for investment. Biotech now has an extensive investor base comprising recognised 
investor firms, among these, renowned Tech firms such as Google Ventures (GV) xvii, 
and Y Combinator xviii. In addition, synthetic biology has more than 20 dedicated 
business incubator programmes (supported by industry, government, or VC firms) 
among them: LABS (Singularity University), IndieBio (US) and RebelBio (Ireland) 
xix.  Undoubtedly, the landscape of biotech investment has changed, the overall marked 
increase in net capital flow and proportion of innovation and early-stage capital, highly 
supported by Corporate VC firms implies a structural change in the markets fostering 
entrepreneurship, as evidenced by funding raised by synthetic biology firms xx [11, 
12].  Innovation is also promoted by increased accessibility and the numerous public-
funded initiatives that recruit young talent to the field (from high-school to university 
undergraduates) through community-building activities such as LEAP xxi, BioBuilder 
xxii and iGEM competition xxiii, which has recently trained more than 25 thousand 
students, providing the workforce with key industry and entrepreneurship skills. These 
programs create an environment encouraging the generation and exchange of ideas 
that may develop into novel applications that expand the scope of synthetic biology 
and its markets xxiv.  
 




3. Enabling new products: The novelty fostered by these initiatives and the increased 
capabilities of its technological contributions has expanded the scope of synthetic 
biology far beyond traditionally biotech-reliant industries (e.g. biopharmaceuticals). 
Novel products that were never previously considered are now emerging for less-
saturated or less-restrictive markets, such as cosmetics, clothing, materials, nutrition, 
education and others, which, coupled with shorter R&D cycles, accelerates the pace 
for their launch to market xxv. Synthetic biology applications are now conquering new 
markets, shaping the bioeconomy by integrating it with industry sectors that are not 
accounted for in traditional biotech. Therefore, synthetic biology participation in the 
global market is not restricted to what is currently defined as biotech. A 2016 survey, 
reported more than 350 synthetic biology dedicated firms across US and EU (in 16 
different industries) raising over $3.3bn between 2009-2015. That same year, 190 US 
SynBio companies raised $830 million xxvi. See a listing of companies at 
SynBioProject.org xxvii.  
4. Replacing traditional industrial processes: The technological advances brought by 
synthetic biology have enabled projects delivering high-value products in the 
traditional biotech sector. In the energy sector, synthetic biology has enabled the 
scalable production of biofuels and petroleum derivative products, which use carbon-
neutral feedstock, improving its sustainability and ecological impact. Equally, the 
diagnostics industry has benefited from synthetic biology tools, applying them to 
multiple novel molecular and/or microfluidics diagnostics platforms that are now 
revolutionising the industry. Synthetic biology has also been adopted in the 
pharmaceutical industry, enabling drug discovery and the creation of more effective, 
safer and cheaper new generation drugs. Synthetic biology has been rapidly adopted 
for vaccine development, as it reduces the time for development significantly. It has 
also been adopted to replace older production methods, for more efficient and cheaper, 
one-step production systems that are more sustainable and harmonious with the 
environment. Similarly, other industries, in particular the chemical industry, have 





It remains to be seen if synthetic biology promises will be realized more than the 
earlier biotech hopes. The synthetic biology community, from the outset, placed much 
attention on bioeconomy aspects (product development needs, routes to market etc.) 
in order to avoid commercial failures observed with traditional biotech. Overall, the 
synthetic biology community-directed evolution approach makes it unique, and 
increasing success stories may lead to future recognition of this ‘way to do business’ 
as a game changer in scientific technology development. 
Glossary 
Diamond v Chakrabarty: court ruling enabling patents on GMOs  
Initial Public Offering (IPO): The act of offering the stock of a company on a public 
stock exchange for the first time.  
IPO Open Window: period with more than 4 IPO per month, indicative of 
market strength  
Moore’s law trend: A prediction made in integrated circuits, where the number of 
transistors in a chip will double every 2 years, while keeping the same price.  
NASDAQ biotech index: is a stock market index for NASDAQ-listed companies, 
which is the second largest stock market.  
Synthetic Biology (European Commission): The engineering of complex biological 
systems with novel functions, done in a rational and systematic matter, at all levels of 













































2. In situ biomolecule production by bacteria; A synthetic 
biology approach to medicine 
The ability to modify existing microbiota at different sites presents enormous potential 
for local or indirect management of various diseases. Because bacteria can be 
maintained for lengthy periods in various regions of the body, they represent a 
platform with enormous potential for targeted production of biomolecules, which offer 
tremendous promise for therapeutic and diagnostic approaches for various diseases. 
While biological medicines are currently limited in the clinic to patient administration 
of exogenously produced biomolecules from engineered cells, in situ production of 
biomolecules presents enormous scope in medicine and beyond.  
The slow pace and high expense of traditional research approaches has particularly 
hampered the development of biological medicines. It may be argued that bacterial-
based medicine has been ‘waiting’ for the advent of enabling technology. We propose 
that this technology is Synthetic Biology, and that the wait is over. Synthetic Biology 
facilitates a systematic approach to programming living entities and/or their products, 
using an approach to Research and Development (R&D) that facilitates rapid, cheap, 
accessible, yet sophisticated product development. Full engagement with the Synthetic 
Biology approach to R&D can unlock the potential for bacteria as medicines for cancer 
and other indications.  
In this review, we describe how by employing Synthetic Biology, designer bugs can 
be used as drugs, drug-production factories or diagnostic devices, using oncology as 
an exemplar for the concept of in situ biomolecule production in medicine. 
Bacterial-Produced Anti-Disease Agents 
In ‘ex vivo’ settings (industrial fermentation), engineered bacteria have long been used 
to produce recombinant proteins, such as insulin, human growth hormone and others 
[16, 17]. More recently, precedents have been set for bacterial production of small 
molecules and chemical entities for pharmaceutical uses [18, 19]. The commercial 
production of semi-synthetic artemisinin is frequently held up as the first 
demonstration of the potential of synthetic biology for the development and 
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production of pharmaceutical agents [18]. E. coli has been the bacterium of choice for 
the majority of agent production systems to date, although the range of bacterial genera 
is recently increasing with advances in engineering technology, and the capacity of 
different genera to provide more optimal agent production depending on the agent 
[20]. Given that E. coli and other bacteria can naturally, or be induced to, colonise 
different parts of the body, we ask if there is potential to ‘skip the middle man’, where 
the producing bacteria themselves may represent the final ‘drug’ product for 
administration to patients. In this context, the bacteria act as in situ drug producing 
‘biofactories’, with the intervention focused at the site of pathology. 
Bacteria as Region-Specific Colonisers 
The microbiome research field has exploded in recent years, and while originally 
primarily focussed on bacterial colonisation of the gastrointestinal tract (GIT), 
research has expanded to various regions of the body, with characterisations of the 
microbiota of humans, animals, insects and non-living locations. ‘Tract’ regions of the 
human body, such as the vaginal and oral tract, feature distinct microbiota [21-23], 
and the microbiome of the skin, the largest organ of the body, is increasingly 
characterised [24]. The growing body of evidence supporting associations between the 
human microbiome and our health has drawn significant attention. The ability to 
modify existing microbiota at different sites presents enormous potential for local or 




Figure 1. Example regions of the body where bacteria can be induced to colonise.  
Sample conditions representing treatment targets for local bacteria are indicated for each 
location. 
While the ability to induce growth of different bacteria in the GIT (via oral 
administration of probiotics) is widely known, there are precedents for artificial 
inoculation of other body sites. Table 1 shows a selection of examples of biomolecule 
production from bacteria at different body sites, examples of these are represented in 
Figure 2. In addition to supplementing the microbiome of more well described tract 
regions with engineered bacteria, targeting of solid tumours by this strategy is also 
under development.  
Various studies have shown that tumours support the growth of different bacterial 
species, and many clinical and preclinical studies are underway to effect tumour-
specific therapies through administration of engineered bacteria (see later). In addition 
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to these directly-acting therapies, associations between the nature of cancer patients’ 
gut microbiota and tumour progression have been established [25]. For example, 
recent research in experimental cancer models has revealed that gut bacteria may 
influence the outcome of chemotherapy or immunotherapy indirectly via influencing 
the immune system [26, 27]. 
Table 1. Examples of in situ bacterial products in development for various 
diseases by body site 
Company/ 
Product 
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Figure 2. Illustration of in situ bacterial products, where:  
(1) Topical application of Nitrosomona eutropha oxidises ammonia into nitrogen dioxide 
(antibacterial) and nitric oxide (anti-inflammatory), preventing and treating acne [30]. (2) 
Intravenously administered E coli MG1655 colonises solid tumours and delivers TNFα 
antibodies, impeding tumour growth [31]. (3) Orally administered L. lactis delivers TNFα 
monobodies to the Colon significantly reducing inflammation in a chronic colitis model.[32]  
 
Synthetic Biology as a Technology 
Synthetic Biology is an evolving discipline focused on engineering biological systems 
for global needs, representing an umbrella term that covers many approaches aimed at 
bestowing biological entities with novel functions or replicating biological functions 
outside a cell [33]. Synthetic biology aims at the rational design of biological systems 
by integrating engineering principles (standardisation, modularity, abstraction) and 
technologies (in silico modelling systems, repositories of standard biological parts) 
[34, 35]. This engineering approach featuring a model-based rational-design, was first 
proven successful with the publication of the first genetic switches, the repressilator 
and the toggle switch [36, 37].  
These have laid the foundation of a promising field whose potential applications 
fostered the creation of dedicated programmes advancing its key enabling 
technologies and expanding its applications by creating a well-knit community, 
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yielding remarkable breakthroughs and potentiating our ability to engineering 
biological systems. The ‘tipping point’ for broad, market-meaningful adoption of 
Synthetic Biology came with the arrival of dramatically cheaper high-throughput 
DNA synthesis and sequencing, easily-employed biodesign tools and the availability 
of public repositories (Figure 3) [38]. The rapid adoption of these technologies by the 
expanding Synthetic Biology community provided evidence of a growing market, 
encouraging competition and further innovation targeting the creation of user-friendly 
toolkits and services accessible for all kinds of end-users. Consequently, the scope for 
synthetic biology has transcended from an emerging discipline to a foundational 
technological framework adopted widely in research and industry [39]. 
Now, Synthetic Biology is applicable to many areas; general bioengineering, editing 
of genomes of organisms in order to improve human health, transforming 
microorganisms to factories for producing certain drugs, creating cell-free systems 
capable of mimicking a cell’s machinery or constructing unnatural molecular biology 
with non-canonical molecules and interactions to be used in diagnostics [33]. The 
engineering potential for bacteria using Synthetic Biology is immense and innovations 
are almost limitless. With Synthetic Biology, it is possible to transform bacteria into 
production vehicles for biomolecules, to design biomolecules to our specifications, 
and to control the behaviour of the vehicle and the biomolecule production. For 
example, we can exploit bacteria as biochemical factories by creating new enzymes to 
produce desired chemicals [40-43]; bacterial genomes can be edited to render the 
chassis-cell compatible with a given strategy [44]; the cell’s environmental sensing 
may be influenced, and much more [45]. Synthetic Biology is now finally delivering 




Figure 3. Synthetic Biology’s design, build, test & learn (DBTL) cycle.   
The foundation of synthetic biology lies in the introduction of engineering principles that 
enables the DBTL cycle.[35] In this figure are also portrayed the different technologies 
developed by the synthetic biology community for the advance of the DBTL cycle [46, 47].  
Path to market 
Full engagement with the Synthetic Biology approach goes beyond the scientific 
aspects of a technology, and incorporates all stages of R&D required to achieve an 
appropriate product. The SB process embraces, from the idea stage, multiple 
actors/stakeholders along the product development chain. The Design-Build-Test 
approach (see later) and rapid prototyping capacity of Synthetic Biology facilitates 
incorporation of design/redesign input to address multiple needs, at earlier, cheaper 
stages of R&D, before it is too late. The power to bestow sophisticated properties on 
bacterial chassis, devices and biomolecules permits early addressing/pre-empting of 
aspects of safety, efficacy in the field, scale-up etc., in addition to reducing the 
duration of the product development path for a product, thereby cost & risk of 





Figure 4. Synthetic Biology ‘Built-In’ Market-driven R&D Considerations (SB – Synthetic 
Biology) 
The synthetic biology approach to bacterial engineering 
Synthetic biology borrows ideas, concepts and lingo from the engineering world and 
applies them to biology. In nature, complex systems comprise highly interconnected 
entities performing synchronized functions. However, synthetic biology, applies 
engineering principles (modularity, composability, abstraction, and standardisation) 
to redefine them into a modular and composable way. Through this framework, the 
elementary unit of a system is a thoroughly characterised and standardised ‘part’ – a 
motif (DNA sequence or genetically encoded product) with a defined task in a coding 
region. These motifs are the building blocks of a ‘Lego like’ scheme, where they are 
mix-matched to build fully functional genetic ‘devices’, capable of performing a 
defined function and an established input/out relationship. Devices are integrated into 
a chassis (e.g. a bacterial cell), to build a ‘system’, capable of producing a targeted 
biomolecule or behaviour (Figures 3, 5) [35, 48-50].  
 
Figure 5. Schematic representation of an abstraction hierarchy. Here, a genetic 
component, (a gene, transcription factor or a promoter) is defined as a ‘part’; a 
collection of parts that together have a defined function = a ‘device’; a collection of 





Furthermore, in order to achieve a logical form of cellular control through rational 
design, synthetic biologists apply electrical circuit analogies to describe genetic 
networks and biological pathways. In this context, a ‘circuit’ is a network-like 
composition of parts and/or devices, perform logical operations, that can be modelled, 
e.g. ‘if’ X condition is met, ‘then’ provide Y output [45]. 
Advancing the design-build-test cycle 
The expansion of open-access catalogues of thoroughly characterised biological parts 
in computer readable formats, has advanced the rational design of biological systems 
[51]. Advances increasing our capabilities for DNA synthesis and assembly [7], and 
genome-scale engineering [52], and their translation into automated, high-throughput 
systems have potentiated our building capabilities, and increased their standardisation, 
efficiency and reproducibility.  
The thorough characterisation and measurement of a system’s functionality (test) in 
‘real-time’, is now made possible through high-throughput quantitative analysis tools 
that provide feed-back, facilitating the parameterisation of predictive models (See 
Figure 3) [51]. Altogether, these advances accelerated the pace of design-build-test 
cycle, and allowed the construction of highly sophisticated systems, built from 
multiple components and implying multiple layers of cellular regulation [53]. The 
arrival of systems with higher complexity, brought along a new level in the abstraction 
hierarchy: biological ‘modules’. These are subsystems made from a collection of 
discrete and defined devices with interconnected functions that together perform a 
complex task, as part of a higher wholesome system. Such operate as pathways 
resembling integrated circuits [48, 49, 54]. 
In this context, intelligent and tuneable systems or circuits, are made possible by 
integrating parts with a thoroughly characterised function. Parts catalogues, now 
supply a vast number of parts (sensors, regulators, actuators). These are constantly 
enriched with de novo parts harvested from nature, or variants created by predictive 
modelling (iterative rational design) or directed evolution [50]. Expansion that paved 
the way for the creation of regulatory elements (devices, modules) capable of 
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manipulating different biological processes, simultaneously. Beyond transcription, 
synthetic systems now include modules regulating translation [55], post-translational 
modifications [56], and epigenomics [57, 58]. Novel parts advancing a multi-layered 
control include: CRISPRi [59], recombinases [60] invertases [61] feed-back and feed-
forward loops [48, 62-64] for transcription; ribozymes and riboregulators [65-67] for 
post-transcriptional processes; and novel receptors [68], secretion tags, degradation 
tags, protein-binding tags for post-translational processes [50].  
These provided the building blocks for building regulatory devices with logic 
behaviour, such as: switches [60, 69], logic gates [70, 71], stable oscillators [72], 
Riboswitches [73], and diverted scaffolds [74-77]. Similarly, these devices have now 
been applied to develop systems integrating logic to create permanent memory or 
produce complex calculations [78, 79], wire circuits through quorum-sensing [80, 81], 
building genetic edge detection programmes [82], controlling multicellular migration 
pattern and population growth [83], and building layered logic programmes enabling 
the construction of large integrated circuits in a cell [78]. There is an abundance of 
literature demonstrating the diversity and potential of these systems [45, 51, 84].  
Applying synthetic biology principles for in situ biomolecule production by bacteria 
now offers controllable strategies to externally controlled or self-regulated 
(intelligent) chassis cell and device behaviour (see later).  Since much of the 
foundational work on Synthetic Biology was carried out on microbes including E. coli, 
the technical knowhow for sophisticated modifications for heterologous agent 
production, controlled expression, and safety-attenuation is readily available for 
deployment in the setting of in situ therapeutic production [85]. Synthetic Biology can 
improve this technology at all levels; i) the vehicle; ii) the production of the 





Figure 6. Synthetic Biology improves the technology at all levels.  
1. The chassis cell (through bacterial genome engineering); 2. The production of the 
biomolecule by the system (through device engineering (including regulation of device 
activity)); 3. The biomolecule (e.g. modelling to obtain the optimal final biomolecule). 
Cancer as an example indication  
In the cancer context, bacteria are being investigated for biomolecule 
production/delivery both locally (direct therapy), and distally to tumours (within the 
GIT; immunotherapy) [27, 86-88].  
Bacterial growth in tumours 
Various studies have shown that tumours support the growth of different bacterial 
species. A tumour microbiome has been described by different laboratories [89-92]. 
Separately, both in clinical and pre-clinical studies, different bacteria have been shown 
to preferentially colonise and proliferate within tumours following systemic 
administration [86, 88, 93]. It is believed that bacteria in the bloodstream leak from 
the abnormal vasculature within tumours and lodge locally where they are protected 
from the immune system due to the immune-suppressed microenvironment of 
tumours. The ‘targeting’ process therefore is more of a passive phenomenon of 
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selective growth, without the involvement of chemo-attractants and relates to the 
tumour environment being permissive to bacterial survival and replication, unlike 
most healthy tissue. Chemotaxis may play a role post tumour targeting, influencing 
the manner in which certain bacteria distribute within the tumour [94]. Further 
parameters that distinguish tumour from healthy tissue include nutrient availability to 
bacteria (from tumour cell turnover in necrotic regions) and regions of low oxygen 
potential (where anaerobes and facultative anaerobes can grow optimally) [87, 93]. 
Bacterial tumour-targeting technology is based on the bacterium to selectively survive 
and replicate within solid tumours, growing to high concentrations, where they can 
‘pump out’ therapeutics or locally activate agents. Depending on the strategy, the 
bacterium itself (the chassis) may possess intrinsic oncolytic properties (often the case 
with pathogens), or may have no effect on tumour growth unless engineered to 
produce an agent. This platform technology is applicable to a wide range of therapeutic 
or diagnostic strategies. Clinical trials have demonstrated the safe use of live 
engineered bacteria in cancer patients, and preclinical studies using modified bacteria 
as tumour-selective agents have demonstrated the high potential for bacterial-
mediated cancer therapy via in situ biomolecule production [29, 86, 93]. 
Bacteria in breast tissue 
The residency of bacteria in breast tissue has been affirmed in several studies 
documenting the microbiota of healthy breast tissue, mammary glands and breast milk 
[91, 95-100]. As a whole, the breast is a favourable environment for the growth of 
bacteria, as it is made up of fatty tissue, with extensive vasculature and lymphatic 
drainage [101, 102].  
Studies to determine the diversity of bacterial species found in the breast suggest that 
there is a more diverse array of species compared to many other body sites [103]. 
Interestingly, these bacteria have important roles attributed to them in supporting the 
healthy development and immune maturation of neonates [101, 104, 105]. The breast 
microbiome has been suggested to be derived primarily from the microbiota of the 
overlying skin and the oral microbiome [95, 98, 100]. This facilitated by ductal 
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openings at the surface of the nipple that allow their entrance from the environment, 
skin and/or mouth [106]. 
Sampling of the microbiome supports this colonisation as it has been reported that the 
breast microbiome is quite similar in composition to that of the skin [95, 98, 100], but 
that this composition shifts towards the oral cavity once breastfeeding begins [99, 
101]. However, the involvement of the gut as a source of these bacteria cannot be ruled 
out. During the late stage of pregnancy and lactation, physiological changes occur 
which allows for an increase in bacterial translocation in the gut. This is facilitated by 
dendritic cells, which cross tight junctions in the gut epithelium and transport bacteria 
from the gut lumen to the mammary glands [101, 104, 105]. It is plausible that certain 
bacterial species inhabiting the breast have health benefits beyond those conferred 
during lactation.  
A healthy microbiome can deter the invasion and growth of pathogens and provide 
protective immune stimulation against disease. Certain bacterial strains found in the 
breast have been shown to produce lantibiotics, a class of bacteriocins capable of 
limiting the growth of pathogenic bacteria which could trigger chronic inflammation 
leading to malignancy if otherwise left to proliferate unchecked [97, 100]. For 
instance, the oral administration of certain lactobacilli has been shown to be effective 
in preventing and treating mastitis in women [107]. Indeed, the production of milk 
oligosaccharides influences the breast microbiome and is key to the establishment of 
the infant gut microbiota [108]. Moreover, several probiotic bacteria can modulate the 
immune system to supress inflammation or may serve to trigger an antitumour immune 
response [109-111]. 
Certain bacterial species found in the breast tissue, such as Lactococcus lactis, have 
also been shown to increase the expression of anti-inflammatory response pathways 
or activate natural killer cells capable of controlling tumour growth [91, 97, 109, 112, 
113]. In fact, epidemiological studies have found a strong correlation between the 
consumption of fermented products and a reduced risk for breast cancer [102].  
Another interaction with host cell physiology, which may play a protective role against 
the development of cancer is the metabolism of oestrogen and phytoestrogens [114]. 
The microbiota, namely species such as Clostridium and Escherichia can increase 
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circulating levels of oestrogen via deconjugation of sulphonated oestrogens by -
glucuronidase, thereby associating these bacterial strains with an increased risk of 
breast cancer [115]. Conversely, the metabolism of dietary phytoestrogens into 
bioactive molecules such as equol, urolithins and enterolactone, that compete with 
human oestrogen at its receptors and can thus reduce oestrogen-driven breast neoplasia 
[116, 117].  
Moreover, bacteria found in the breast have been associated with the production of 
antioxidants that neutralise free radicals [95, 97]. Supporting all the aforementioned 
benefits to breast health provided by bacteria, is the evidence raised by large clinical 
studies correlating the use of antibiotics with an increased risk of breast cancer [118]. 
The role of the microbiome in immunity 
Numerous studies have now provided evidence of the pivotal role of the gut 
microbiome in the development and regulation of our immune system, both locally 
and systemically. Locally, the gut microbiome has been found to promote the 
development and maintenance of a robust mucosal layer and associated epithelial and 
lymphoid tissue, where it regulates the maturation of dendritic cells (DC) that activate 
naïve T-cells and enhances the secretion of Immunoglobulin A. This effect has been 
recently found to include all mucosal tissue in the body where it regulates adaptive 
immunity [119, 120].   
Systemically, the gut microbiota has been shown to modulate both the innate and 
adaptive immune system. For the innate immune system, microbial molecules (LPS, 
SFCA, and Peptidoglycans) have been found to stimulate myelopoiesis/granulopoiesis 
of granulocyte-macrophage progenitor cells ensuring homeostatic levels of 
neutrophils, monocytes and macrophages. In addition, certain microbial antigens, such 
as SCFA, have been found to increase dendritic cell differentiation by enhancing 
haematopoiesis of their precursors [121]. [37]. The microbiome has also been found 
to regulate the adaptive immune system by promoting the proper development of distal 
lymphoid tissue that harbour the development of B- and T- cells [122]. The adaptive 
immune system is also regulated by the APC nature of DC, which present microbial 
antigens to B- and T-cells triggering their differentiation. Importantly, this mechanism 
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has been found essential for the pro-/anti- inflammatory balance of the immune 
response. In this regard, the microbial composition of the microbiome can influence 
the CD4+ Th1 to Th2, and the Th17/Treg balance, where it has been shown that by 
introducing bacterial taxons derived from high fibre diets, skewed ratios of pro-
inflammatory cytokines can be alleviated and immune balance restored [119, 123, 
124].    
The role of the microbiome in cancer immunotherapies 
The intricate connections between our immune system and our microbiome have been 
found to influence the outcomes of immunotherapies. This was first found for 
immune-check point inhibitors, namely, anti-PD1/PD-L1 and anti-CTL4 [122, 125-
127]. Clinical studies reported a higher response to therapy and overall survival in 
patients with diverse microbiome profiles (eubiosis), containing Bifidobacterium, 
Akkermansia and Enterococcus, among others. On the other hand, patients with a 
reduced microbiome diversity (dysbiosis) responded poorly to this therapy [128, 129]. 
The effects of these bacterial profiles were confirmed in GF murine models where 
mice that received FMT from responders also exhibited an improved response and 
those who received an FMT from non-responders developed resistance to the therapy 
that was reversed upon administration of Akkermansia and Enterococcus. It was 
observed here that responders had an increased immune infiltration in the tumour 
microenvironment with a marked increase CCR9+CXCR3+CD4+ and CD8+ T-cells, 
and a decrease in Treg cells [130, 131]  
Similar results have been shown in murine models for anti-CTL4 (ipilimumab), where 
the efficacy of the therapy was shown to be reliant on the microbiome. Here, ablation 
of the microbiome reduced response to treatment and introduction of taxons 
corresponding to the Bacteroides and Burkholderia genus to non-responders triggered 
a Th1 response and promoted DC maturation, restoring the efficacy of the therapy. 
Interestingly, some studies have shown that the therapy can induce detrimental 
changes to the microbiome that may influence the development of resistance [132]. 
This highlights the relevance of managing the microbiome richness during the course 
of treatment [127]. Murine studies with other immunotherapy agents, namely anti-IL-
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10 and Adoptive Cell Therapy, have also shown that the microbiome stimulates the 
effectiveness of these therapies [122, 127].   
Non-tumour targets for cancer therapy 
The vaccination using live microbes field is, by comparison to the above, a mature 
area of research with significant commercial interest that employs different types of 
microbial vehicles including modified viruses or bacteria, which confer 
immunological responses against infectious diseases or cancer. The goal of cancer 
vaccines is to break tolerance of the immune system to specific antigens known to be 
expressed mainly or exclusively by particular tumour cells - tumour-associated 
antigens (TAA). Bacteria are advantageous as antigen delivery vehicles due to their 
ease of bioengineering and diverse collateral effects on the immune system.  
As part of their natural life cycle, infectious bacteria, following entry to the body, are 
internalized by phagocytes, followed by MHC presentation of their antigens to the rest 
of the immune system. Through addition of synthetic antigens to a bacterial system, 
the process can be hijacked to mount a host immune response to a desired antigen (e.g. 
tumour-associated). Used in this setting, the chassis delivers an antigen to antigen 
presenting cells (APC), such as M cells in the gut mucosa, and does not involve growth 
in tumours. The bacterium is safety attenuated to render it non-infectious, and 
equipped with a device to produce specific tumour antigens (either genes or proteins).  
The vehicle itself also induces a desirable immune response in the vaccine context 
(similar to an adjuvant). Following administration (per oral, intramuscular, or 
intravenous), the bacterium is taken up by the patient’s antigen presenting cells. The 
bacterium releases genetic material or antigens into the immune cells that then initiate 
a systemic immune response specific to the target antigen.  
There are multiple safety-attenuated strains under study as vehicles for vaccination; 
Listeria monocytogenes, Salmonella, E. coli and strains of Shigella, Lactobacillus and 
Yersinia of which L. monocytogenes (Lm) and Salmonella are being studied clinically 
[133, 134]. Significant, highly promising therapeutic outcomes are being realised from 
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these vaccine platforms in multiple Phase II and III trials with patients of disparate 
cancer indications i [134]. 
 
Synthetic biology approaches to improvement of bacterial agents and 
treatment strategies  
The chassis cell 
Safety attenuation. Employment of bacterial strains with a natural ability to survive 
and grow within human tissues (i.e. pathogens) is attractive from an efficacy 
standpoint, but obviously undesirable from a safety perspective due to off-target 
growth within healthy organs, coupled with recognition by the patient’s immune 
system as a disease-causing agent. Strain attenuation can be used to limit capacity to 
survive in non-target healthy tissues e.g. liver, or to reduce pro-inflammatory 
reactions.  
Traditionally, attenuation was achieved by random mutagenesis of a wild type strain 
and selection for certain favourable phenotypes e.g. tumour invasion, proliferation etc. 
Purpose-designed systems are preferable, involving editing of genes that are known to 
be involved in pathogenesis. For example, msbB and purI are two genes that have been 
eliminated from the genome of Salmonella in order to create VNP2009 [135] the first 
Salmonella clinical trial agent. Another attenuated S. Typhimurium defective in 
guanosine 5′-diphosphate-3′-diphosphate (ppGpp) synthesis (a molecule responsible 
for regulating salmonella pathogenesis [136]) was also generated by genomic editing. 
Similar editing can also reduce unwanted host responses to non-pathogenic bacteria; 
e.g. the probiotic E. coli Nissle 1917, which is part of our natural gut microbiome, has 
been attenuated via an msbB deletion which reduced pro-inflammatory cytokine 
stimulation compared with wild type [137]. 
Cell targeting.  Although bacteria do not actively home to tumours, it is 
possible to improve their specificity to the tumour environment and limit their ability 
to proliferate in healthy tissue through exploitation of unique tumour traits to guide 
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the design of more tumour-selective bacteria. For example, Yu et al [138] restricted 
the growth of bacteria to hypoxic regions, a phenotype found only within tumours 
inside the body. An essential gene for cell wall synthesis, asd, was placed under a 
hypoxia-inducible promoter (PpepT) which allowed expression to take place only 
under hypoxic or anoxic conditions. In parallel, a second device expressed the 
antisense of asd under an aerobic promoter (PsodA). This device inhibited growth 
under normoxic conditions. Integrating both devices into a module, enabled a logic 
gate restricting replication to areas with low oxygen concentration, such as those found 
inside the tumour. Such a circuit would eliminate the capacity of bacteria to grow in 
healthy tissue, thus adding another layer of safety. ‘Trapping’ bacteria within tumours 
can also be achieved via addition of tumour cell ligands. Using a sophisticated surface 
display system, the peptide RGD was surface tethered to Salmonella in order to 
improve its targeting capabilities towards specific integrin expressing cancer cells 
[139]. Similar strategies could be used in other systems to target bacteria to specific 
cells/tissues. Such levels of bioengineering sophistication can upgrade chassis cells in 
both efficacy and safety.  
Bacterial vs Viral chassis. Both, bacteria and viruses are effective delivery 
vehicles for different cargoes. Here we outline the characteristics that will determine 
their feasibility under different scenarios.  
Table 2. Bacteria v Viral vectors.  
Pro-Bacterium Pro-Viral vector 
Bacterial chassis = final biofactory. Multiple 
components of the biofactory cell genome can 
be engineered in vitro (see Figure 4 part 1) 
 
Bacteria can generally carry more devices  
Bacteria can produce biomolecules 
independent of / external to host cells. 
 
 
If biomolecule must be delivered internally to 
host cell, viral vector transduction efficiency is 
much higher than bactofection 




Viral vector better as in situ host cell 
(biofactory) editor. 





Bacterial manufacture cheaper  
Bacterial biomolecule type may be nucleic acid, 
protein or small molecule, while viral vector 
biomolecules are restricted to nucleic acid 
 
 
Bacterial expression of eukaryotic gene 
sequences may not be as efficient as with viral 
vectors. 
Bacteria may naturally colonise and replicate in 
specific tissue/location, more so than viruses. 
 
Bacteria more transient than viral vector (safer 
is some circumstances) 
Bacteria more transient than viral vector (viral 
vector better for integrating device in host cell 
genome) 
 
Viral vectors have a closer relationship to 
human cells. 
 
Biomolecule delivery and production 
There are two broad ways to deliver a biomolecule in the bacterial context – i) at the 
tissue level, normally external to target cells, or ii) internal to target cells. The delivery 
modality must be matched with the biomolecule’s therapeutic modality. For several 
therapeutic strategies, simply ‘flooding’ the environment with bacterial-produced 
protein is sufficient, and non-invasive chassis are suitable, and from a safety 
perspective, desirable. 
Bactofection.  Delivery of biomolecule internal to cells involves chassis lysis after 
which its contents are released to the cytoplasm of the target cell. In this context, the 
biomolecule may be protein, RNA or DNA depending on the strategy employed. This 
strategy is often referred to as bactofection (bacterial transfection).  
Bactofection can be ‘active’, involving an invasive bacterium mediating its entry to a 
cell, or ‘passive’, as is the case with phagocytic immune cells [140]. ‘Smart’ target 
cell entry may be achieved through Synthetic Biology approaches, using devices that 
sense different inputs leading to an invasive output. Host cell invasion by E. coli was 
achieved by expressing the protein inv gene from Yersinia pseudotuberculosis which 
was triggered by hypoxia, cell density or an exogenous inducer [141]. Once the 
bacterial cells came into proximity with the host cell membrane and reached a certain 
density, the circuit became activated leading to the production of inv gene resulting in 
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tumour cell invasion. Some strategies utilise occurrences post-invasion, for example 
van Pijkeren et al [142] devised a system by which a lysin was expressed only 
following host cell internalisation, in order to induce a cascade of bacterial lysis.  
Types of biomolecule ‘payloads’ and optimal production. There is a large and 
diverse collection of biomolecules which have been investigated in studies with 
bacteria to date, and may be peptide-based, RNA or DNA in nature (Figure 7).  
 
Figure 7. Example types of biomolecules and relevant medical strategies  
 
 Controllable and intelligent systems. Currently, a tight regulation of multi-
module circuits is more easily achieved, increasing the predictability of desired 
phenotypes. This applies to biomolecule production, which kinetics benefit from a 
sophisticated control in gene expression. By applying a rational design, different 
layers of control over biomolecule production and/or the vehicle can be applied, when 
appropriate for a chosen strategy.  
Such a system can incorporate a sensing module able to respond to numerous stimuli. 
A rich-repertoire of now available, characterised sensory parts, enables the creation of 
systems capable of responding to a variety of physical or chemical inputs, such as 
oxygen concentrations, acidity, cell density, drugs, molecules, radiation. Sensors are 
often built upon promoters whose activity can be regulated by environmentally 
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responsive DNA binding protein [50, 143, 144]. Here, regulation is mediated by the 
binding of the protein into a transcription activator or repressor site in the promoter 
sequence. This generates a conditional ‘switch (ON/OFF)’ behaviour – nominated 
positive or negative feedback loops. A combination of these parts can be used to create 
AND/OR/NOR gates [45]. Depending on requirements, designs can range in 
flexibility and sophistication. The design of complex systems, whose multi-
components’ interaction rely on multiple factors, (e.g. DNA-protein 
binding/dissociation constants, kinetics and other biophysics), is now made possible 
by in silico analysis. These tools enable the prediction of such level of regulation by 
applying mathematical based, known biophysical constants and coefficients to model 
biological processes [145, 146]. 
An early example of a controllable system in this context involved an engineered 
Clostridium [147]. These authors created a switch turned on by radiation that could 
trigger the production of a protein with therapeutic properties (e.g. TNF, cytosine 
deaminase (CD)) and induce a cytotoxic response in preclinical models. In an 
analogous manner [148] used a device switched on by the sugar arabinose to give a 
toxic output in order to treat colon carcinoma.  
More recently, circuitry was taken to the next level. A circuit was designed whose 
input is cell density but leads to several outputs regulated by a common part. The 
circuit is composed of an activator, a reporter, a therapeutic and a therapeutic gene 
delivery device [149]. The circuit is based on the quorum sensing system lux. LuxI 
catalyses the synthesis of N-3-oxohexanoyl-L-homoserine lactone (AHL) which 
freely diffuses and accumulates in the surrounding proportional to cell density. AHL 
activates the transcriptional activator LuxR to activate genes that have a downstream 
luxI promoter. The LuxI promoter itself was inserted in front of luxI gene in order to 
create a positive feedback regulation to support the integrity of the circuit. GFP was 
used to give a light signal output. The bacteriophage lysis gene (ϕX174 E) was used 
to aid bacterial lysis and deliver the cytotoxic payload, and finally, the payload itself 
was the cytolysin, a pore forming protein. In an analogous circuit, two parallel devices 
where employed to deliver a cytotoxic payload to tumours in mice [150]. Therapeutic 
protein production was controlled by salicylate and lysis of bacterial cells was 
controlled by tetracycline. Such a system first allows bacteria to target to tumours 
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without putting a metabolic burden on them. Production begins only after bacteria 
reach optimum numbers within the tumour, and lysis serves to deliver the therapeutic 
protein to the surroundings in the most efficient manner. More recently, the Hasty 
group engineered an elegant ‘synchronized lysis circuit’ in S. Typhimurium to induce 
lysis at a threshold population density (through quorum sensing) and release its 
therapeutic cargo [81]. 
 
Figure 8. Examples of controllable/intelligent bacterial systems in oncology studies 
Treatment strategies 
As Synthetic Biology became more sophisticated, new possibilities became realized. 
Strategies could now be re-designed to deliver maximum efficacy. We now have the 
capacity to deliver protein, RNA, DNA and to activate small drug molecules 
specifically at bacterial-specified sites. Production of biomolecules can now occur in 
bacteria and/or host cells and parameters such as the kinetics, location and level of 
production and the function of the product itself can be controlled. 
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Therapeutic Production  
Peptide production. Bacterial production of peptides is well described in several 
research domains, and is commonly used industrially for recombinant protein 
production [151, 152]. In in vivo strategies, non-invasive/apathogenic bacteria are 
primarily employed in this context. As an example, Lactic Acid Bacterial chassis 
producing in situ antiproteases and antioxidant enzymes have been tested successfully 
for their prophylactic and therapeutic effects in murine models of colitis [153]. 
Numerous intratumoural bacterial production of various peptides at both clinical and 
pre-clinical stages have been described [29, 154]. A wealth of technology has been 
developed for optimisation of protein production by bacteria [155].  
Bacterial cells are enveloped by sophisticated membranes that regulate what enters 
and exits the cell. In Gram-negative bacteria, for example, the cytoplasmic interior is 
separated from the exterior by a thick outer membrane, a periplasmic space and an 
inner membrane. Depending on the nature of the therapeutic biomolecule used, 
cytoplasmic expression may hinder its activity. A number of systems exist that place 
biomolecules of interest in different compartments of the bacterial cell or secrete them 
to the exterior. Secretion to the surrounding environment is frequently desirable, and 
a number of systems are available for different bacterial genera employing signal 
sequence ‘parts’ in devices to promote appropriate secretion [155, 156]. Surface 
display parts can direct proteins to the outer membrane of bacteria [139, 157]. 
Recombinant proteins commonly surfaced exposed are antigens and antibodies [158].  
RNA production. Small interfering RNA and microRNA has generated much 
interest in recent years in both basic and applied biology. For example, S. 
Typhimurium has been utilised in various preclinical cancer studies as a chassis to 
deliver small hairpin RNA (shRNA) against GFP, STAT3 or bcl-2 [159, 160]. 
 Small molecule activation. In order to address the problem of target specificity of 
small drug chemotherapy, researchers have been using synthetic biology to enable 
bacterial-colonised tumours to act as the final stage of toxic drug ‘synthesis’. Here, 
enzymes are produced by bacteria at the tumour site, while the chemical reactants 
(prodrugs) are administered later. The active drug generation takes place at the tumour 
site, mediated by the bacteria which enzymatically activate the actual 
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chemotherapeutic (reviewed in [161]). Recent work suggests that multiple drugs can 
be activated concurrently [162] and opens doors to new ideas such as having devices 
that can concurrently activate in situ, multiple drugs with diverse mechanisms of 
action in order to overcome drug resistance. 
 
Host cell modification 
In some circumstances, it may be desirable to induce the host cell to produce the 
biomolecule itself. Invasive chassis deliver devices or biomolecules to mammalian 
cells by bactofection. Such devices feature parts that are compatible with eukaryotic 
environments, and therefore switched on post-delivery. Usually, the specificity in such 
systems comes from bacteria and the devices themselves have a constitutively active 
switch (a eukaryotic promoter such as CMV) which fires upon delivery to any host 
cell. However in other cases, another layer of regulation can be introduced at the 
device itself, by using a switch that is only turned on by cancer cells (though use of a 
tumour-selective promoter [163]) therefore providing an extra level of specificity as 
well as therapeutic potency.  
Delivery of eukaryotic devices is not limited to cancer cells, or invasive bacteria. 
Byrne et al used a non-invasive E. coli to infect phagocytic cells (Tumour Associated 
Macrophages (TAM)) and deliver DNA modules that produced light as an output 
[140]. In this case, the specificity towards the phagocytes was brought by the ‘non-
invasiveness’ of the bacteria. Vaccine strategies employ a similar strategy.  
Diagnostics 
Co-localisation of a bacterial agent with a specific site/cell type presents opportunities 
for diagnostic strategies. For example, in the context of oncology, tumour detection 
can either be direct, for example by intratumoural bacterial imaging, or indirect by 
biological fluid analysis of biomarkers (liquid biopsy). In this context, representing a 
prototype Point of Care test, a prototype system has been developed to detect cancer 
by urine sampling. E. coli expressing a regulated LacZ was constructed in order to 
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detect murine liver tumours [164]. Following bacterial colonization of hepatic tumours 
in mice, bacteria express LacZ enzyme following induction by IPTG. Subsequently, a 
derivative of luciferin is administered which is cleaved by LacZ to pure luciferin and 
cleared through the urine. Luciferin is then measured by emission of light directly 
from the urine sample offering quick non-invasive tumour detection. Similar to the 
above, [165] created an inducible reporter/biomarker module that can be detected in 
blood samples by antibodies in an ELISA type assay. The biomarker, ZsGreen 
expressed by Salmonella, was shown to be suitable for detection of colon carcinoma 
in mice.  
 
Regulatory agency aspects 
The expanding scope for and adoption of biological engineering applications 
potentially presents the need for our current ethics and governance to evolve also [38]. 
If Synthetic Biology actors approach this aspect correctly, regulatory concerns can be 
overcome. Currently, Bacillus Calmette-Guerin (BCG), a local treatment for bladder 
cancer, is the only live bacterium in clinical use, and is not genetically modified. 
However, precedents for licencing of live GM microbes have been set, with viral-
based chassis. 2012 yielded the first licensing of a gene-based therapy in the western 
world, with the EU EMA licencing of Glybera - an AAV chassis engineered to express 
lipoprotein lipase in the muscle of deficient patients [166]. Talimogene laherparepvec 
(also known as T-Vec) was approved by the FDA in 2015, with the brand name 
Imlygic, for the treatment of advanced inoperable melanoma. In 2016, it was approved 
in Europe. It is an oncolytic virus and consists of a genetically modified Herpes 
Simplex Virus (HSV) chassis carrying a device producing in situ a cytokine (GM-
CSF) that helps to induce immune responses following intralesional injection. [167] 
Engineered bacteria for vaccine use have advanced to late stage clinical trials and 
therefore the safety/regulatory aspects of live GM bacteria are also being tested 
concomitantly. Clinical candidates have medical and environmental safety 
requirements, which can only be met by the use of bioengineering, involving 
biological containment of both the vehicle and any ‘non-natural’ DNA elements. For 
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example, Aduro Biotech has been developing a Listerial monocytogenes agent for use 
in patients [168]. An attenuated form was created by deleting two genes critical to 
pathogenicity – internalin B and act A, while antigen gene cassettes are inserted in the 
bacterial genome therefore obviating antibiotic use [169]. To maximize agent 
production, it may be desirable to maintain the antigen gene on an episomal plasmid 
in order to increase gene copy number.  
While plasmid maintenance in the lab environment employs antibiotic resistance 
modules, this is not acceptable for a market product from a regulatory aspect. 
Alternative plasmid maintenance systems have been created, based on modifications 
of both chassis and plasmid. Conditional or Balanced Lethal Systems involve genes 
required for bacterial survival being deleted from the genome of a chassis and 
transferred to a plasmid into which the device is also inserted. Bacteria produce the 
biomolecule as long as the plasmid is retained [170] and die in the event of a plasmid 
loss. There are many more examples demonstrating that Synthetic Biology offers 




Synthetic Biology is a burgeoning field that is driving the progression of bacterial 
agents in the health industry. The application of Synthetic Biology to improve bacterial 
agents for use in the strategies described is key to fulfilling earlier promises. Unlike 
before, intelligent precision engineering will permit the generation of effective agents. 
Further new developments pertaining to the regulation of bacterial safety will also be 
attractive to market stakeholders, paving the way for state of the art bacterial 
therapeutics. Perhaps the most valuable aspect overall, is the Synthetic Biology all-
stakeholder-inclusive approach to R&D from idea to product. Thanks to Synthetic 






3. FFPE-induced DNA Damage; Relevance to microbiome 
analysis 
As the fields of human genomics and human microbiome expand, so too does the need 
for access to high-quality nucleic acid samples which are truly representative of the 
genes/cells under study. Formalin-fixed, paraffin-embedded (FFPE) tissue specimens 
have now become a main source material for these studies. However, there is still 
missing a generalised consensus on the type and frequency of FFPE-induced sequence 
artefacts. A higher discerning capacity could be achieved by a better understanding of 
recent and foundational knowledge of formalin-biomolecule interaction and the effect 
that downstream treatments have on reacted molecules. Data quality could also be 
enriched by recently elucidated intrinsic DNA damage and mechanisms of repair. Use 
of FFPE samples is growing, and while most genomic research using FFPE samples 
has been focused on cancer, these samples are increasingly being exploited for other 
genomic research, such as microbiome surveys, where DNA quality has a larger 
impact. 
A holistic understanding of FFPE-induced DNA damage, its impact on sequencing 
studies, and possible mechanisms for repair, stands to empower the overall genomics 
research community. Gathered experience and foundational knowledge enables design 
of suitable strategies for processing and repairing this sample type, as well as 
improving sequence analyses. In this review, we consolidate existing data on FFPE-
induced DNA damage in human DNA. This includes a comprehensive review of the 
current state of understanding of formalin fixation and its interaction with DNA and 
other macromolecules, both in vitro and within the context of the native cellular 
milieu, as well as a discussion on the as yet uncharacterised FFPE-induced bacterial 
DNA damage and consequent effects on downstream microbiome analysis. Methods 
to repair FFPE-induced DNA damage to improve the quality of genomic analyses are 
discussed. Collating and considering this information highlights the value to be gained 






Formalin-fixed, paraffin-embedded (FFPE) tissue is the gold standard for pathology 
tissue storage. Tissue samples of this type represent the largest and longest time-
spanning collections of patient material in pathology archives [171-173] and the 
availability of FFPE samples to be used as a source material for sequencing has been 
vital for progress in human genomics [174]. Numerous sequencing workflows enable 
use of these samples [175-180], which has in turn validated them as a viable and 
valuable source material for human genomics [181]. Investigations on the quality of 
DNA/RNA from human FFPE samples have revealed that processing and storage of 
these samples negatively impact the integrity of nucleic acids and the efficacy of their 
downstream analyses [182, 183].  
As the sensitivity and specificity of sequencing strategies increased, attention was 
drawn to the study of the bacterial genetic material also within the body [184-186]. It 
is now well established that distinct microbial profiles can be found throughout the 
body, influencing human health [187-190]. As this field continues to expand, 
numerous body sites previously considered sterile have been found to harbour 
endogenous bacterial communities [191-196]. Such microbiome studies have 
traditionally availed of ‘fresh’ non-invasive samples (faeces, swabs etc.). However, 
microbiome studies targeting body sites for which sampling requires invasive 
procedures are constrained by access to samples [197, 198]. The use of FFPE tissue 
could open access to samples from cohorts of large numbers, accompanied by a clear 
medical/clinical history and thoroughly characterised histopathology report. These 
samples could be the source material for retrospective or longitudinal microbiome 
studies with sample numbers that guarantee statistical power. FFPE samples are 
already being utilised in microbiome research, albeit to a limited extent to date relative 
to genomics [91, 199-205]. 
In order for the potential value of increased usage of FFPE samples for microbiome 
research to be realised, the necessary workflows, protocols and quality control 
standards need to be in place [177, 206-208]. Microbiome studies to date have 
typically utilised approaches and tools designed for FFPE human sample analysis. 
Relevant to microbiome research, unique factors to consider in quality control of FFPE 
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samples are: 1) DNA fragment length suitable for 16S sequencing (460bp), 2) 
Presence of sequence alterations that may lead to false speciation events, 3) Low 
biomass – influence of contamination and host DNA, and 4) Unlike in human 
genomics where a single reference genome is available, microbiome genomes 
comprise DNA from a variety of bacterial, archaeal, fungal and viral sources. In many 
cases, the individual genomes themselves may be poorly characterised, or not at all. 
Accurate sequencing data is paramount in these circumstances.    
Presented here is a thorough investigation of both foundational [209-218] and recent 
[177, 207, 219-225] research covering the interactions between formaldehyde and 
biological molecules to improve understanding of the mechanics of formalin fixation. 
Research using more sensitive techniques (MS, NMR) has provided new evidence on 
which molecules are more prone to these interactions, and their strength (in vitro and 
in vivo) leading to higher frequency. This also informs on the resulting type of DNA 
damage. Also discussed are the effects of downstream FFPE processing as additional 
sources of DNA damage.  
Consolidating this information, coupled with new insights into intrinsic cellular DNA 
damage, can benefit sequence-based studies, such as cancer research where the aim is 
the detection of low frequency genetic variants present in a small number of cancerous 
cells [226], as they can provide a higher discerning capacity into the origins of 
sequence alterations. A considerable amount of NGS studies on FFPE samples have 
been published recently [177, 178, 206-208, 222, 227], revealing different patterns of 
sequencing artefacts, sometimes differing between similar studies. This lack of 
consensus could be explained by the nature of intrinsically damaged nucleotides and 
the molecular heterogeneity of samples analysed. In addition, after reviewing each 
type of DNA damage encountered in FFPE DNA, we propose pursuable strategies to 
repair such damage, representing the first review of repair strategies for FFPE-induced 
DNA damage. Finally, we highlight evidence of possible effects this might have in 
human microbiome sequencing studies. 
The FFPE process 
Standard histology processing of tissue samples begins with fixation in buffered 
formalin (4% formaldehyde in PBS) [228]. This tissue is then dehydrated with 
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increasing gradients of ethanol and cleared with solvents such as isopropanol and/or 
xylene and embedded in paraffin. Formaldehyde (HCOH) is a small electrophilic 
molecule, easily targeted by relatively strong nucleophiles, such as amino groups, 
generating crosslinks between them. In brief, HCOH crosslinking is initiated by a lone 
pair of electrons from a nucleophilic group attacking the partially positively charged 
carbon of HCOH, generating a methylol adduct in fast dynamic equilibrium. Upon 
dehydration, methylol adducts are converted into Schiff bases that can be stabilised 
into methylene bridges when these interact with other nucleophilic groups. (See Figure 
1) [229, 230].  
 
Figure 1. Chemical reactions for formation of formaldehyde derived methylene 
bridges between biomolecules. 
 In red: Formaldehyde. In blue – reactive amino group in Lysine. In green: dG. The reaction 
takes place in 3 steps: 1) Formaldehydes reacts with an amino group in an amino acid (most 
frequently). 2) Upon dehydration, a reactive Schiff base is formed. 3) Reaction of the Schiff 
base with a nearby reactive species, forms a methylene bridge (crosslink). 
 
Formaldehyde interaction with nucleotides 
The chemical reaction of HCOH with nucleotides has been thoroughly characterised 
mathematically and experimentally in vitro. HCOH reacts with the endocyclic amino 
groups (NH) of deoxythymine monophosphate (dT) and the exocyclic amino groups 
(NH2) of deoxyadenine monophosphate (dA), deoxycytosine monophosphate (dC) 
and deoxyguanosine monophosphate (dG), leading to the formation of hydroxymethyl 
adducts (hmN) in N3 of dT (3-hmT), N6 of dA (6-hmA), N4 of dC (4-hmC), N2 of dG 
(2-hmG) (Figure 2) [211, 213, 214, 221, 225, 231]. The rate of formation, 
disintegration and accumulation of these adducts vary per nucleotide. Nucleotides 
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with reactive endocyclic NH (3-hmdTMP), the reactions are instantaneous, thus 
considered in dynamic equilibrium [214, 221, 231]. Conversely, nucleotides with 
exocyclic NH2, have a slower formation rate, but hm adducts are more stable and reach 
higher levels of saturation, sometimes leading to an irreversible reaction, e.g. 2-hmG 
and 6-hmdA [213, 221, 225]. The rates of reaction are influenced by temperature, pH 
and ionic strength. In all cases, increase in temperature catalyses both reactions, while 
pH and ionic strength only significantly affect reaction rates of endocyclic adducts 
(with a positive correlation) [214, 231] and only marginally affect reaction rates in 
exocyclic adducts [215, 221]. In addition to mono-hydroxymethyl adducts, exocyclic 
NH2 can form di-hydroxymethyl adducts (dhmN), such as 6-dhmdA, 4-dhmC and 2-
dhmG, whoever, dhmN occur at a low rate (2-3 fold slower) and reach lower 
concentration (35-40 X lower) than mono adducts, but their reverse reactions is up to 
100 X slower, thus more stable. For example, Shishodia et al. observed that while 4-
dhmC degrades at 0.003 µM/s, 4-hmC degrades at 0.133 µM/s, similarly, 2-hmG 
degrades at 0.003 µM/s while 2-dhmG at 0.033 µM/s) [214, 215, 221]. 
 
Figure 2. Sites of hydroxymethyl adduct formation in nucleobases.  
In red: hydroxymethyl adducts formed by formaldehyde. 3-hmT is the most reactive base, but 
unstable. 6-hmA is the least reactive base but forms the most stable interactions.  
 
Formaldehyde interaction with DNA 
HCOH has been found to reversibly denature native DNA in vitro, destabilising both 
CG- and AT-rich regions equally. However, the kinetics of adduct formation are 
highly inhibited by base stacking, since interaction sites are involved in hydrogen bond 
base pairing. Therefore, for HCOH to interact with native DNA, bases need first to 
unstack [216]. Once the hydrogen bonds are broken and bases are unstacked, the rate 
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of mono-adduct addition reaction is the same as observed for mononucleotides. In 
vitro models (naked DNA) have shown the HCOH-DNA interaction initiates at 
thermodynamically unstable AT-rich regions with the formation of a 6-hmdA forming 
a weaker dA-dT bond. This bond significantly reduces the helix stability and melting 
temperature (Tm), inducing the denaturation of neighbouring nucleotides and enabling 
their reaction with HCOH. This results in the formation of methylene bridges and 
nucleotide crosslinks [211, 215, 218]. In these studies, crosslinked nucleotides have 
been found in 2 % of HCOH-fixed DNA, as inter- or intra- strand crosslinks, with a 
symmetric (6-hmdA-dA, 2-hmdG-dG) or asymmetric conformation (2-hmdG-dA, 6-
hmdA-dC and 6-hmdG-dC) (Figure 3). Their occurrence relies on the spacing and 
orientation provided by the helix structure, since they form upon contact of reactive 
groups. Here, the most common crosslinked nucleotides found were inter-strand dA-
dA crosslink, at AT-rich regions. The second most common type of DNA crosslink 
found is dG-dG, occur in nucleotide sequences CG, GNC and GC [217, 218, 232].  
 
Figure 3. Example of a DNA crosslink: Adenine - Adenine dinucleotide crosslink. 
Methylene bridge shown in red.  
 
Formaldehyde-driven DNA-Protein Crosslinks (DPC) 
HCOH has been found to react highly with the side chains of Lysine (Lys), Cysteine 
(Cys), Histidine (His), Arginine (Arg) and Tryptophan (Trp) [219]. DPCs have been 
thoroughly investigated in vitro. Here, Lys-dG and Cys-dG were found in high yields, 
followed by Cys-dA, Cys-dC, and by His-dA and Trp-dG after prolonged incubations. 
Lys-dG is the most prominent DPC, dG reacts with Lys through the exocyclic N2 and 
endocyclic N1 and N3, with three possible products: (i) single crosslink at N2, (ii) a 
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double crosslink at N1 and N2, forming a triazinane ring, and (iii) a tricyclic nucleotide 
with a hm group at N3 (Figure 4). All species were detected even at low HCOH 
concentrations, but the prevalence of tricyclic structures was found to be concentration 
and fixation-time dependent. These were also shown to be reversible in solution, with 
a higher lability in single-bond structures. The second most common crosslink found 
was Cys-dG, forming a single and stable bond between N2 in dG and the sulfhydryl 
group (SH) of Cys. To a lower extent, Cys (SH) was shown to react with the N6 of dA 
and the N3 in dC [230, 233-235]. 
 
Figure 4. Triazinane ring formed by interaction of Lysine with Guanine.  
Red: the methylene bridges forming the structure. Green: the reactive amino groups in 
Guanine. Blue: the reactive amino group in Lysine.  
 
The cellular milieu 
Despite the multiple products that can be derived from HCOH interaction in vitro, the 
conditions allowing their formation are not met in vivo. In the cellular milieu, the 
number of structures that can be generated is limited because: (i) lower HCOH 
concentrations reduce its reach; (ii) reactive groups in amino acids are better 
nucleophiles than those in nucleotides; (iii) HCOH does not alter tertiary structures of 
proteins. Thus, residues on protein surfaces or in interaction centres of native proteins 
provide the most accessible substrate. (iv) Temporal distribution is a determinant for 
HCOH interactions in the multi-macromolecular cellular milieu. Here, exposed groups 
of proximal macromolecules are more likely to interact, and interacting molecules 
more likely to be crosslinked together. [229, 234-237]. In line with this, the addition 
of Lys containing DNA binding proteins has been shown to exponentially accelerate 
the kinetics of the HCOH-DNA interaction, while non-DNA interacting proteins do 
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not crosslink with DNA nor exert any effect on this interaction. Accordingly, Lys 
residues are ubiquitous in DNA binding proteins, serving as mediators of DNA-
Protein interactions and constitute the main crosslinked residues found in histone 
complexes [212, 238, 239]. These observations suggest that the HCOH-DNA 
interaction is facilitated or triggered by interacting DNA binding proteins. In this 
context, crosslinks are formed between Lys ε-NH3 and proximal nucleotides, and after 
this crosslink is broken, an hm adduct persists in the nucleosides [225, 229, 238, 239]. 
Congruently, the most ubiquitous hmN found in vitro and in vivo is 2-hmdG, which 
can interact with Lys through three reactive groups [225, 230]. Surprisingly, 2-hmdG 
has been found to predominate in DPCs formed by other chemical agents [240] and 
has also been found to crosslink with aldehydes of abasic sites at opposite strands 
[241].  
In summary, in double stranded DNA, HCOH-DNA interactions are severely limited 
by base stacking. Within the cellular milieu, denaturation is more likely driven by DPC 
formation (dG-Lys) and to lower extent by 6-dhmA formation in AT rich regions [225, 
230]. This is supported by in vivo and in vitro evidence reporting favourable reaction 
kinetics and ubiquitous release of 2-hmdG upon crosslink reversal. Once the double 
helix is destabilised and nucleotides exposed, the kinetics of HCOH-DNA interaction 
follow that of free nucleotides, generating the same ratio of products, but to a lower 
extend than in vitro, more likely involving exocyclic NH2 of purines, with a high 
prevalence of dG adducts and/or crosslinks (Table 1).   
Table 1. DNA crosslinks and their frequency of occurrence in vitro or in vivo [213, 




Test Prevalence Lability 
dG dG – Lys or Cys DNA-Protein in vivo High High 
dA dA – Cys or His DNA-Protein in vivo Low High 
dG dG – Lys or Cys DNA-Protein in vitro High High 
dA dA – Cys DNA-Protein in vitro Low High 
dC dC – Cys DNA-Protein in vitro Low High 
dG dG – dA or dG DNA-DNA in vitro High Low 
dA dA – dA or dG DNA-DNA in vitro High Low 
dG 2-hm-dG hm adduct in vitro High Low 
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dA 6-hm-dG hm adduct in vitro High Low 
dC 4-hm-dG hm adduct in vitro High High 
 
Effect of tissue processing and storage on FFPE samples 
Data from the few studies available on this topic, indicate that post-fixation tissue 
processing is detrimental to DNA. It was found that anhydrous conditions (after 
dehydration) prompts molecular dehydration, which increases the formation of Schiff 
bases and crosslinks. Additionally, under these conditions, a fraction of hm adducts 
are converted into ethoxymethyl (ehm) adducts, which are more stable (10X half-time 
of hm adducts) and structurally bulkier, which may exacerbate depurination [243, 
244]. Similarly, prolonged exposures to warm hydrocarbon solvents during paraffin 
embedding were found detrimental to nucleic acids [245]. In addition, storage time of 
FFPE specimens was shown to remarkably increase DNA damage. It has been 
calculated that nucleic acids from FFPE samples stored at room temperature (22 oC) 
reach lowest integrity values upon storage for 6 -12 months [223]. Related DNA 
degradation was attributed mainly to oxidation and hydrolysis, caused by residual 
water molecules in the sample or the environment. This is exacerbated in exposed 
tissue sections [246]. Accordingly, it has been shown that only changing storage 
conditions (low temperature and humidity) can significantly prevent degradation 
[223].  
 
DNA Damage found in FFPE specimens  
DNA damage as products of the above described HCOH interactions in FFPE samples 
have been found to be in the form of: (i) Crosslinks (DNA-DNA, Protein-DNA), (ii) 
depurination leading to (iii) DNA fragmentation and (iv) sequence alterations 
(chimeras, SNPs) [182, 228]. These accumulate with time of storage and also correlate 
with suboptimal fixing conditions (low pH and higher incubation times) [228, 247].  
Crosslinks:  
The product of the interaction of HCOH and biomolecules is the formation of 
crosslinks. These are ubiquitous in FFPE sample, and occur as DNA-DNA and 
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Protein-DNA crosslinks. As described before, these are more frequently found 
between dG and amino acids Lys and Cys in the form of DPCs [230, 233]. DPCs 
inhibit DNA amplification by blocking the processivity of DNA polymerases, 
terminating primer extension [248]. Despite their high prevalence in FFPE samples, it 
has been demonstrated that HCOH crosslinks are reversible, as seen in Figure 1, Schiff 
bases intermediaries can be reversed by hydration and methylene bridges formed by 
HCOH are heat liable with a half-life reduced from 179 h to 11.3 h upon heating from 
4 oC to 47 oC [242]. In addition, the crosslink reversal reaction has been found to be 
influenced by pH, salt concentration and the incorporation of quenchers such as Tris-
HCl. As seen in Figure 5, quenchers can sequester released HCOH in the solution, 
preventing the formation of additional crosslinks or act as transamination catalysts 
[219, 229, 249].  
Heat treatment for crosslink reversal or decrosslinking is essential for DNA 
purification of FFPE samples and all protocols and kits for FFPE DNA purification 
incorporate it, typically as a 1h incubation at 90oC [250]. However, recent studies 
have found that this high temperature incubation can lead to a high frequency of ss-
breaks, and sequence artefacts, such as chimeras. It was also observed in these 
studies that reducing the decrosslinking temperature led to a reduction sequence 
artefacts, but also reduced the amount of sequencing reads (DNA available) [220, 
222]. This suggests that there is still room to optimise a decrosslinking reaction 
conditions in order to reduce the incubation temperature, without affecting the 
yields of decrosslinked DNA. As mentioned before, the most abundant DNA crosslinks 
found, are in the form of DPCs, more frequently between DNA and DNA binding 
proteins[238]. These crosslinks could strain the double helix structure and promote 
depurination or ss-breaks. Thus, targeting these crosslinks could reduce the 
prevalence of sequencing artefacts.  
All FFPE DNA purification methods include a protein lysis step, before 
decrosslinking, and decrosslinking is performed in the protein lysis buffer [251]. The 
efficiency of the protein would influence the dissolution of Protein-DNA crosslinks. 
Sodium Dodecyl Sulphate (SDS) is the protein denaturing agent of choice. SDS 
activity is favoured by boiling temperatures [252], which might explain 90 oC 
decrosslinking incubations. In addition, its ionic nature limits its interaction with DNA 
and does not denature DNA. The efficiency of lysis buffers on FFPE tissues and their 
63 
 
impact in decrosslinking has yet to be investigated. It has been suggested that utilising 
chaotropes might improve the quality of yielded nucleic acids [254].  
Chaotropes, such as Guanidium hydrochloride (GuHCL) are among the most potent 
protein denaturants [255]. The high denaturing activity of GuHCL is due to its ability 
to associate with different protein groups, including the carboxylic groups, non-polar 
hydrophobic groups (through hydrophobic interactions), and polar side chains 
(negatively or positively charged Arginine). This activity is also due to their capacity 
to self-associate, despite electrostatic repulsion and their high affinity for water 
molecules [256]. This reduces the likelihood for proteins to self-associate and reduces 
the penalty for unfolding in the presence of water [257]. Furthermore, unlike SDS, 
chaotropes interacts with nucleic acids, altering their secondary and tertiary structure 
[258, 259]. In fact, 1M concentrations of GuHCL have been shown to reduce the 
melting temperature of DNA by 13oC, and increase the stringency of its hybridisation, 
promoting correct base pairing[260]. Similar concentrations of GuHCL have been 
shown to increase the activity of Proteinase K and other Proteinases [261, 262], which 
might be facilitated by the ability of GuHCL to increase the torsional mobility of 
denatured proteins [263], thus facilitating access to Proteinase while also protecting 
the DNA structure at DPC sites. In addition, GuHCL activity is not affected by 
temperature [264]. Altogether, these features might enable a lower decrosslinking 
temperature. Furthermore, while interactions between the Guanylyl groups in GuHCL 
and HCOH have not been studied in these settings, these have been reported under 
different experimental conditions [265]   
 
Figure 5. Tris as a scavenger of HCOH.  
Reactive amino groups in Tris (green), interact with HCOH (red) sequestering it from the 





N-glycosylic bonds in DNA are labile to spontaneous hydrolysis rendering 
(Apurinic/Apyrimidinic) AP sites. This has been observed to occur at a rate 10 times 
higher in purines than pyrimidines. In fact, depurination is the main route for DNA 
degradation in DNA deprived of DNA repair mechanisms [266]. Depurination is heat 
activated and highly susceptible to low pH and salt concentration. Furthermore, 
depurination is accelerated by modification of purines bases comparable with those 
induced by HCOH [210, 266]. Similarly, anhydrous DNA, similar to DNA in FFPE 
samples, has been shown to undergo spontaneous depurination. This is due to residual 
endogenous (intramolecular) and exogenous (environmental humidity) water, pH 
memory and a possible catalysis driven by orthophosphates (from buffered formalin). 
In addition, upon dehydration, the secondary structure of DNA is distorted to a 
conformation (from B DNA to A DNA) more prone to denaturation, which, coupled 
with bulky structures found in HCOH fixed DNA, facilitates the breakage of labile N-
glycosylic bonds [243, 267, 268]. Abasic sites dramatically weaken the double-helix, 
inducing its denaturation and exposing nucleotides to HCOH. Additionally, open-
chain aldehyde residues in abasic site have been found to crosslink with dG and dA or 
undergo spontaneous β-elimination forming ss breaks (Figure 6) [209, 224, 241, 269-
271]. Finally, abasic sites can obscure DNA analysis. DNA polymerases have very 
low tolerance to abasic sites and stall replication upon their encounter, thus inhibiting 
PCR. In the rare event of bypassing them, they would either favour the incorporation 
of dA (A-rule) or produce frame-shifts [272-276]. Given the ubiquity of these lesions 
in metabolically active cells (10,000 events/day) these are efficiently repaired by 
ubiquitous AP (Apurinic) endonucleases, which initiate the base excision repair (BER) 
pathway [266]. The in vitro recreation of this pathway might offer a solution for repair 




Figure 6. Depurination leading to ss-breaks.  
Chemical interactions leading to spontaneous strand breaks in depurinated sites. 
 
Fragmentation:  
DNA fragmentation has been widely reported in FFPE samples, and fragments above 
300 bp are unlikely to amplify under standard PCR reaction conditions [173, 277]. In 
fact, protocols for DNA analysis of FFPE specimens are usually developed to target 
fragments below or equal to 200 bp [172]. DNA fragmentation is age-dependent, 
accumulating over time and is accelerated by poor fixation practices [244, 247]. As 
described above, abasic sites lead to the formation of single-strand (ss) breaks that if 
located within 10 bp of an opposite ss-break will turn into double strand (ds) break 
[266, 269]. It has been estimated that 18 ss breaks per day occur in archival samples. 
At this rate, models predict an average fragment length drop from 1 Mbp to < 2 Kbp 
in 5 years [247, 278]. This fits the time-depended fragmentation of FFPE samples, in 
which samples fixed for over 5 years appear as smears of less than 1.5 Kbp [223, 277]. 
While there is no repair mechanism that could faithfully correct ds breaks for unknown 
genomic targets in vitro, the repair of ss breaks has been achieved via the BER system 
and DNA mismatch repair (MMR) system. In addition, the reduction of ss breaks in 
FFPE has also been investigated by regulating the temperature and time of 
decrosslinking incubation [279, 280]. 
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Sequence artefacts:  
The quality of sequencing analysis is affected by sequence artefacts found in FFPE 
samples, as evidenced by the reduction in sequencing depth and uniformity, shorter 
fragments read, reduced ratio of pass-filter reads, high number of chimeric reads and 
reduced GC ratios. FFPE derived artefacts are also present in the form of single 
nucleotide polymorphisms (SNPs), translocations, and insertions and deletions 
(indels) [222].  
Deamination of Cytosine. C:G > T:A transitions are a product of deamination of 
dC to dU or 5-methyl deoxycytosine (5m-dC) to dT (Figure 6) in CpG regions. Early 
genomic studies on FFPE tumour specimens found disproportionally high rates of 
C:G > T:A transitions that were thought to be FFPE derived artefacts [228, 281]. As a 
consequence, use of Uracil-DNA glycosylase (UDG) to remove Uracil moieties was 
proposed, to improve the sequencing quality of FFPE DNA [282]. However, 
improvements were questionable, with only marginal reductions of C > T SNPs [283-
285], which was partially attributed to higher rates of C > T originating from 5m-dC 
in CpG sites [284, 286, 287].  
The occurrence of these artefacts was recently clarified by whole genome/exome 
sequencing studies using paired FFPE/Frozen tissues of non-cancerous and cancerous 
origin. These studies revealed that C > T transitions occur at much lower rates than 
previously proposed, and demonstrated that a large extent of SNPs disparities were 
products of intra-tumour or sampling heterogeneity and not FFPE derived [220, 222, 
250, 288]. Remarkably, these studies confirmed that artefacts derived from oxidative 
stress (i.e. G > A) DNA damage are unique to FFPE samples [289]. Further studies 
using similar experimental conditions revealed that sample age, ischemic time and 
fixation conditions were also confounding for these disparities, and low template DNA 
input and shallow sequencing analysis were shown to be exacerbating factors [290, 
291].  
Congruently, dU is a common DNA base damage in metabolically active cells [292]. 
In this context, dU ubiquity is largely attributed to DNA metabolism and 
misincorporation events during replication. However, dU also arises from the 
deamination of an inherently unstable dC. This is reflected in the multifaceted dU 
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repair system comprising 4 DNA glycosylases in mammals (2 in bacteria) [276, 293, 
294]. Of particular interest for FFPE samples, which exhibit oxidation patterns, is the 
oxidation of dC bases. It has been shown that these lesions yield unstable species that 
are easily deaminated, such as 5-hydroxydC (5-OHdC), 5-hydroxydU (5-OHdU) and 
uracil-glycol (Figure 7). These lesions have been found to be bypassed by polymerases 
leading to C > T and C > G SNPs, the most common SNPs found in FFPE samples. 
These damaged nucleotides are targeted by DNA glycosylases shown in Figure 7. 
Thus, it is worth investigating the reconstitution of BER using these DNA 
glycosylases that target oxidised and deaminated Cytosine (Fpg, Endo III, Endo V and 
Endo VIII) to reduce the rate of these SNPs and improve the overall sequencing quality 
of FFPE samples.  
Deamination of 5-methyl cytosine. Also congruent to the above studies is the fact 
that methylated dC is 3–4 fold more labile to deamination than dC. In mammals, 5m-
dC is present at high levels (1% of the genome) at CpG sites, where 80-90 % of dC 
are methylated. CpG are mutational hotspots, with a remarkably high rate of 
spontaneous C > T SNPs [295]. Their high rate of occurrence can be partially 
explained by the trade-off between their vestigial role in preventing the integration of 
transposable elements and their recent evolution in complex vertebrates for gene 
regulation [296]. Here, while dU is targeted by 4 glycosylases, dT arising from 5-mdC 
deamination is only targeted directly by Thymidine DNA glycosylase (TDG) (Figure 
7) [270, 295], even though the recognition and excision of this lesion is far more 
complex than that of non-canonical dU. It has been recently revealed that in the 
cytosine demethylation pathway, intermediate products such as 5-
hydroxymethylcytosine (5-OHmdC) are oxidised to target their removal by TDG. 
These oxidised intermediates are randomly distributed across CpG sites, further 
obscuring the discrimination of FFPE derived artefacts. Given the high rate of SNPs 
naturally occurring in the biological context, it is difficult to draw conclusions on the 
influence of FFPE in the deamination of 5-mdC. The processivity of TDG is enhanced 
by Neil (Endonuclease VIII in bacteria), which has overlapping substrates with TDG 
(oxidised pyrimidines) [297].This encourages the use of these DNA glycosylases to 
target oxidised and deaminated products of 5-mdC.  
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Oxidative Damage. Variable levels of SNPs derived from oxidative DNA damage 
have been identified in FFPE samples, frequently in the form of C:G > A:T, 
A:T > G:C, T:A > C:G [289]. As explained in previous sections, dG provides the most 
favourable template for HCOH interactions forming very stable products, resulting in 
a high crosslinking reactivity [230, 234]. This is reflected in a high rate of oxidised 
dG adducts in FFPE samples, where it has been found at 4 -7 X higher ratios then in 
paired frozen controls [298]. These observations have been confirmed by in vivo 
studies demonstrating a marked increase in biomarker reactive oxygen species known 
to induce dG oxidation upon HCOH exposure [299]. In agreement with this, oxidative 
damage is the main form of DNA damage in metabolically active cells, and more than 
50 different oxidised DNA base modifications have been identified. dG has the lowest 
redox potential, and is therefore the most frequently oxidised base [300], and the most 
frequently observed dG (8-oxo-dG) is considered a marker for oxidative stress damage 
(Figure 7). The biological relevance of these lesions is also confirmed in bacteria by 
the complex and robust systems that repair them. Here, oxidative damage is targeted 
by DNA glycosylases capable of DNA backbone cleavage, increasing the repair 
processivity. These enzymes also have overlapping substrate specificities, thus 
ensuring substrate repair even when one is missing (Figure 7) [294, 301].Chimeras.
 Finally, new studies have provided compelling evidence indicating that, to a 
large extent, structural rearrangement chimeras (indels and translocations) found in 
FFPE samples, are formed during library preparations with methods that include end-
repair (with T4 DNA ligase) and by high temperature incubation used for 
decrosslinking DNA. It was found that by annulling and/or modifying this treatments, 
these were significantly reduced [220].  
Finally, it has been shown that sequence alterations in FFPE samples do not interfere 
with cancer diagnostics in clinical settings as long as optimal conditions are in place: 
high input (> 250 ng) template DNA, high quality of DNA (scored through a quality 
assessment) and high sequencing depth (8X). However, when these conditions are not 
met, the rate of sequence artefacts can be detrimental to the analysis. Here, the number 
of reads and the overall sequencing coverage are significantly reduced and the 
frequency of SNPs can increase to 1/1000 bp and lead to erroneous sequence analysis 
[286, 290, 302, 303]. Under these conditions, the quality of the analysis will be more 
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reliant on optimised methods for DNA purification, DNA quality control, library 
preparation, sequencing analysis and the incorporation of DNA repair to the workflow 
[250, 302-304]. 
 
Figure 7. Common base lesions caused by formalin fixation and the BER DNA 
glycosylases that target them. 
 
FFPE Effects on Bacterial DNA  
Despite the plethora of accrued knowledge on FFPE in mammalian/human DNA, very 
little is known on the effects of HCOH fixation on bacterial DNA [305]. In principle, 
bacterial DNA will interact with HCOH as described in in vitro assays. However, there 
are certain differences in the conformation and packaging of bacterial DNA, as well 
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as differences in methylation pattern and replication and transcription rates (less single 
stranded DNA) that might influence the rate of this interaction. For example, the small 
sized bacterial chromosome is in most cases circular and packaged in set of 
independent supercoiled domains with uncoupled topological states. Hence, a 
depurination event in one domain will have very little effect on another [306, 307]. 
This, coupled with the low rate of depurination events observed for bacteria (in E. coli 
– one occurring every 2 generations), reduces the likelihood of depurination driven 
DNA damage [210]. Conversely, the supercoiled DNA structure is held by an array of 
histone-like proteins and has been found to interact with proteins localised all over the 
cell, including the cellular envelope [306], likely to facilitate HCOH-DNA interactions 
and crosslink formation.  
Likewise, while C > T transitions might be the most common reported SNPs in human 
cancerous DNA, this might differ in bacteria. As explained above, a higher proportion 
of C > T SNPs in humans derive from deamination of 5m-dC. However, in bacteria 
5m-dC are constrained to unique very short-patch repair (VSR) sequences at a log fold 
lower rate than observed in eukaryotes and signalling methylation is mostly done 
through amino groups of dA [308]. Congruently, spontaneous deamination in 
eukaryotic cells occurs at a 40-fold higher rate than in bacteria [266]. Altogether, the 
differences between structure and dynamics of bacterial and eukaryotic genomes raise 
many queries on the HCOH interaction with the bacterial genome. A better 
understanding of this interaction might lead to a clearer path to pursue microbiome 
analysis of these specimens. Despite the lack of this foundational knowledge, the 
targeted detection of microbial DNA in FFPE tissues has already proven feasible for 
the detection of pathogens by PCR and, to a certain degree, by 16S sequencing [199, 
202, 309]. In addition, they are now serving as templates for microbial barcoding 
surveys [199, 204, 205]. 
 
Considerations for sequence-based analysis of bacterial FFPE samples: 
As with investigations into FFPE induced DNA damage or repair strategies, the glut 
of research carrying out sequence-based analysis of FFPE human should be used as a 
resource to attempt to mitigate errors in the analysis of bacterial DNA. If the effects 
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of FFPE on bacterial DNA are similar to those in human DNA, then at a minimum the 
following can be expected. 1) Fragmentation: The fragmentation of DNA will impact 
sequencing strategies. Long read single molecule real time sequencing strategies may 
not be a viable option in these circumstances, and depending on the severity of the 
fragmentation, the popular amplicon sequencing strategies employed to characterise 
bacterial communities may be affected. As an example, the variable regions most 
commonly targeted in 16S rRNA gene sequencing (V3-V4) have a combined length 
of ~460 bp on average, which may exceed the fragment length of much of the DNA 
in an FFPE sample, reducing the already limited amount of DNA available. DNA 
fragment length should be assessed in advance and choices on amplicons and/or 
sequencing chemistry dictated by this.  
DNA damage: In the field of human cancer genomics, there is the recurring problem 
of differentiating low frequency genetic variants present in a small number of 
cancerous cells from decoys resulting from DNA damage[226]. The anticipated effect 
transposed onto bacterial genomic research is an increase in mutations possibly 
leading to erroneous speciation events. To combat this, there is further potential to 
take advantage of existing research if it can be successfully extrapolated into bacterial 
research. Bioinformatics tools have been developed to differentiate between true low 
frequency variants and artefacts of the FFPE process [310], and with sufficient FFPE 
bacterial DNA sequence data available, approaches such as this could be adapted.  
 
DNA Repair 
The Base Excision Repair (BER) system is the main cellular pathway for repair of 
lesions that do not cause significant distortions in the DNA helical structure, such as 
damaged bases, AP sites and ss breaks. This pathway is well conserved across 
evolution. The enzymatic repair of DNA by the BER pathway consists of five basic 
steps: (i) base excision by a DNA glycosylase (ii) Backbone incision by AP lyase, (iii) 
Ends processing by a polynucleotide kinase or 3’ – 5’ exonuclease, (iv) Gap filling by 
a polymerase, and (v) Nick ligation by a ligase [294, 300]. 
BER is initiated by the recognition and removal of damaged base by a DNA 
glycosylases [311]. These identify and remove damaged nucleotides by base-flipping 
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(Figure 8), which allows the insertion of the base onto a recognition pocket that holds 
the active cleavage site. The affinity at which recognition pockets bind their target 
dictates the target selectivity; for example, glycosylases recognising dU bind tighter 
to their targets, while those recognising oxidative damage are looser and able to 
process a wider range of damage [312, 313]. Similarly, those targeting uracil lesions 
only operate as glycosylases (monofunctional), while those targeting oxidative 
damage also operate as AP lyase (bifunctional) and the downstream BER pathways 
will be dictated by these modes of action (Figure 8) [294, 300, 313].  
In bacteria, for monofunctional DNA glycosylases, the AP site yielded after base 
removal is excised by an AP endonuclease (Endo IV/ Exo III), by cleaving the 
phosphodiester bond 5’ of the AP site, generating a nick with deoxyribose phosphate 
(dRP) residue in the 5’ terminus and a clean 3’OH terminus (Figure 9A). The 5’dRP 
residue can be removed by the 3’ – 5’ exonuclease activity of DNA polymerase during 
strand displacement, where 2-8 nucleotides downstream are displaced, thus leading to 
long-patch BER sub-pathway. The filled gap is later sealed by DNA Ligase I (Figure 
8) [292, 294, 300, 311-313]. For bifunctional glycosylases, after base excision, the 
ribose cleavage by β-elimination yields a Phospho-α,β-unsaturated aldehyde residue 
at the 3’ end (Figure 9B). This residue can be either removed by an AP endonuclease, 
leading to long-patch repair, or in the case of β /δ – glycosylases, this residue will be 
removed by the cleavage of the phosphate-ribose bond by the glycosylase, and yields 
a 3’ end phosphate. This blocking phosphate is later removed by either an AP 
endonuclease or a polynucleotide kinase (PNK) and the lesion filled through short-




Figure 8. BER sub pathways.  
The 5 steps for BER reaction illustrated: (1) base excision by a DNA glycosylase; (2) AP 
incision by an AP lyase/AP endonuclease; (3) Ends processing by polynucleotide kinase or 





Figure 9. Base excision and end repair.  
End repair driven by mono- or bi- functional DNA glycosylases. 
 
Concluding Remarks 
Only through a holistic understanding of FFPE-induced DNA damage can methods to 
repair relevant damage, thus improving the quality of genomic and microbial 
sequencing analyses, be devised. The latest developments in DNA repair and 
reconstitution of the BER pathway offer a unique opportunity to achieve this. Overall, 
a deepening in appreciation of the impacts that FFPE-induced DNA damage has on 
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CHAPTER 2:  
Protoblock - A biological standard for 









Formalin-fixed, paraffin-embedded (FFPE) tissue samples are being recognised as 
viable source material for bacterial analysis. However, several features of this sample 
type have limited their use for microbiome research. Among these, the lack of 
standardise methods or workflows. Now, the development of such workflows, could 
be facilitated by biological standards. In fact, the development and systematic use of 
reliable standards has been set as a key priority for microbiome research. As such, we 
aimed at developing a standard for the microbiome analysis of FFPE sample, namely, 
the Protoblock  
The Protoblock is a cell matrix, which can be populated with cell types and numbers 
as desired, such as to resemble those of the FFPE tissue specimens. Its accuracy for 
representing bacterial load and cell architecture proven by microscopy. With this 
model, the performance of the human gold standard FFPE kit for microbiome analysis 
of FFPE samples was evaluated, and found unsuitable for microbiome research. 
Additionally, the Protoblock allowed for the characterisation of bacterial FFPE DNA, 
where it was found highly fragmented (  length = 143 bp), a poor PCR template (with 
a log-fold loss of amplifiable 200 bp fragments) and with a significant extent of 
sequence alterations. Finally, this model also allowed for the characterisation of FFPE 
contaminants. Evidence raised here indicates that to unlock the potential of FFPE 
samples for microbiome analysis, it is necessary to develop a robust quality control 







Increased sequencing capabilities have driven progress in the study of the human 
microbiome [1-3], and distinct microbial profiles have been reported in body sites 
previously thought of as sterile (although many are potentially influenced by 
environmental contamination) [4-9]. These discoveries have steered a higher demand 
for patient samples, availability of which can be highly constrained when sampling 
from body sites that involve invasive sampling procedures [10, 11].  
In an attempt to satisfy this demand, the use of formalin fixed paraffin embedded tissue 
(FFPE) has been explored for microbiome research [12-19]. FFPE tissue is the gold 
standard for pathology tissue storage and thus represents the largest collection of 
available patient material [20-22]. The availability of this material has been vital for 
progress in human genomics and numerous sequencing workflows have been designed 
to enable use of, or are based upon, these samples [23-28]. The use of FFPE tissue for 
microbiome research could open access to large sample cohorts (guaranteeing 
statistical power), accompanied by a clear clinical history and histology reports. 
However, FFPE samples carry several limitations and considerations to be taken into 
account before their reliable use in microbiome research. Investigations in the quality 
of DNA from human FFPE samples have revealed that factors in the processing and 
storage (e.g. length of exposure to formalin, pH of formalin and sample storage time) 
negatively impact the integrity of nucleic acids and the efficacy of their downstream 
analyses [29, 30]. Relevant to microbiome research, unique factors to consider in 
quality control of FFPE samples are:  
(1) Low biomass renders samples extremely susceptible to the high burden of 
contaminants to which they are exposed during the non-sterile FFPE processing [31]. 
Additionally, it aggravates the influence of host DNA, rendering samples ineffective 
for whole genome sequencing (WGS) and introducing PCR bias to 16S rRNA gene 
sequencing [32].  
(2) FFPE causes DNA damage, in the form of crosslinks, DNA fragmentation, and 
sequence alterations [33]. In this context, 16S rRNA gene sequencing (V3-V4) 
necessitates DNA fragments with a length of 460 bp [34] and sequence alterations may 
lead to false speciation events.  
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(3) No sample-prep methods available for microbiome study of this sample type. FFPE 
microbiome studies to date have utilised approaches designed for FFPE human 
samples, which are suboptimal for this aim [35].  
In order for the potential value of increased usage of FFPE samples for 
metataxonomics/metagenomics to be realised, the necessary workflows, protocols and 
quality control standards need to be in place [25, 36-38]. Among these, the 
development and systematic use of Biological Standards have been recently 
highlighted as a key priority for microbiome research [39-42]. Given the multiple 
variables (FFPE processing, storage and DNA isolation process) that directly 
influence the quantity and quality of DNA recovered from FFPE samples, more than 
perhaps any other sample type, FFPE tissue urgently requires the development of 
standards to ensure the validity and reproducibility of results.  
A model that serves as a standard for metataxonomic and metagenomic analysis of 
FFPE samples requires: 1) A defined bacterial and host cell load, 2) Exposure to the 
same treatment as FFPE specimens (fixation & dehydration), 3) A format that 
resembles FFPE blocks – enabling the same treatment as the source material 
(sectioning, deparaffination). Here is presented the Protoblock, to serve as a biological 
standard for FFPE samples. The Protoblock is a cell matrix, which can be populated 
with cell types and numbers as desired, such as to resemble those of the FFPE tissue 
specimens. It can be integrated in the workflow at either the FFPE processing stage 
for prospective studies, or at the sample prep stage for retrospective studies, allowing 
the assessment of either workflows, highlighting caveats that must be considered when 
analysing the sequencing results.  
This study describes: 1) the procedures to make the Protoblock and its validation by 
microscopy, 2) validation of their value as a standard for the 16S rRNA gene 
sequencing and shotgun metagenomics. The Protoblock was found to be effective in 
enabling: (i) Assessment of currently used methods for their lysing capabilities; (ii) 
Measurement of the influence of host DNA and the effectiveness of host depletion 
strategies; (iii) Characterisation of bacterial FFPE DNA damage; (iv) Identification of 




1. Preparation of Protoblocks 
Moulds. Moulds used to make a cylinder-shaped disks were made from a 54 x 
11 mm adapter tube with a flat base (SARSTEDT, Cat No. 55.1570).  
Cell culture. Mus musculus mammary gland cancer cells (4T1) were grown at 37 oC 
5% CO2, in RPMI-1640 (Sigma-Aldrich) media supplemented with 10% FBS (Sigma-
Aldrich), 100 U/mL penicillin and 100 μg/mL of streptomycin (ThermoFisher), and 
counted with a NucleoCounter® NC-100™ (chemometect, Copenhagen).   
Bacterial growth conditions. E. coli K12 MG1655 or E. coli Nissle 1917 
carrying a P16Lux plasmid [43], were grown aerobically at 37 oC in Luria-Bertani 
(LB) medium with 300 µg/ml Erythromycin (Sigma-Aldrich). Staphylococcus aureus 
Newman (ATCC 25904) was grown aerobically at 37 oC in Todd-Hewitt broth 
(Sigma-Aldrich). Bifidobacterium longum 35624 was grown anaerobically at 37 oC 
for 24 h in MRS medium (Sigma-Aldrich). Lactobacillus amylophilus (ATCC® 
49845™) was grown in MRS medium (Sigma-Aldrich) at 30 oC in 5 % CO2 for 24 h. 
Bacteroides thetaiotaomicron (ATCC®29741™) was grown anaerobically at 37 oC 
for 24 h in FAB medium (NEOGEN, Lancashire, UK). Bacterial cultures were 
harvested by centrifugation and suspended in PBS. A 1 ml aliquot of the suspension 
was used for to count colony forming units (CFU) by retrospective plating. The rest 
was resuspended in Neutral Buffered Formalin and left to fix for 18 h at RT. 
Counting fixed bacterial cells. The cell suspension was counted using a 
bacterial counting kit for flow cytometry (Invitrogen). In brief, a 10 % aliquot from 
the bacterial suspension was serially diluted to 1x 106 cells in 989 µl of NaCl. Bacterial 
cells were stained with 1 µl of SytoBC and 10 µl (1X 106) of counting beads were 
added to the suspension. Cells were counted in an LSR II Flow Cytometer (BD 
Biosciences). The acquisition trigger was set to side scatter and regulated for each 
bacterial strain to filter out electronic noise without missing bacterial cells. This value 
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was approximately 800. The volume corresponding to approximately 2 x 107 CFU of 
each bacterial strain and 2.2 x 107 4T1 cells were mixed together. 
 
Fixing cells in an agar matrix. An equal volume (270 µl) of sterile agar (1.5X 
of elution specified by the manufacturers) pre-aliquoted and kept at 56 oC, was 
pipetted into the cell suspension and thoroughly mixed by vortexing. The mixture was 
pipetted into the moulds, and left to solidify for 3 min at RT.  Once solidified, the disk 
was placed in 5 ml of formalin for an extra 24 h for 48 h fixation blocks or immediately 
processed for 24 h fixation blocks.   
 
Dehydration and paraffin embedding of cell disk. Cell disks were placed 
into a processing cassette and processed automatically with a LOGOS J (Milestone 
Medical, Bergamo). Here, they were dehydrated for 4 h with increasing concentrations 
of ethanol (37oC), cleared 2X with xylene for 2 h 20 and 2X with isopropanol for 1 h 
40 min at 37 oC, and 1X with isopropanol for 50 min at 60 oC. Finally, the blocks were 
embedded in paraffin for 8 h 32 min at 62 oC. Once paraffinised, the Protoblocks’ 
volume, diameter and height were measured with a calliper and by volume 
displacement [44]. Processed Protoblocks were placed in a 1.5 x 1.5 cm embedding 
mould and mounted to a processing cassette.   
 
2. Confirmation of cell content by microscopy 
Sectioning. The blocks were sectioned using aseptic technique, either at 4 µm for 
imaging or at 10-20 µm for DNA purification. The cell load of each slide was 
calculated by multiplying the total bacterial load by the volume of each slide.  
Immunofluorescence and histochemistry. Cell integrity was evaluated with Gram 
staining (Sigma-Aldrich) or H&E staining with Mayer’s haematoxylin (Sigma-
Aldrich). Bacterial counts were confirmed in 3 sections stained with either 1:50 α-
E. coli  (Abcam, 137967) or 1:400 α-S. aureus (Abcam, 20920), counterstained with 
either Alexa Fluor 488 (Jackson Immunoresearch Laboratories Inc., USA) or 
Alexa Fluor 555-conjugated (Abcam 150062) donkey anti-rabbit Ig. Stained sections 
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were mounted in ProLong Gold antifade reagent with DAPI (Invitrogen, UK).  Gram-
stained sections were counted in bright field using an Olympus BX51 microscope, 
with a 100X lens. Immunofluorescent stained slides were counted at 20X (4T1 cells) 
or 60X (bacteria) with a fluorescence microscope (Evos FL Auto). For each slide, at 
least 20 randomly selected fields of view were counted. The area of the field of view 
(FOV) was recorded using the microscope’s software and used to calculate the volume 
counted.  
3. DNA Analysis  
DNA Purification. For purifying DNA from Protoblocks, unless specified, 10 x 15 
μm sections aseptically collected sections were deparaffinated with 2X xylene washes 
and processed following procedures specified in the QIAGEN FFPE DNA kit protocol 
(Qiagen Inc., Valencia, CA, USA). DNA was eluted in Tris-HCL buffer and quantified 
with a Qubit™ dsDNA HS Assay Kit (Invitrogen, USA). For non-fixed bacteria, 
bacterial cultures were grown to an OD600 of 1. 2 ml aliquots were processed following 
procedures of the GenElute™ Bacterial Genomic DNA Kit Protocol with Lysozyme 
and Lysostaphin (Sigma) and eluted in 50 µl of Tris-HCl. In all cases, DNA was stored 
at -20oC until further analysis. 
Fragment analysis.  1 µl of DNA purified from FFPE blocks was analysed in an 
Agilent 21000 bioanalyser using a High Sensitivity DNA kit (Agilent, Cat. No. 5067-
4626). For Genomic Quality Number (GQN), the threshold was set to 10,000 bp and 
the ratio of DNA above this threshold measured for each sample. Average fragment 
lengths and %CV are from area underneath a maximum peak were also measured.  
Quantitative PCR (qPCR). For dye-based qPCR, reactions were prepared using 
LUNA Universal qPCR master mix (NEB, USA) and 0.25 µM of each primer (sTable 
2). Multiplex qPCR reactions were prepared using LUNA Universal Probe qPCR 
master mix (NEB, USA) and 0.5 µM of each primer (sTable 2) and 0.25 µM of probe 
for each strain. Reactions for simultaneously quantifying three bacterial strains were 
set using the fluorochromes: FAM, HEX, and CY3. The thermal profile included a 1 
min at 95oC initial denaturation, followed by 40 cycles of denaturation at 95oC x 10 
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sec, annealing for 15 sec at the temperature specified by NEB’s Ta calculator for Hot 
Start Taq, followed by 20-40 sec of extension at 68 oC. For each assay, a 5-point 
standard curve was made from log10 dilutions of a gene block corresponding to 
species-specific genetic regions, using an initial concentration of 106 copies. Primers 
and gene-blocks were acquired from IDT (Coralville, USA) (see sTable 2 and 
sMaterial 1). Efficiency between 95% - 105% and R-square values > 0.995 were 
deemed as acceptable. All samples were run in triplicate. 
qPCR Melt Curve Analysis. For melt curve analysis, FFPE E. coli DNA was 
normalised to 1 x 106 copies/µl.  Reactions were prepared using 1X NEB Luna probe 
qPCR mix, 1.25 µM EvaGreen Dye (Biotium, CA, USA), 37.5 nM ROX as a reference 
dye, 0.25 µM of each primer  (sTable 2) and 2.5 µl of template DNA. Cycling 
conditions used are as described for absolute quantitation with addition of a final 
extension step of 2 min at 68 oC. This was followed by high-resolution melt analysis 
set to read fluorescence every 0.2 oC with 10 sec soak time from 65-95 oC. Values for 
the first derivative of the normalized fluorescence multiplied by -1 were exported and 
analysed in R environment, v3.4.4. 
16S rRNA sequencing Library Preparation. Amplification of the 
hypervariable V3-V4 region of the 16S rRNA gene (see sTable 2) was performed in 
50 µl reactions, containing 1X NEBNext High Fidelity 2X PCR Master Mix (NEB, 
USA), 0.5 µM of each primer, 8 µl template (5-15 ng/µl) and 12 µl nuclease free water. 
The thermal profile included an initial 98 oC x 30 sec denaturation, followed by 25 
cycles of denaturation at 98 oC x 10 sec, annealing at 55 oC x 30 sec and extension at 
72 oC x 30 sec and a final extension at 72 oC x 5 min.  Amplification was confirmed 
by running 5 µl of PCR product on a 2 % agarose gel. Hereafter, procedures were 
performed as per the Illumina 16S Metagenomic Sequencing Protocol (Illumina, CA, 
USA). PCR products were cleaned and sequencing libraries were prepared using the 
Nextera XT Index Kit (Illumina). Libraries were cleaned and quantified using a Qubit 
fluorometer (Invitrogen) using the ‘High Sensitivity’ assay. Further processing was 
performed by GENEWIZ (Leipzig, Germany) where samples underwent a 300 bp 
paired-end run on the Illumina MiSeq platform. 
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Negative Controls.  (i) Processing control: sterile agar exposed to the complete 
FFPE processing workflow. (ii) Wax control: wax taken from edges of an FFPE block. 
(iii) Sample prep-control was included by running an empty sample-prep reaction. (iv) 
PCR control: a 16S PCR reaction loaded with microbial DNA free water.   
WGS sequencing library preparation. For NF controls, DNA from bacterial 
cultures of Escherichia coli MG1655 and S. aureus Newman were grown as per 
section 1 to and OD600 of 1 and their genomic DNA purified using the GenElute™ 
Bacterial Genomic DNA Kit Protocol with Lysozyme and Lysostaphin (Sigma). For 
FFPE bacteria, DNA from Protoblocks containing either strain was purified using the 
QIAGEN FFPE kit. In all cases DNA was eluted in 50 µl of Tris-HCl. Total purified 
DNA was sent to GENEWIZ (Leipzig, Germany) where WGS was performed using 2 
x 150 bp chemistry on an Illlumina HiSeq.  
4. Murine models 
Animals, mammalian cell culture, and tumour induction. Murine 
experiments were approved by the Health Products Regulatory Authority (Dublin, 
Ireland) and the Animal Experimentation Ethics Committee of University College 
Cork (Cork, Ireland). RENCA cells were grown in RPMI media (Sigma) + 10% FBS 
(Sigma) and counted with a NucleoCounter (Chemometec). Tumours were induced in 
8 week-old BALB/c mice by subcutaneous injection of 1 x 106 cells suspended in 200 
µl serum-free RPMI media. Tumours were measured daily with a Vernier calliper and 
their volume calculated by measuring their longest diameter, and at the diameter 
perpendicular to this.   
Bacterial preparation and administration. Bacteria were prepared for 
administration once murine tumours were approximately 5 x 5 mm in diameter. E. coli 
Nissle 1917 was grown to an OD600 of 0.8 in LB media, with 300 µg/ml erythromycin, 
harvested by centrifugation and washed 3X with PBS. Bifidobacterium breve 
UCC2003 was grown anaerobically for 24 h in Man, Rogosa, and Sharpe (MRS) 
media (Oxoid), + 0.05% L-cysteine hydrochloride (Sigma), harvested and washed 3X 
with PBS + 0.05% L-cysteine. Both bacterial strains were serially diluted to 1x107 
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CFU/ml. Tumour-bearing mice were administered 100 µl of either bacterial 
suspension or PBS (negative control) via lateral tail vein injection, as per [43]. 
Bacterial counts were confirmed by retrospectively plating in LB agar supplemented 
with 300 µg/ml erythromycin (E. coli) or RCA supplemented with 50 mg/L mupirocin 
(B. breve). 
Bacterial recovery from mice. Mice were culled 7 - 11 days after bacterial 
administration. Tumours were aseptically excised, and halved. One half was placed in 
10 % buffered formalin and fixed for 24 h at RT. The other half was placed in 1 ml 
PBS (+ 0.05% L-cysteine for B. breve) and homogenised using a 70 µm nylon cell 
strainer (Corning). Cell strainers were washed with 1 ml PBS. Homogenised tumours 
were serially diluted with PBS and plated for retrospective counting as per [45].  
Formalin-fixed tissue processing. Formalin-fixed murine tissues were placed 
between two biopsy pads (Kaltek) in a histology cassette and processed using a 
LOGOS J Hybrid Tissue Processor (Milestone) and paraffin embedded as per section 
1. 
DNA extraction and analysis of FFPE tissue. 8 x 10 µm sections were 
processed for each specimen. Samples were subsequently processed with a QIAamp 
DNA FFPE Tissue kit (Qiagen) per the standard protocol, with the following 
exceptions: Tissue was deparaffinated with 2X xylene washes and the incubation with 
Buffer ATL and Proteinase K was performed for 1 h 45 min. DNA was eluted in 35 
µl Buffer ATE. Quantitative PCR reactions were set up as per section 3, using primers 
and probes specified in sTable 2.  
5. Bioinformatics and Statistical Analysis 
Statistical analysis. All statistical analysis were performed in the R environment, 
v3.4.4, using methods stated in the figure legends. 
16S rRNA Gene Sequence analysis. The quality of the paired-end sequence 
data was initially visualised using FastQC v0.11.6, and then filtered and trimmed using 
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Trimmomatic v0.36 to ensure a minimum average quality of 25. The remaining high-
quality reads were then imported into the R environment v3.4.4 for analysis with the 
DADA2 package v1.8.0. After further quality filtering, error correction and chimera 
removal, the raw reads generated by the sequencing process were refined into a table 
of Amplicon Sequence Variants (ASVs) and their distribution among the samples. As 
the aim was to characterise if contamination is present, rather than to remove it, 
negative controls were included to compare with the FFPE Protoblocks, with no 
further action taken.  
Variant Calling from Whole Genome Sequence data 
Filtering:  HiSeq sequence data was quality filtered. Only very high quality bases were 
considered, to minimise the risk of sequencing errors causing false positive variants. 
Short fragments were also removed to reduce the likelihood of spurious alignments of 
regions from contaminant bacterial genomes. Trimmomatic was used to remove all 
reads shorter than 50 bp in length, and to trim reads when the average per base quality 
in a sliding window of size 4 dropped below 30.  
Alignment: Of the three possible Burrows-Wheeler alignment tools, the BWA-mem 
aligner was used as the average read length was 150 bp, and BWA-mem is 
recommended when reads are over 70 bp in length as per the manual reference 
pages[46]. Default settings were used with the exception of allowing alignments with 
a minimum score of 0, rather than the default 30 as we were unsure of the extent of 
DNA damage induced sequence alterations. Given the stringent parameters used for 
read length and quality filtering, relaxing the minimum alignment score gave the best 
possible chance of variant detection. Samples were aligned to the original reference 




1. Protoblock generation and validation.  
Making the Protoblock: The Protoblock is generated by embedding a known number 
of fixed cells in an agar matrix that is poured into a mould that renders a defined 
uniform shape, in this example, a disk. Once the agar solidifies, the blocks are 
processed as per routine FFPE processing protocols for dehydrating and paraffin 
embedding, and verified by microscopy. See Figure 1. 
To achieve the desired cell numbers, formalin fixed cell suspensions were counted 
(Figure 2, Table 1 (column 2)) and the volume of the cell suspensions normalised to 
cell contents (Table 1 (column 3)). For bacteria, the viable cell fraction was obtained 
by retrospective plating, and for murine tumour cells, viability was obtained with a 
NucleoCounter (Figure 1, Table 1 (Column 4)). The Protoblock radius, height, and 
volume were measured after dehydration. Average measurements for Protoblocks 
presented here were 4.99 ± 0.15 mm, 3.57 ± 0.24 mm, and 245.2 ± 14.2 µl, 
respectively. A slide’s estimated cell population was calculated by multiplying the cell 
content per microliter of block (Table 1(column 5 ( ) & 6 (σ)) by the volume of a 15 
µm slide (x̄ = 1.57 µl, σ = 0.098 µl) or 4 µm slide (x̄ = 0.39 µl, σ = 0.02 µl).  (See 
Figure 1B). A slide’s estimated cell population (Table 1(column 10)) was calculated 
by multiplying this value by the volume of a 20 µm slide (x̄ = 1.57 µl) or 4 µm slide 
(x̄ = 0.3 µl). The cell content was confirmed by immunofluorescence microscopy in 
blocks containing individual cell types and mixed cell content (Table 1(column 8 ( ) 
& 9 (σ)). Cell wall/membrane integrity was assessed by Gram or Haematoxylin & 
Eosin (H&E) staining. See Figure 2.  
Protoblock validation: Protoblocks were populated with cell types and cell loads that 
provided the best resolution for each experimental aim. Comparable ratios of a mix of 
5 bacterial strains and 4T1 cells (in the same order of magnitude  1 x 107) were aimed 
for. Estimated cell content was confirmed by immunofluorescence microscopy in 
blocks containing individual cell types (Figure 2C) and mixed cell content (sFigure 
1). Cell wall/membrane integrity was assessed by Gram (Bacteria) or Haematoxylin 
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& Eosin (H&E) staining (4T1 cells). See Figure 2B. The calculated and confirmed 
contents for each Protoblock are specified in Figure 3 and sTable1.  
 
Figure 1. Making a Protoblock.  
A) Schematic of the workflow for making a Protoblock described in methods.  
B) Schematic of the architecture of a Protoblock, demonstrating average measurements of 
volume, height and radius. 
 
Table 1. Cell input to Protoblocks and confirmation of cell contents 





























4T1 1.22E+05 180 79 2.20E+07 -- 8.00E+04 2.20E+07 1.24E+05 9.07E+05 
Escherichia 3.87E+06 13 84 3.94E+07 4.12E+06 1.79E+05 3.88E+07 1.32E+05 1.78E+06 
Staphylococcus 1.16E+07 12 70 1.16E+08 1.55E+07 3.34E+05 9.11E+07 9.68E+05 5.04E+06 
Bifidobacterium 3.57E+06 25 98 1.07E+08 2.38E+06 1.01E+05 9.03E+07 8.76E+05 5.02E+06 
Lactobacillus 1.18E+07 11 100 1.75E+08 1.04E+07 2.27E+05 1.31E+08 1.23E+06 8.13E+06 





Figure 2. Validation of cell architecture and numbers in a protoblock.  
a)  Flow cytometry dot plots measuring the cell density of fixed bacterial suspensions used to 
make protoblocks. Events were gated either for SYTOBC+ cells or beads. The averages of 3 
reads for 4 populations per cell type are shown here and in Table 1.  
b) Light microscopy images confirming cell architecture of protoblocks slides stained with 
H&E (4T1 cells) or Gram-staining (Bacteria).  
c) Fluorescence microscopy images confirming cell content of protoblocks. Slides were with 
α- E. coli (Green), α- S. aureus (Red), or DAPI (Blue).  Counts in Figure 2 are the average of 
20 FOV in 3 x 4 µm slides.  
2. Protoblock for assessing bias introduced by sample prep methods 
Total DNA from 10 x 15 µm slides was purified using the ‘gold standard’ DNA 
purification method for FFPE samples used in previous FFPE 16S rRNA gene 
sequencing studies (QIAGEN FFPE DNA kit). Protoblocks used were fixed in 
formalin for 24 or 48 h. Recovery by quantitative PCR was determined by quantifying 
the amplification of strain-specific  460bp DNA fragments (length relevant for 16S 
rRNA sequencing). As seen in Figure 3A (i), FFPE treated samples had at least a 10-
fold reduction of amplifiable DNA, shown to be statistically significant (p < 0.001). 
Although similar amounts of DNA were purified from the samples (Figure 3C), the 
PCR readability of DNA is reduced by FFPE treatment, which is aggravated with 
increasing fixation time. Furthermore, after compensating for the 2-log fold loss of 
readable DNA, statistically significant under- and over-representation of all 5 genera 
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present was evident, with a clear bias towards Gram-negative (G-) bacteria 
(Bacteroides and Escherichia). This was more evident for Bacteroides and 
Staphylococcus, which were over- and under-represented by 605 % and - 93.1 % 
respectively (Figure 3A.ii). This effect was exacerbated by longer fixation periods. 
Lysis bias was confirmed with 16S rRNA gene sequencing (Figure 3 B). Altogether, 
these data indicate that a bacterial lysis mechanism must be incorporated in the 
workflow for processing of FFPE samples (this is not included in the QIAGEN kit, 
optimised for human DNA purification) and that for bacterial FFPE DNA, the baseline 
recovery of 460 bp fragments is ≤ 2-log the input. The results from these tests in 




Figure 3. Assessing the recovery of FFPE bacterial DNA by quantitative PCR and 
16S rRNA sequencing.  
A) Evaluating PCR recovery of FFPE bacterial DNA from Protoblocks fixed for 24 h (green) 
or 48 h (cyan) and compared with the recovery of paired NF samples (red). i) % of absolute 
PCR recovery (% shown above corresponding box). A 2-log fold decrease in recovery is 
observed for FFPE treated samples, which was found to be statistically significant in all cases 
as per 1 sample Wilcoxon Signed Rank test. In addition, longer fixation periods lead to a 
significantly greater reduction in recovery (p = 0.04). ii. % deviation in recovery after 
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compensating for 10-fold loss in recovery. Input = 0 (dotted line). % deviation shown above 
corresponding box. Significant deviation from input values, even after compensation for 10-
fold decrease shown in all FFPE treated samples. (In all cases p = <0.1, * < 0.05, ** < 0.01, 
*** < 0.001) 
B. Sample composition Bar plot of: Calculated input of bacterial cells added to Protoblock 
and 16S rRNA gene sequence analysis of Protoblocks fixed for 24 h or 48 h.  
C. Average concentration of DNA purified from samples. 
3. Assessment of bacterial DNA integrity following FFPE 
DNA fragmentation: DNA integrity was investigated with a fragment analyser by 
comparing DNA purified from matched NF and Protoblocks (FFPE) samples 
containing either a mix of NF bacteria (ratios as Table 2) or Escherichia only. As seen 
in Figure 4A, DNA fragments from NF Escherichia (x̄ = 27,102 bp, %CV =65.84) or 
the bacterial mix (x̄ = 31,100 bp, %CV =59.19) were highly integral (no 
fragmentation), with a Genomic Quality Number (GQN) > 6.6, and no significant 
difference was observed between sample type. On the other hand, DNA fragments 
from Protoblocks loaded with Escherichia (x̄ = 143 bp, %CV = 41.93) or a bacteria 
mix (x̄ = 110 bp, %CV =53.62) were highly fragmented with a GQN = 0.1 in both 
sample types. These results were in agreement with FFPE tissue DNA (sFigure 2). 
These results are comparable with those found in human FFPE samples, where GQN 
between 0.75 - 2.5 are considered high quality FFPE DNA and GQN ≤ 0.3 are low 
and not recommended for sequencing [47].  
Assessment of PCR readable bacterial FFPE DNA: Since DNA fragmentation of 
FFPE bacteria was observed to be equal across taxa investigated here (Figure 4A), the 
effect of fragmentation on PCR recovery was investigated with Protoblocks loaded 
with 108, 106 and 104 Escherichia cells, as confirmed with Gram staining (Figure 4B 
(iii)). Quantitative PCR reactions loaded with 107 (61.2 +/- 5.2 ng), 105 (0.8 +/- 0.21 
ng) or 103 ( 0.02 ng) bacterial cells, were tested for the recovery of a 200 bp 
(recommended for FFPE) [48, 49] or 460 bp DNA fragment (required for V3-V4 16S 
rRNA sequencing [34]). This was compared with the recovery of a 460 bp fragment 
from paired NF (Non-fixed) samples (Figure 4B (i)). While comparable DNA 
quantities of paired FFPE/NF samples were loaded into the PCR reactions, a 
significant (> 1-log) reduction was observed in the quantity of DNA recovered from 
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Protoblock samples (p<0.001). A further decline in recovery (3-8 X) was evident when 
targeting longer (460bp) DNA fragments (Figure 4B (ii)), a trend that held true across 
all groups, which varied in terms of quantity of bacteria loaded, thus indicating that 
DNA fragmentation has a significant effect in the PCR recovery of bacterial DNA 
(p<0.001).  
 
Figure 4. DNA fragmentation in FFPE bacteria 
A) Evaluation of DNA integrity with fragment analyser. Electropherograms of DNA purified 
from Protoblocks with a mix of 5 bacterial strains (red) and Protoblocks loaded with 
Escherichia only (yellow) and compared with matched NF bacterial mix (Blue) and 
Escherichia (Green). NF bacterial DNA had a higher integrity (GQN >6.6), while FFPE 
bacterial DNA from either sample was highly fragmented (GQN ≤ 0.1). No significant 
difference was observed between Protoblocks or NF samples. GQN = % of DNA above the 
threshold. The GQN threshold (dotted line) was set to that used for sequencing libraries 
(10,000).  
B) Measuring the recovery of PCR readable DNA from FFPE bacteria in Protoblocks by 
qPCR. (i) Schematic of primer design for targeted fragments. Both 200 bp and 460 bp DNA 
fragments target the same E. coli K-12 regions. (ii) PCR recovery. Box plot of DNA recovery 
from 460 bp (green) and 200 bp (orange) FFPE DNA fragments (for each box, n=9) compared 
with NF DNA (cyan; for each box n= 6) normalised to 107, 105, 103 genomes. Mean recovery 
of DNA from Protoblocks compared with input DNA significantly differed in both FFPE 
sample types (p<0.001) as per One-Sample Wilcoxon Signed Rank test. Fragment length also 
significantly influenced DNA recovery of FFPE samples (p<0.001), as per Wilcoxon Signed 
Rank test. (iii) Gram-stained slides used for confirming bacterial content. (In all cases p = + 




Presence of DNA Sequence artefacts:  This was assessed in a Protoblock model 
populated with E. coli. Purified DNA was normalised to 106 genome copies. High 
resolution melt (HRM) analysis was performed in 3 contiguous DNA fragments 
(length  100 bp) that make up a region of the InsH1 gene (See Figure 5A (ii)). To 
determine the presence of any sequence aberrations in Protoblock FFPE DNA, their 
melting temperature (Tm) was compared with that of NF DNA and the differences 
measured. Figure 5A (i) shows the final Tm for each fragment investigated. Tm shifts 
with variable levels of significance were observed in all fragments. Here, changes in 
Tm <0.1oC from that of NF DNA are indicative of low-level, non-identical sequence 
changes randomly distributed across the template that are typical of FFPE DNA [50]. 
To confirm these results, DNA purified from Protoblocks loaded with Escherichia and 
Staphylococcus and their paired NF samples were analysed by WGS. Findings from 
the DNA melting temperature analysis correlated with the results of WGS. For both 
bacterial strains, a higher number of sequence artefacts (chimeras and SNPs) were 




 Figure 5. Evaluating sequence quality of bacterial FFPE DNA. 
A) Evaluation of DNA sequence aberrations by high-resolution-melt analysis. i) Box plots 
of normalised DNA quantities from Protoblock FFPE Escherichia (Cyan) and NF Escherichia 
(Orange). Significant shifts in the melting temperatures in 2 of the 3 sequences were observed 
as per Wilcoxon Signed Rank test, with temperature shifts that were on average 0.1-0.5oC 
apart from NF counterparts. ii) Schematic of sequences used for HRM analysis: 3 DNA 
fragments with an average length of 100 bp were analysed. For each test and each sample 
type, n = 6.   
B) Confirmation of sequence alteration by WGS. DNA from Protoblocks loaded with 
Escherichia and Staphylococcus and their NF paired reference was analysed by whole 
genome sequencing to determine chimeric reads and Single Nucleotide Polymorphisms (SNP) 
against the reference genome E. coli K12 MG1655 and S. aureus Newman. Here, the SNP are 
plotted on the x axis and the rate of occurrence on the y-axis. Variant calling, and level of 
coverage is measured using SAMTOOLS/BCFTOOLS. i) Chimeric reads per layer of 
coverage. ii) Distribution of SNPs found per bacterial strain. 
 
 
4. Characterising contaminants in the FFPE and sequencing workflow  
The Protoblock is susceptible to contamination in a similar way to clinical FFPE 
samples. The priority of the fixing process is to preserve the tissue for later histological 
analysis, not to prepare a sample suitable for high throughput bacterial sequencing. In 
this instance, contamination was detected as shown by the number of reads in the 
negative controls (Figure 6). It is unlikely to have had a significant effect on the overall 
biological signal in this instance, given that the bacterial reads detected and their 
taxonomic classifications differ completely from those of the Protoblocks analysed. 
However, the quantity of reads detected in negative controls samples dictates that 
contamination remains a threat for low biomass samples, a characteristic expected in 




Figure 6. Evaluation of sources of environmental contamination and their effect on 
Protoblock samples.  
Composition bar plot per sample showing proportional composition of bacterial taxa per 
negative control, with corresponding number of reads detected by 16S rRNA gene sequencing. 




FFPE tissue specimens are a huge potential resource that have driven research in 
human cancer genomics, where numerous workflows have been developed for these 
samples. Over a decade of study has revealed that FFPE DNA damage is influenced 
by many factors during processing and storage. This results in a high inter-sample 
variability in the degree of DNA damage, with some samples being unsuitable for 
sequencing analysis [51]. To address this, the development of a robust quality control 
(QC) system has been crucial in directing workflows maximising the recovery, while 
guaranteeing the fidelity of analysis outputs. Most notable among these are the 
analysis of DNA fragment length (fragment analyser) and PCR readability of DNA in 
a sample (Infinium FFPE QC, Illumina). 
Likewise, before any reliable and reproducible use of FFPE samples for microbiome 
analysis can be performed, a robust QC system must be developed and systematically 
implemented. The Protoblock presented here represents a highly relevant starting 
point. This method is advantageous in that the cell populations and fixation strategies 
can be adapted to meet the requirements for sample type and sample-prep/sequencing 
workflow to inform on their effects on analysis outputs [52]. Ideally such a standard 
would be developed in specialist facilities and distributed to researchers to guarantee 
sample accuracy and reproducibility across the field. This will also allow optimisation 
of the method to achieve a higher resemblance to tissue, such as using a larger number 
of host cells or incorporating extra cellular components found in tissue to the matrix. 
However, this method could also be adapted by researchers with specialised needs.  
It has been shown here that the Protoblock is a representative FFPE model, since its 
contents are exposed to the same processing as FFPE experimental samples and has 
the same degree of DNA damage (fragmentation, PCR recovery and sequence 
alteration) as clinical FFPE tissue samples (Figure 4, 5 and sFigure 2). Moreover, the 
degree of DNA damage in the Protoblocks can be modulated by changing the severity 
of fixation (Figure 3A). This advantage can be exploited to develop a system similar 
to Infinium FFPE QC (Illumina), where a sample with a good DNA quality score 
serves as a standard and Cq deviations from this inform on the suitability of samples 
for sequencing analysis. The Protoblock can also serve as a quantitative standard to 
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determine cycle number at which tested FFPE samples will have detectable levels of 
16S rRNA gene sequences, if any.  
From the results shown here, it is clear the QIAGEN FFPE DNA sample prep is 
unsuitable for microbiome analysis, since it is strongly biased towards Gram-negative 
bacteria (Figure 3). Given the lack of a standardised method to process FFPE samples 
for metagenomic studies, the use of standards such as the Protoblock is essential to 
develop this workflow and guarantee the accuracy, precision, and limit of detection of 
the analysis. An unexpected finding was a higher than expected recovery of FFPE 
Bifidobacterium in samples processed without undergoing bacterial lysis. The 
opposite was found for Staphylococcus. This reinforces the need to thoroughly study 
the effect of FFPE on bacteria prior to any microbiome analysis of FFPE specimens. 
Principally, a thorough investigation on the effect of FFPE in bacterial membrane/cell 
walls and bacterial DNA itself.  
Finally, contamination is a considerable threat to the accuracy of sequence-based 
analysis of low biomass samples such as FFPE specimens. Steps in the processing of 
FFPE samples require the use of solutions that are difficult to keep sterile, and 
contamination from these sources could easily obscure the true results in cases of low 
microbial load. Use of a combination of an empty (agar only) and a bacterial loaded 
Protoblock along with a sample of the paraffin wax used for embedding can inform 
on the most common contaminants and the level of contamination introduced by any 
processing of FFPE samples required, in advance of a sequencing study. Although, 
contamination was minimal, due to sufficient bacterial biomass, clinically collected 
FFPE blocks can be expected to have a much lower level of microbial biomass and 
are thus more susceptible.  
CONCLUSION  
Unlocking the potential of FFPE samples for microbiome analysis could have a huge 
effect on the field. For this to be a reality, a robust quality control system needs to be 
developed. The Protoblock presented in this study is foundational in building towards 
this. Evidence generated here shows its value in investigating the effect of FFPE in 









Supplementary Figure 1. Microscope images of Protoblocks with 5-strain mix 
contents 
A) Microscope image (40X) of Protoblock loaded with the 5 bacterial taxa specified in Figure 
2. DAPI (Blue), staining all bacterial cells. In green, α-Escherichia. 
B) Microscope image (40X) of Protoblock loaded with the 4T1 cells and the 5 bacterial taxa 
specified in Figure 2. DAPI (Blue), staining 4T1 and bacterial cells. In green, α-
Staphylococcus. 
B) Microscope image (40X) of Protoblock loaded with the 4T1 cells and the 5 bacterial taxa 







Supplementary Figure 2. Validation of findings in FFPE tissue. 
A) DNA fragmentation. Electropherograms comparing the integrity of NF tissue DNA 
(green), with FFPE tissue DNA (red) and the contents of Protoblocks (blue). NF tissue 
fragment length = 4,406 ± 1,939 bp, DNA from FFPE tissue = 229 ± 20 bp and DNA from 
Protoblocks = 192 ± 48.5 bp.  
B) 16S rRNA recovery of FFPE tissue. Bar plot showing bacteria recovered by 16S rRNA 
sequencing from murine tumours models loaded with either Escherichia, Bifidobacterium or 
PBS. Here, Escherichia was readily detected, while Bifidobacterium was not detected. 
C) PCR recovery of Escherichia and Bifidobacterium from FFPE tissue. i) Assessment of 
strain specific gene and 16S rRNA gene in the recovery of non-fixed E. coli. Bar plot 
showing the number of gene copies retrieved for either a strain specific gene (  = 8.14 ± 0.43 
copies) or 16S rRNA gene (  = 10 ± 1.2 copies) after amplifying an input of 1 x 105 
Escherichia cells. ii) Recovery of Escherichia from FFPE tumours. Box plot showing the 
PCR recovery of an input of 3.3 x 105 Escherichia genomes with a strain specific 137 bp DNA 
fragment (2.33 x 104 ± 8.8 x 104 genomes) and that of the 16SrRNA gene (2.7 x 102 ± 3.2 x 102 
genomes). iii) Recovery of Bifidobacterium from FFPE tumours. Box plot showing the PCR 
recovery of an input of 1.8 x 103 Bifidobacterium genomes with a strain specific 174 bp DNA 
fragment (3.2 x 101 ± 21 x 101 genomes) and that of the 16SrRNA gene for which there was 
not a reliable amplification detected (only 2/6 replicates returned an average amplification of 
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Key elements to be considered when creating accurate Protoblock models are a precise 
cell load estimation, maintenance of cell integrity and a shape that facilitates a uniform 
cell distribution that allows for slides to be representative of the block’s populations. 
To achieve this, the following points   must be considered when preparing blocks.  
Cell counts. The protoblock consists of cell populations of viable and non-viable cells. 
Downstream quantification of bacterial content via microscopy and qPCR informs the 
total bacterial content, with no distinction between viable and non-viable cells. 
Moreover, DNA from non-viable cells is more readily accessible and more easily 
recovered during DNA isolation, which could introduce bias in the downstream 
analyses. To avoid this, it is important that cell counts are done on the fixed population 
as a whole, with the viable cell content calculated to estimate bias introduced by 
readily accessible DNA during sample preparation.  Flow cytometry and fluorescent 
microscopy were deemed as feasible approaches to obtain a total bacterial count.   
124 
 
Cell displacement volume.  Displacement volume can have a significant effect on total 
cell counts and must be taken into account. The volume used to re-suspend the cells 
will not represent the final volume of cell suspension if the displacement volume is 
not considered. Higher effects were observed for mammalian cells (2.4 x 10-6 µl/cell) 
and bacteria excreting exopolysaccharides, such as Bifidobacterium (1 x 10-6 µl/cell). 
It is therefore essential that the final volume of cell suspension is confirmed when 
calculating cell density. Displacement volumes for the strains used in the Protoblocks 
presented here are outlined in the material and methods. 
Volume of the block:  During dehydration the water content of the Protoblock is 
removed and the volume of the block significantly reduced. The cell density of the 
block in terms of volume and diameter, must therefore be calculated in dehydrated 
blocks. In addition, dehydration enhances the presence of a meniscus, which also has 
an effect on the final volume. To account for this, the volume should also be measured 
using a method designed for irregular objects. Here, the blocks were measured 
successfully with the Archimedes’ principle, wherein their volume is equal to the 
volume of water they displace. Given the small volume of the block, it is important to 
take repeated measurements and confirm the volume measurements manually using 
Vernier calliper measurement. 
Maintaining cell integrity: The accuracy of the Protoblocks as a standard is also 
determined by the cell integrity of its population. This ensures an accurate 
representation of the fixation and purification processes carried out. . In order to ensure 
cell integrity, there are 3 key aspects to consider: 1) Centrifugation must be kept to a 
minimum and adjusted to the lower speed settings (<5000 x g) to allow pelleting of 
each cell type. 2) Formalin fixation should be performed immediately after harvesting 
the cells. 3) The molten agar must be kept below 60 ℃ when embedding the cells  
Maintaining the shape of the block:  The shape of the block must be maintained during 
processing to ensure an accurate representation of the cell population throughout the 
block. This can be ensured by: 1) Using a higher concentration of agar to compensate 
for the input volume of cells, 2) Incubating the cells at 50oC for 1 min before mixing 
with the agar to prevent solidification before placing in the mould, 3) Keeping agar 
aliquots with 30 -50 µl more than the desired volume at 60oC to avoid evaporation, 
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prevent solidification of the agar during pipetting and avoid bubble formation. 4) 
Swirling the mould after depositing the mix to ensure an even distribution. 5)  
Removing any bubbles with a bacterial loop before it solidifies 6) Using filter paper 
to protect the block inside the cassette. 7) Embedding the block with the bottom face 
at the base of the block   and ensure that sections correspond to full face sections. To 
avoid oversaturating the reactions with paraffin, use smaller (2 x 2 cm) embedding 
moulds.  
Considerations during DNA isolation: Cells are embedded in an agar matrix. To avoid 
interference of the agar with column-based DNA isolation procedures, centrifuge the 
samples at 17,000 x g for 1 min before transferring to spin columns. Ensure to avoid 
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CHAPTER 3:  
Characterisation of FFPE-Induced Bacterial DNA 
Damage and Development of a DNA Repair Method 







Formalin-fixed, paraffin-embedded (FFPE) samples have huge potential as source 
material in the field of human microbiome research. However, the effects of FFPE 
processing on bacterial DNA remain uncharacterised. Any effects are relevant for 
microbiome studies, where DNA template is often minimal and sequences studied are 
not limited to one genome. As such, we aimed to (i) characterise FFPE-induced 
bacterial DNA damage, and (ii) develop strategies to reduce and repair this damage.  
Our analyses indicate that bacterial FFPE DNA is highly fragmented, a poor template 
for PCR, crosslinked and bears sequence artefacts derived predominantly from 
oxidative DNA damage. Two strategies to reduce this damage were devised - an 
optimised decrosslinking procedure reducing sequence artefacts generated by high-
temperature incubation, and secondly, an in vitro reconstitution of the Base Excision 
Repair (BER) pathway. As evidenced by whole genome sequencing, treatment with 
these strategies resulted in 3X increase in fragment length and a significant reduction 
in sequence artefacts. This translated to an increased sequencing readability. 
Application of this strategy to mammalian FFPE DNA produced similar 
improvements. 
This study provides a new understanding of the condition of bacterial DNA in FFPE 
specimens and how this impacts downstream analyses, in addition to a strategy to 





Formalin fixed paraffin embedded (FFPE) samples represent the most comprehensive 
collections of patient materials in hospital pathology archives [1-3]. These samples 
can provide access to bacterial communities inhabiting a variety of body sites for 
which access to ‘fresh’ tissue samples is limited [4, 5] due to the invasive nature of 
their sampling [6-11]. However, as has been definitively shown from analysis of 
human DNA [12], FFPE processing induces DNA damage. In mammalian DNA, this 
damage occurs as: (i) Cross-links (DNA-DNA, Protein-DNA) [13, 14], (ii) 
Depurination [15-17], (iii) DNA fragmentation [18, 19], and (iv) Sequence alterations 
(chimeras, SNPs) [20, 21], which accumulate further with storage time and suboptimal 
fixing conditions [12, 22]. This DNA damage has been found to negatively affect 
mammalian DNA sequencing outputs, by reducing: a) the sequencing depth, b) 
sequencing uniformity, c) read length, d) ratio of reads passing quality filtering; and 
increasing a) the number of chimeric reads, b) FFPE derived single nucleotide 
polymorphisms (SNPs), translocations, and insertions and deletions (indels) [12, 23-
29].  
Bacterial DNA is likely to be similarly damaged, but this is uncharacterised to date. 
The consequence of such bacterial DNA damage is that FFPE samples will have 
several associated limitations that must be considered before their effective use in 
microbiome studies. DNA fragmentation reduces the quantity of DNA fragments 
within a sample of suitable length for amplicon-based sequencing strategies such as 
16S rRNA gene sequencing (~460 bp for V3-V4 [30]). This can exacerbate the 
characteristic low bacterial biomass found in FFPE samples. FFPE-induced sequence 
alterations can decrease sequence quality and lead to false speciation events. These 
are considerable hurdles standing in the way of accurate, reproducible microbiome 
research from FFPE samples.  
All research reported to date, and protocols for purifying and repairing FFPE DNA, 
relate to mammalian (human) DNA. Differences in DNA conformation and 
packaging, methylation patterns, and replication and transcription rates, between 
human and bacteria may lead to different FFPE damage profiles [31-33]. A better 
understanding of potential differences is essential for the proper design of workflows 
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that ensure bacterial DNA quality and guarantee reliable and reproducible sequencing 
analysis [34]. No characterisation of FFPE-induced bacterial DNA damage exists to 
date. 
Assuming the existence of such damage, the Base Excision Repair (BER) pathway 
represents a promising opportunity to repair it before subjecting it to analyses. BER is 
the main cellular pathway for repair of lesions, such as damaged bases, AP sites and 
ss-breaks [35, 36]. Strategies to improve the sequencing quality of FFPE human 
samples using an individual enzyme from the BER pathway have been adopted - 
namely, Uracil DNA glycosylase [37]. In addition, commercial kits for some degree 
of FFPE DNA repair have recently become available: ‘NEB FFPE DNA Repair’ and 
‘Illumina Infinium FFPE Repair’; however, their composition is undisclosed. Despite 
such advances, there is a gap in the literature characterising DNA damage recognition 
by DNA glycosylases on FFPE samples, which is essential for designing approaches 
to reconstitute the BER pathway to repair FFPE DNA damage. To our knowledge, the 
only reports available were designed to assess the outcomes of human DNA repair 
after treatment with a commercial kit [38].  
The BER pathway can be summarised in 5 steps. i) Base excision by a DNA 
glycosylase, followed by ii) backbone excision by an AP lyase, iii) ends processing by 
a polynucleotide kinase or exonuclease, iv) gap filling by a polymerase, and v) nick 
ligation by a ligase [35, 36]. The type of DNA glycosylase determines downstream 
repair workflow. Excisions made by monofunctional DNA glycosylases are repaired 
through long-patch BER [39, 40], and excisions made by bifunctional glycosylases, 
through short-patch BER [35, 36, 39-43].  
In this study, a ‘mock’ FFPE model replicating the conditions found in clinical FFPE 
samples, was used to characterise the nature and severity of FFPE-induced damage in 
bacterial DNA, followed by development of an effective strategy for repairing it. 
Quantitative PCR and high resolution melt analysis, along with Sanger Sequencing 
were used to screen a set of available DNA repair enzymes, and shortlist those found 
most effective. These were then further tested individually and in combination, with a 
final validation of Whole Genome Sequencing (WGS) analysis used to determine the 




1. Preparation of FFPE blocks  
Bacterial growth conditions. E. coli K12 MG1655 or E. coli Nissle 1917 
carrying a P16Lux plasmid [44], were grown aerobically at 37 oC in Luria-Bertani 
(LB) medium with 300 µg/ml Erythromycin (Sigma-Aldrich). Staphylococcus aureus 
Newman (ATCC 25904) was grown aerobically at 37 oC in Todd-Hewitt broth 
(Sigma-Aldrich). Bifidobacterium longum 35624 was grown anaerobically at 37 oC 
for 24 h in MRS medium (Sigma-Aldrich). Lactobacillus amylophilus (ATCC® 
49845™) was grown in MRS medium (Sigma-Aldrich) at 30 oC in 5 % CO2 for 24 h. 
Bacteroides thetaiotaomicron (ATCC®29741™) was grown anaerobically at 37 oC 
for 24 h in FAB medium (NEOGEN, Lancashire, UK). Bacterial cultures were 
harvested by centrifugation and suspended in PBS. A 1 ml aliquot of the suspension 
was used for to count colony forming units (CFU) by retrospective plating. The rest 
was resuspended in Neutral Buffered Formalin and left to fix for 18 h at RT. 
Counting fixed bacterial cells. The cell suspension was counted using a 
bacterial counting kit for flow cytometry (Invitrogen). In brief, a 10% aliquot from the 
bacterial suspension was serially diluted to 1x 106 cells in 989 µl of NaCl. Bacterial 
cells were stained with 1 µl of SytoBC and 10 µl (1X 106) of counting beads were 
added to the suspension. Cells were counted in an LSR II Flow Cytometer (BD 
Biosciences). The acquisition trigger was set to side scatter and regulated for each 
bacterial strain to filter out electronic noise without missing bacterial cells. This value 
was approximately 800. The volume corresponding to approximately 2 x 107 CFU of 
each bacterial strain and 2.2 x 107 4T1 cells were mixed together. 
Cell culture. Mus musculus mammary gland cancer cells (4T1) were grown at 37 oC 
5% CO2, in RPMI-1640 (Sigma-Aldrich) media supplemented with 10% FBS (Sigma-
Aldrich), 100 U/mL penicillin and 100 μg/mL of streptomycin (ThermoFisher), and 
counted with a NucleoCounter® NC-100™ (chemometect, Copenhagen).   
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Fixing cells in an agar matrix. An equal volume of sterile agar (1.5X of elution 
specified by the manufacturers) pre-aliquoted and kept at 56 oC, was pipetted into the 
cell suspension and thoroughly mixed by vortexing. The mixture was pipetted into a 
sterile cylindrical mould made from a 54 x 11 mm adapter tube (SARSTEDT, Cat No. 
55.1570) and let solidify for 3 min.  Once solidified, the disk was placed in 5 ml of 
formalin for an extra 24 h for 48 h fixation blocks or immediately processed for 24 h 
fixation blocks.   
Dehydration and paraffin embedding of cell disk. Fixed cell disks were removed 
from the formalin and placed into a processing cassette. The cassettes containing the 
Protoblocks were dehydrated and paraffin embedded automatically with a LOGOS J 
(Milestone Medical, Bergamo). This protocol included 4 h dehydration with 
increasing concentrations of ethanol, clearing with 2 x washes of xylene and 3 x 
washes of isopropanol. Finally, the blocks were embedded in paraffin for 8 h and 32 
min at 62 oC. . Once paraffinised, the Protoblocks’ volume, diameter and height were 
measured with a calliper and by volume displacement [45]. Processed Protoblocks 
were placed in a 1.5 x 1.5 cm embedding mould and mounted to a processing cassette.   
Sectioning. Blocks were sectioned keeping an aseptic technique either at 4 µm for 
imaging or at 15 µm for DNA purification. The cell load of each slide was calculated 
by dividing the total bacterial load by the volume of each slide.  
Immunofluorescence and histochemistry. Cell integrity was evaluated with Gram 
staining (Sigma-Aldrich) or H&E staining with Mayer’s haematoxylin (Sigma-
Aldrich). Bacterial counts were confirmed in 3 sections stained with DAPI, 1:50 α-
E. coli  (Abcam, 137967), or 1:400 α-S. aureus (Abcam, 20920), and counterstained 
with either Alexa Fluor 488 (Jackson Immunoresearch Laboratories Inc., USA) 
donkey anti-rabbit Ig. Stained sections were mounted in ProLong Gold antifade 
reagent with DAPI (Invitrogen, UK).  Gram-stained sections were counted in bright 
field using an Olympus BX51 microscope, with a 100X lens. Immunofluorescent 
stained slides were counted at 20X (4T1 cells) or 60X (bacteria) with a fluorescence 
microscope (Evos FL Auto). For each slide, at least 20 randomly selected fields of 
view were counted. The area of the field of view (FOV) was recorded using the 
microscope’s software and used to calculate the volume counted.  
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2. DNA Analysis 
DNA Purification. For purifying DNA from Protoblocks, unless specified, 10 x 15 
μm sections aseptically collected sections were deparaffinated with 2X xylene washes 
and processed following procedures specified in the QIAGEN FFPE DNA kit protocol 
(Qiagen Inc., Valencia, CA, USA). DNA was eluted in Tris-HCL buffer and quantified 
with a Qubit™ dsDNA HS Assay Kit (Invitrogen, USA). For non-fixed bacteria, 
bacterial cultures were grown to an OD600 of 1. 2 ml aliquots were processed following 
procedures of the GenElute™ Bacterial Genomic DNA Kit Protocol with Lysozyme 
and Lysostaphin (Sigma) and eluted in 50 µl of Tris-HCl. In all cases, DNA was stored 
at -20oC until further analysis. 
Quantitative PCR. For quantitative qPCR, reactions were prepared using LUNA 
Universal qPCR (NEB, Ipswich, MA, USA) and 0.25 µM of each primer (sTable 1). 
The thermal profile included an initial denaturation of 1 min at 95 oC, and 40 cycles 
of denaturation at 95 oC for 10 sec, annealing for 15 sec at the primers’ optimal 
temperature [54-56oC] (specified by NEB’s calculator for Hot Start Taq) and 20-40 
sec of extension at 68 oC (20 sec for 200bp amplicons and 40 sec for 400-500 bp 
amplicons).  
High-fidelity quantitative PCR reaction setup. Reactions were prepared using 
NEBNext-Ultra II Q5 Master Mix, 0.5 µM of each primer (sTable 1), 1.25 µM 
EvaGreen Dye (Biotium, CA, USA) and 37.5 nM ROX (Biotium, CA, USA) as a 
reference dye. The thermal profile included an initial denaturation of 30 sec at 98 oC, 
and 40 cycles of denaturation at 98 oC for 10 sec, annealing for 15 sec at the primers’ 
optimal temperature [64-67oC] (specified by NEB’s calculator for Q5 High-Fidelity 
Master Mix) and 20-40 sec of extension at 72 oC (20 sec for 100 – 200 bp amplicons 
and 40 sec for 400 – 500 bp amplicons).  
Quantitative qPCR assays parameters. Amplification was performed in an 
AriaMx (Agilent Technologies, USA) using DNA binding dye absolute quantitation 
experiment type. Each assay included triplicates of 5 points standards using log-
dilutions of a 107 copies gene block, designed upon a species-specific genetic region. 
Primers targeting these regions and maintaining a similar Tm (+/-2oC) were designed 
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using the NCBI primer design tool and their parameters (ΔG, hairpins and dimers) 
verified using IDT’s Oligo analyser tool. Primers and gene-blocks were acquired from 
IDT (Coralville, USA) (see sTable 1). qPCR efficiencies between 95% and 105% and 
R-square values higher than 0.995 were deemed as acceptable, all samples were ran in 
triplicate. 
High-Resolution Melt (HRM) Curve Analysis. For melt curve analysis, it was 
essential to first normalise the amplifiable DNA fraction of samples tested. To achieve 
this, a quantitative qPCR was performed for fragments of the same length. The 
measured copy-numbers obtained by qPCR, were used to normalise the samples to 1 
x 106 copies/µl. 20 µl reactions were prepared using 1X NEB Luna probe qPCR mix, 
1.25 µM EvaGreen Dye (Biotium, CA, USA), 37.5 nM ROX as reference dye, 0.25 
µM of each primer and 2.5 µl of copy-number normalised template DNA. E. coli 
primers rendering amplicons of 100, 200 and 500 bp were used for this assay (sTable 
1). The amplification of the analysed target region was first amplified as specified for 
absolute quantitation, but included a final 2 min at 68oC extension step. This was 
followed by high-resolution melt (HRM) analysis set to read fluorescence every 0.2 
oC with a 10 sec soak time from 65-95 oC. All experiments were performed using an 
AriaMx thermocycler (Agilent Technologies). 
Here, normalized fluorescence (Rn) obtained every 0.2oC, across the temperature 
gradient (65-95 oC) was used to monitor the melting temperature (Tm) profile of the 
template. Changes in the Tm profile are indicative of changes in the template 
sequence. To better observe this changes, the Tm profiles were plotted on a Tm 
difference (ΔTm) plot, where the Tm difference is represented by the deviation of the 
recorded Rn values of a Test plotted against those recorded for a non-fixed reference, 
for which the ΔTm is 0. Therefore, ΔTm = Rn Test – Rn of reference. Here where 
aberrant profiles that differ from the NF DNA with ΔTm <0.1oC are typical of FFPE 
DNA, and are indicative of low-level, non-identical changes randomly distributed 
across the template [46]. Therefore, in these plots a lower ΔTm, is indicative of a 
reduced/lower number of sequence artefacts in the template. Raw Tm values were 
extracted from the AriaMx software and analysed in R environment, v3.4.4.  
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Sanger sequencing. Sanger sequencing was performed on 500 ng of purified and/or 
treated DNA for each replicate on the same genomic regions analysed by qPCR. 
Sequencing was performed by Eurofins Genomics. 
WGS sequencing library preparation. For NF controls, DNA from bacterial cultures 
of Escherichia coli MG1655 and S. aureus Newman were grown as per section 1 to 
and OD600 of 1 and their genomic DNA purified using the GenElute™ Bacterial 
Genomic DNA Kit Protocol with Lysozyme and Lysostaphin (Sigma). For FFPE 
bacteria, DNA from Protoblocks containing either strain was purified using the 
QIAGEN FFPE kit plus specified treatment. In all cases DNA was eluted in 50 µl of 
Tris-HCl. Total purified DNA and/or repaired DNA was sent to GENEWIZ (Leipzig, 
Germany) where WGS was performed using 2 x 150 bp chemistry on an Illlumina 
HiSeq.  
 
3. Optimising cross-link reversal 
As described in Chapter 1, section 3, the product of the interaction of HCOH and 
biomolecules is the formation of crosslinks. These are ubiquitous in FFPE samples, 
and occur more frequently between dG and amino acids Lys and Cys in the form of 
DPCs [47, 48]. DPCs inhibit DNA amplification by blocking the processivity of DNA 
polymerases, terminating primer extension [49]. Despite their high prevalence in 
FFPE samples, it has been demonstrated that HCOH crosslinks are reversible. This 
reverse reaction is heat dependent [13], and can be assisted by pH, salt concentration 
and the incorporation of quenchers [50-52]. Heat treatment for decrosslinking, is 
essential for FFPE DNA purification and all available protocols and kits for FFPE 
DNA purification incorporate it, typically as a 1h incubation at 90oC [14]. However, 
recent studies have found this high temperature incubation detrimental to DNA and 
shown that upon a reduction of temperature or time of decrosslinking, the appearance 
of sequence artefacts was reduced, although also reducing the amount of sequencing 
reads (decrosslinked DNA) [21, 24]. Thus, optimising the reaction conditions to allow 
lower incubation temperatures with equal decrosslinking yields, would reduce the 
adverse effects produced by high temperature incubation. 
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Temperature-point experiments.  10 x 15 µm sections from blocks loaded with 
108 E. coli and S. aureus cells fixed for 24 h and stored for 3 months were distributed 
into 12 x 1.5 ml tubes. The deparaffinated and digested contents were pooled and 
distributed into 24 experimental replicates, 6 replicates per temperature point tested 
(90oC, 80oC, 72oC and 65oC). For temperature points 90 oC and 80 oC, incubation time 
was set for 1 h and for 72 oC and 65 oC it was set for 2 h. After decrosslinking, the 
DNA content was purified with the QIAGEN FFPE protocol. 
Cross-link reversal buffer. Lysis buffers tested for crosslink reversal were TB1 (50 
mM Tris-HCL (pH 8.0), 30 mM EDTA, 800 mM GuHCL, 0.5% Triton-X, 0.5% 
Tween-20), TB2 (50 mM Tris-HCl (pH 8.2), 100 mM NaCl, 1 mM EDTA, 0.5 % 
Tween-20, 0.5% NP40, 20 mM DTT) and TB3 (50 mM Tris-HCl (pH 8.0), 100 mM 
EDTA (pH 8.0), 100 mM NaCl, 1% SDS). 10 x 15 µm slides from blocks loaded with 
108 E. coli and S. aureus cells fixed for 24 h and stored for 3 months were used per 
experimental replicate (6 per buffer tested). The samples were lysed and digested in 
the experimental buffer at 56 oC for 1 h and decrosslinked at 80 oC for 1h. After testing 
for decrosslinking buffers, an equal volume of buffer AL (column binding buffer) was 
added to the reaction and the DNA content purified following the QIAGEN FFPE kit 
protocol.  
Verifying cross-link reversal strategy. A total of 10 x 15 µm slides from blocks 
loaded with 108 E. coli cells fixed for 48h and stored for 1 year were used per 
experimental replicate (6 per test). After decrosslinking, the DNA content purified 
with the QIAGEN FFPE kit.  
4. DNA repair 
Treatment with individual glycosylases.  DNA purified from FFPE blocks loaded 
with 108 E. coli cells fixed for 24h or 48h was pooled and its concentration measured 
and normalised across tests. Aliquots with equal DNA concentration were used for 
each experimental replicate. All enzymes tested were acquired from NEB (Ipswich, 
MA, USA) and the verified enzyme activity provided by the supplier used to calculate 
amount of enzyme input. To calculate the enzyme input per ng of E. coli K12 MG1655 
DNA, E. coli genomic data in sTable 2 was used. 
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For this, enzymatic activity was first normalised in terms of number of damaged 
nucleotides or lesions repaired by an enzyme unit in a standard 30 minutes reaction. 
An estimate of 0.05 – 0.1 % of damaged bases in FFPE DNA was used as a baseline. 
With this information, the number of damaged bases was first calculated per ng of 
DNA in the reaction and the enzyme units required to repair this damage. The units of 
enzyme used were optimised to fit the activity in a universal buffer and after titration 
experiments.  The final units used in the reaction and the number of bases corrected 
per ng of E. coli DNA are listed in sTable 3. 40 µl reactions were set-up using a total 
of 400 – 1,000 ng of bacterial DNA. The reactions were run at 37 oC for 30 min, after 
which enzymes were heat-inactivated with incubations specified in sTable 3. Treated 
DNA was cleaned using the Monarch PCR & DNA Clean-up Kit (NEB, USA). DNA 
concentration was measured with QUBIT (Invitrogen) and normalised DNA quantities 
analysed by quantitative PCR or HRM.  
Assembling Base Excision Repair reaction.  
Buffer: The BER pathway was reconstituted in a final buffer with 1X NEB CutSmart 
buffer (50 mM Potassium acetate, 20 mM Tris-Acetate, 10 mM Magnesium acetate 
and 100 µg/ml of bovine serum albumin, pH 7.9), supplemented with 100 µM of 
dNTPs, 50 µM of NAD+ and 2 mM of DTT. Enzyme efficiency in this buffer was 
analysed by comparing its activity with the buffer provided by the manufacturer. The 
compared enzyme activity was used to adjust the enzyme units used for the BER 
reaction.  
Repair of excised bases: The repair of excised bases was accomplished with long 
(UDG) and short patch BER (FPG, Endo VIII), by incorporating the downstream 
enzymes that repair blocked ends (PNK) or AP sites (Endo IV), plus DNA polymerase 
and DNA ligase (sTable 4). The reactions were prepared with the buffer described 
above, using normalised DNA quantities and carried out at 37oC for 30 min. The 
reactions were stopped with the addition of 2X volumes of Agencourt AMPure XP 
magnetic beads (Beckman Coulter, IN, USA) for DNA clean-up. Following the 
manufacturer’s instructions, DNA was washed twice with 80% ethanol and eluted in 
36 µl of Tris-HCl. DNA concentration was again measured for each reaction and 
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normalised DNA quantities were used for quantitative PCR, HRM, or by Sanger 
sequencing.  
BER with combined glycosylases. These reactions were setup and carried out as 
described for BER reactions using only one glycosylase, with the difference that these 
reaction also included the downstream lesion repair enzymes (Endo IV and PNK) 
specified for the sub-pathway triggered by the glycosylases included. The reactions 
were analysed by HRM, Sanger sequencing and WGS. 
 
5. Bioinformatics and statistical analysis 
qPCR data analysis.  Statistical analysis performed in the base R environment 
(v3.6.1). Visualisations were carried out using the ggplot2 package (v3.2.1). 
Sanger sequence analysis. The effect of DNA repair enzymes on DNA sequence 
length and readability was assessed by Sanger Sequencing. The ratio of clipped 
sequence length to unclipped sequence length between samples was compared to 
elucidate this. Statistical analysis performed in the base R environment (v3.6.1). 
Visualisations were carried out using the ggplot2 package (v3.2.1). 
WGS sequence analysis. All metrics relating to sequence data were calculated in 
the Linux environment, and using the QUAST tool (v5.0.2) and statistical analysis 
performed in the base R environment (v3.6.1). Visualisations were carried out using 
the ggplot2 package.  
Method for variant calling: 
Filtering: HiSeq sequence data was quality filtered. Only very high quality bases were 
considered to minimise the risk of sequencing errors causing false positive variants. 
Short fragments were also removed to reduce the likelihood of spurious alignments of 
regions from contaminant bacterial genomes. Trimmomatic (v0.38) was used to 
remove all reads shorter than 60bp in length, and to trim reads when the average per 
base quality in a sliding window of size 4 dropped below 30.  
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Alignment: Of the three possible Burrows-Wheeler alignment tools, the BWA-mem 
aligner was used as the average read length was 150bp, and BWA-mem (v0.7.17) is 
recommended when reads are over 70bp in length. Default settings were used with the 
exception of allowing alignments with a minimum score of 0, rather than the default 
30. Given the stringent parameters used for read length and quality filtering, relaxing 
the minimum alignment score gave the best possible chance of variant detection.  All 
samples were aligned to the original reference genomes. 
Variant Calling: Variant calling was done with BCF tools, using the BCF call function. 
The variants were then filtered using the norm and filter functions within BCF tools. 
Filtering was done to remove variants when the read depth was below 10, the quality 
was below 40, or when the variant identified was not supported by both the forward 
and reverse read of a read pair.  The number of variants identified was then normalised 
between samples based on the read coverage in the initial alignment BAM file.  
Validation: Using the Picard tool within the GATK suite, all samples were down-
sampled to ensure SNP: Coverage ratio remained constant when coverage was reduced 







1. Characterisation of bacterial FFPE DNA damage 
Measuring fragmentation of PCR readable DNA: The length of PCR-readable 
fragments from bacterial DNA subjected to FFPE treatment was measured by 
quantitative PCR. Targeting a 525 bp chromosomal region, primers were designed to 
amplify DNA fragments of lengths 200bp, 300 bp, 400 bp and 500 bp. Template DNA 
was purified from FFPE blocks loaded with 1 x 108 E. coli cells, fixed for 48 h and 
stored for > 6 months. Each qPCR reaction was loaded with 5 ng of DNA, 
corresponding to 1 x 106 CFU. As seen in Figure 1a, the quantity of amplifiable DNA 
is significantly reduced after FFPE treatment. For non-fixed (NF) DNA, the 
amplification of PCR-readable fragments is almost 100 %, and is independent of 
fragment size, whereas a log-fold reduction of amplifiable DNA is observed for even 
short (200 bp) fragments of FFPE DNA (p < 0.001). Importantly, this becomes more 
pronounced as fragment length increases, with significant correlation between 
reduction in the quantity of amplifiable DNA and fragment length, leading to a log-
fold reduction in amplifiable DNA quantity between 200 bp and 500 bp fragments (p 
<0.001). 
Assessing the extent of formaldehyde cross-links in FFPE bacterial DNA: The 
presence and frequency of formaldehyde crosslinks present in bacterial DNA was 
assessed by comparing the quantity of amplifiable DNA obtained after performing or 
omitting a crosslink reversal incubation on paired-samples (n = 6), ), a strategy 
resembling the straightforward FAIRE method [13]. As can be seen in Figure 1b, 
crosslinking was evident regardless of fragment size, with an 18.5 (500 bp) – 30 (200 
bp) fold increase in amplifiable DNA observed after crosslink reversal, indicating that 
95% –97% of the amplifiable DNA in the sample held crosslinks that inhibited its 
amplification. 
Evaluating the presence of damaged nucleotides: The presence of damaged bases in 
bacterial FFPE DNA was investigated by subjecting FFPE-DNA to the activity of 
DNA glycosylases targeting base oxidation, deamination and carboxylation with 
enzymes listed in sTable 3. DNA lesions resulting from DNA glycosylase activity (AP 
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sites and 3’P) [36, 39], inhibit amplification [53]. Therefore, DNA glycosylase activity 
can be measured by comparing the quantity of amplifiable DNA in a sample after 
treatment/no treatment with a DNA glycosylase, with a decrease in amplification 
implying the presence of the targeted DNA damage. As seen in Figure 1C, a decrease 
in amplifiable DNA was noticeable in concentration normalised samples after 
treatment with all glycosylases, with the highest activity observed for UDG and FPG 
as indicated by the 35% – 50% and 67 – 80% reduction in the recovery of PCR 
readable DNA fragments after treatment (p < 0.001) (Figure 1c). It should be noted 
that Endo VIII activity is not measurable by this PCR analysis, as lesions targeted by 
this enzyme (hydantoins) are PCR inhibitory, thus, the removal of this damage would 
not have any effect on the amount of amplifiable DNA template. [54].  
Assessment of DNA sequence quality by sequencing: Overall DNA damage is reflected 
in the outputs of sequencing. Damaged bases and single strand breaks present as 
sequencing misreads, such as chimeras, indels and SNPs that lead to poor quality 
reads, which will be routinely filtered out prior to analysis. As seen in Figure 1d, a 
significant decrease in high-quality, sequencing-readable DNA was observed in both 
Sanger sequencing and WGS, for FFPE samples compared with their paired NF 
samples. This was accentuated by prolonged DNA fixation, where the reduction of 




Figure 1. Analysis of DNA damage.  
a) Measuring fragmentation of PCR-amplifiable DNA. For NF bacteria, amplification of all 
fragment lengths was equal and grouped in the same box (n = 28). For FFPE bacteria (n = 
24 for each box), a linear fragment-length correlation is evident, with a log-decrease observed 
from NF to FFPE 200bp fragments and a log-decrease between short (200bp) and long (500 
bp) fragments (P < 0.001).  
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b) Assessing the extent of cross-links in bacterial DNA. DNA from FFPE blocks containing 
E. coli cells was subjected (n = 6) or not (n = 6) to a high temperature crosslink reversal 
treatment. The bar-plot shows the quantity of amplifiable DNA obtained +/- crosslink reversal 
for long and short DNA fragments. Without decrosslinking, only 3 - 5% of the available DNA 
template is amplifiable for PCR. 
c) Evaluating the presence of damaged nucleotides via glycosylase treatment. Box plots 
show the quantity of amplifiable DNA post treatment with the respective glycosylase (n = 6 in 
all cases).  
d) Assessment of DNA sequence quality by sequencing. (i) Sanger sequencing showing the 
percentage DNA falling within the high-confidence read region for each sample. (ii) Whole 
genome sequencing showing the number of quality filter pass reads for FFPE and NF 
bacteria.  
 
2.  Development of a DNA repair strategy 
Having characterised the nature of FFPE-induced damage to bacterial DNA, an 
appropriate repair strategy was devised, as outlined in Figure 2. 
 
Figure 2. Summary of strategies applied for improving integrity, quantity and 
quality of bacterial DNA derived from FFPE samples.  
(a) Exposure of DNA to denaturing temperatures (90 oC) aids decrosslinking, but increases 
the rate of depurination and ss-break events that lead to the formation of ss-DNA regions 
known to favour the misincorporation of nucleotides (A – rule) or generate sequence chimeras. 
Therefore, milder decrosslinking reactions will reduce the rates of these occurrences.  
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(b) The FFPE process damages DNA bases. The removal of damaged bases by glycosylases 
improves the quality of readable DNA by removing from the PCR pool damaged template that 
would otherwise lead to misincorporation of bases leading to SNPs. The product of either 
glycosylase treatments are AP sites (UDG) or 3’ blocked ends (FPG, Endo VIII) that block 
polymerase activity.  
(c) These blocking artefacts are repaired by either an AP endonuclease (AP sites  Endo 
IV), leaving a 3’OH and 5’dRP, or a Phosphokinase (3’P  T4 PNK), leaving a 3’OH and a 
5’P. Only when ends are repaired (3’ OH and 5’ P / 5’dRP) is the DNA repair polymerase (Pol 
I) able to incorporate nucleotides that are subsequently sealed with a high fidelity DNA ligase 
(E. coli DNA ligase). 
 
Optimisation of decrosslinking  
Crosslinks block polymerase processivity, reducing yields of PCR readable DNA [49]. 
Formalin induced crosslinks are reversible upon heat exposure and all available FFPE 
DNA preps include a high-temperature (decrosslinking) incubation step [13]. 
Recently, it has been shown that this incubation, despite improving PCR yields, 
reduces DNA sequence quality and fragment length [21, 24], making it unsuitable for 
microbiome research of FFPE samples. For this reason, we aimed at investigating 
strategies that reduce heat-exposure in order to find the optimal balance that improves 
the output DNA sequence quality without significantly affecting its yield.  
Temperature: The effect of decrosslinking temperature on the yield of amplifiable 
DNA was investigated by quantitative PCR in DNA extracted from FFPE blocks 
loaded with Staphylococcus aureus (Figure 3ai) and E. coli (Figure 3aii), fixed for 24 
h and stored for 3 months. Reactions were loaded with 106 copies of template and 
incubated at 90 oC for 1 h (reference protocol = industry standard mammalian DNA 
isolation from FFPE tissue), 80oC x 1 h, 72 oC x 2h or 65 oC x 3 h.  Compared with 
the reference 90 oC (QIAGEN protocol), no significant difference in amplification of 
PCR readable DNA was observed at 80 oC for both bacteria (p > 0.05), while a 4X (E. 
coli) and a 10X (S. aureus) decrease in the amount of PCR readable DNA was evident 
at both 72 oC and 65 oC (p <0.001). In this case, PCR amplification is indicative of the 
template fraction that was efficiently decrosslinked.  
Buffers : The ability of three protein lysis buffers (also used for protein digestion) in 
setting conditions (pH, ionic strength, enthalpy disruption) that facilitate 
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decrosslinking at 80oC were examined: Test Buffer 1 (TB1) – based upon the protein 
denaturing properties of chaotrophic agents (Guanidine hydrochloride); Test Buffer 2 
(TB2) – Denaturing proteins with a reducing agents (DTT); Test Buffer 3 (TB3) – 
relying on the denaturing properties of an ionic detergent (Sodium dodecyl sulphate). 
Decrosslinking with the three buffers was tested against the reference buffer (Buffer 
ATL, Qiagen FFPE Kit) at 80 oC x 1 h. The effect of each buffer upon decrosslinking 
efficiency was assessed quantitatively by comparing the quantity of amplifiable DNA 
recovered after treatment. Contents of FFPE slides loaded with E. coli and S. aureus 
cells were suspended in each buffer (n = 6). Purified DNA was subjected to qPCR for 
amplification of a 500 bp fragment. TB1 and ATL buffer displayed the highest yield 
(p > 0.05), significantly higher than TB2 (p < 0.05) and TB3 (p <0.01); (Figure 3b). 
Evaluating DNA sequence quality of optimised strategy: The optimised strategy 1 
h at 80 oC in TB1 was tested against the standard protocol 1 h at 90 oC in QIAGEN 
ATL Buffer for its capacity to decrosslink DNA, indicated by the yield of 500 bp PCR 
products (Figure 3ci), and the sequence quality of the fragments yielded (Figure 3cii, 
iii). This was tested in DNA sourced from FFPE blocks loaded with E. coli fixed for 
48 h and stored for 1 year (representing maximum damage conditions). For 
quantitative analysis, reactions were loaded with normalised DNA concentration. For 
qualitative analysis, reactions were loaded with 106 amplifiable copies of the DNA 
fragments. As shown in Figure 3c (i), with the new strategy, the yield of amplifiable 
DNA did not differ significantly from that of the QIAGEN protocol. However, the 
sequence quality of DNA recovered was improved with the new strategy. As seen in 
Figure 3c (ii), the melting temperature (Tm) of samples treated with the new strategy 
was less variable and closer to that of paired-NF DNA, exhibiting a Tm difference 
[ΔTm (%)] of 2.82 (not significant), versus 3.02 (p < 0.05) for the QIAGEN protocol.  
This was further explored with HRM (detailed in methods), where aberrant profiles 
(from that of NF DNA) are indicative of sequence aberrations typically found FFPE 
DNA [46]. ΔTm plots in Figure 3ciii, show that the ΔTm for samples decrosslinked 
with the new strategy (ΔTm (%) = 3.5) is significantly lower than that of the QIAGEN 
protocol (ΔTm (%) = 6.1) (p < 0.05). This indicates that with the new strategy, without 
compromising DNA yields, the sequence quality of decrosslinked template is less 




Figure 3. Optimising a decrosslinking strategy.  
a) Temperature. The bar plots shows the recovery of 500 bp PCR readable DNA fragments 
after testing 3 crosslink reversal incubations (blue, for each bar n = 6) against a reference 
(90oC) incubation  (grey, n = 6).  
b) Buffer. Three buffers were tested against the reference buffer (ATL) at a 90oC x 1h 
incubation. The amount of amplifiable DNA measured by qPCR of a 200 bp fragment in E. 
coli and S. aureus (for each bar n = 6).  
c) Evaluating the optimised strategy. The quantity of amplifiable DNA (i) and the sequence 
quality of DNA (ii, iii) was assessed for a 500 bp DNA fragment. The performance of the 
optimised protocol (blue) was measured by comparing with the reference protocol (90oC with 
ATL buffer) (grey). Box plot (i) shows the absolute quantity of amplifiable DNA from template 
DNA with normalised concentration (n=6 for each box). In box plot (ii), the Tm of the tested 
conditions (n=6 for each box) is compared with that of NF DNA (orange, n =6). The Tm 
difference (ΔTm) between the test and NF DNA is indicated above each box. (iii) HRM plot – 
ΔTm of tests plotted against the Tm of NF sample (orange), with average ΔTm from NF shown 
above each plot (n= 6 for each line). 
 
DNA glycosylases reduce sequence alterations in FFPE DNA  
After examining their activity on FFPE DNA (Figure 1c), the effect of treatment with 
DNA glycosylases on DNA sequence quality was assessed by: a) Tm analysis, b) 
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Sanger sequencing, and c) HRM. For Tm analysis and HRM, all reactions were loaded 
with 1 x 106 genome copies of DNA sourced from FFPE blocks loaded with E. coli 
and set to amplify 3 x 100 bp fragments (Figure 4a and sFigure 1). For all the regions 
analysed, the Tm of samples treated with glycosylases significantly changed from 
FFPE untreated samples (p < 0.001) and came closer to resemble that of the NF 
reference. This was further assessed by HRM, by comparing the melting profile of a 
200 bp fragment (as explained in figure 3 and methods). As seen in Figure 4c, the 
plotted ΔTm (from paired-NF) of glycosylases treated FFPE DNA was found to be 
much lower than that of untreated FFPE DNA. The same effect was evident with 
Sanger Sequencing (Figure 4b), where treatment with DNA glycosylases significantly 
improved (p < 0.001) the number of high-quality reads recovered, increasing the 
readability of DNA to levels no longer significantly different from NF DNA. 
 
Figure 4. DNA glycosylases reduce sequence alterations in FFPE DNA. The 
reduction of sequence alterations in FFPE DNA (fixed for 48h) by treatment with the selected 
glycosylases was confirmed by: a) Analysis of their melting temperature (Tm) (n = 6 for each 
box). b) Sanger sequencing readability (n = 3 for each box). c) HRM (n = 6 for each line). In 
all tests performed, treatment with DNA glycosylases improved the amplifiable sequence 




Development of an in vitro Base Excision Repair system 
For the in vitro reconstitution of the BER pathway, a suitable universal buffer was 
sought and tested by examining enzymatic activity for each enzyme (see Methods) 
and compared with activity in their recommended buffer (see sFigure 2). Optimisation 
of enzyme and co-factor quantity usage was then performed (sTables 3 and 4).  
First, the BER pathway was reconstituted for single repair pathways triggered by a 
single DNA glycosylase, with units and enzymes listed in Table 2 and 3, and its 
performance tested by HRM analysis. Figure 5a shows the HRM plots of DNA 
exposed to the BER pathway reconstituted for FPG, UDG or Endo VIII. As explained 
in methods, the more similar a DNA sequence is to the NF reference, the lower the 
difference in melting temperature (ΔTm closer to 0). As seen in Figure 5a, exposure 
of DNA to each reconstituted BER pathway led to a reduction in ΔTm in FFPE DNA 
and an increase in the quantity of PCR readable template (sFigure 3) suggesting a 
reduction in the frequency of sequence artefacts. The frequency of sequence artefacts 
observed after treatment was more effective for the FPG driven BER reaction, with a 
~50% decrease in ΔTm observed for untreated samples, this was followed by Endo 
VIII with a ~31% reduction and finally UDG with a ~14% decrease in the ΔTm. These 
results indicate that BER was reconstituted correctly and that these reconstituted 
pathways effectively corrected sequence artefacts without reducing the PCR readable 
template.  
Subsequently, the reconstitution of a BER system able to target different types of DNA 
damage found on FFPE samples was addressed by mixing the pathways for the 
glycosylases treated in the system. Since FPG-BER (Figure 5a) yielded the best results 
for single glycosylase-BER reactions, this enzyme was combined with ENDO VIII 
and/or UDG and their efficiency in reducing sequence artefacts tested by HRM. As 
shown in Figure 5b, all combinations resulted in sequences with ΔTm lower than those 
of untreated FFPE DNA. The FPG + UDG mix showed the best performance at 
reducing the ΔTm (31 %), followed by FPG + Endo VIII (18 %). However, in terms 
of improving the PCR readability of a 500 bp fragment, FPG + Endo VIII (47% 
increase, p < 0.01) outperformed FPG + UDG (30% increase, p < 0.01), as measured 
by Taq qPCR. This effect was confirmed by high-fidelity qPCR (providing a more 
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stringent discrimination of damaged and repaired sequence), where FPG + UDG 
showed a 20% increase and FPG + UDG only a 4% increase of amplifiable DNA 
(sFigure 4). To confirm these results, a normalised DNA quantity from 6 replicates for 
each BER mix and 6 unrepaired samples were pooled into one (n = 6) and sent for 
analysis by WGS (Figure 5c). At this level of resolution, it is evident that the repair 
mix with FPG + Endo VIII offered the highest improvements in sequence quality in 
terms of providing (i) a coverage 4X higher than unrepaired, (ii) 4X more total reads 
and quality filter (QF)-passed reads, and (iii) a 50% reduction in the number of variants 
detected per sequence coverage. This repair mix was thus selected as the best repair 
mix for bacterial FFPE DNA. 
 
Figure 5. Reconstitution of BER pathway repairing FFPE DNA damage.  
a) Single glycosylase BER. The BER pathway was reconstituted first as single pathways 
triggered by either UDG, FPG or Endo VIII. The efficiency of each system in correcting DNA 
damage was tested by HRM (n = 7 for each line). The more similar a DNA sequence is to the 
NF reference, the lower the difference in melting temperature (ΔTm closer to 0). FPG showed 
the highest efficiency in correcting FFPE DNA damage as evidenced by the lowest ΔTm of 
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0.054. b) Multiple glycosylase BER. Mixes containing FPG show improved sequence quality 
as evidenced by reduced ΔTm vs untreated. c) WGS. To further confirm these results, 6 
replicates treated with each mix were pooled (n = 6) and analysed by WGS. Data validated 
that all mixes improved the sequence (i) coverage, (ii) number of reads and QF passed reads 
and reduced the amount of SNPs (iii). The best performance in all cases was observed in the 
BER mix with FPG and Endo VIII.  
Analysis of combined decrosslinking and BER treatment  
The sum of the above treatment strategies (decrosslinking and DNA repair), was tested 
by WGS in DNA sourced from FFPE blocks containing a mix of 5 bacterial strains, 
fixed for 48 h and stored for 2 months. DNA was decrosslinked at 80 oC with TB1 
(methods) and repaired with the FPG + Endo VIII-BER repair mix. The results of this 
were compared with those obtained from paired-samples treated with the reference 
protocol (decrosslinking at 90 oC with QIAGEN ATL buffer, without DNA repair), 
and NF DNA obtained from equal cell contents. Experimental replicates were pooled 
(n = 6) and sent for WGS analysis. Results for this analysis are shown in Figure 6 
and sFigure 5. The results obtained from exposing bacterial FFPE DNA to the 
proposed new protocol indicate that bacterial FFPE DNA treated with the proposed 
method shows an improvement in integrity, readability, and sequence quality, as 
evidenced by: (i) Integrity [Average fragment length (a, b)]: Plotted in Figure 6a, are 
the average fragment lengths measured with a fragment analyser. Fragment length of 
DNA treated with the new protocol (444 bp) is 3.3X longer than that treated with the 
reference protocol (decrosslinking at 90 oC with QIAGEN ATL buffer, without DNA 
repair) (136 bp). Importantly, this raises the average fragment length to that of 
fragments typically desired for 16S sequencing (460 bp). The same effect was 
observed in the length of fragments read by WGS, where fragment lengths were 2-3 
bp longer on average (Figure 6b). (ii) Readability: With the new protocol, the number 
of Total Reads and (QF)-pass reads per layer of coverage were increased by 24% and 
34% respectively, and the ratio of QF-passed to Total reads increased by 8.4%. (iii) 
Sequence quality: This was measured in terms of number of sequence artefacts 
detected. The number of chimeric reads per coverage detected in samples treated with 
the new protocol was reduced by 57 % (p = 0.37) (Figure 6e). Similarly, the number 
of SNPs detected was reduced by 58% (p = 0.41) (Figure 6f and sFigure 5) in all strains 
tested. Despite the reduction in SNP’s being uniform across all strains tested, FFPE 
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was found to produce a different SNP profile in Gram positive bacteria vs Gram 
negative bacteria (sFigure 6), which warrants further investigation.  
Similar improvements in DNA quality and quantity to those shown in bacterial DNA 
were also obtained for the mammalian cell line used (4T1), where a 21% decrease in 
the amount of SNPs per layer of genome coverage and a 65% increase in the breadth 
of genome coverage was observed in the DNA treated with the proposed method 
(Figure 7). All of these findings are coherent with results from quantitative PCR and 
Tm analysis. Although these improvements are not supported by statistical 
significance, given the considerable effect size, we are confident that this lack of 
significance is due to sample size alone. Altogether, the sum of strategies proposed 
here were thoroughly investigated by PCR/sequencing. These results consistently 
indicate an improvement in the sequence integrity, readability and quality of readable 
bacterial FFPE DNA.   
 
Figure 6. Combined protocol – bacterial DNA.  
Outputs of Bioanalyser and whole genome sequencing for bacterial FFPE DNA exposed to 
the combined treatment (blue, labelled as New Protocol, n = 6). This was compared with 
that obtained from 6 pooled paired-samples decrosslinked with the reference protocol (90oC, 
ATL) and unrepaired (grey, Labelled reference protocol, n = 6) and that from DNA obtained 
from NF samples with the same bacterial and DNA content (orange, Labelled NF, n = 3). 
Improvement in DNA readability, sequence quality and integrity was measured by: Integrity 
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(fragment length): (a) fragment analyser (b) WGS. Readability: (c) Quantity of reads and 
filter pass reads per coverage. (d) % Breath of genome coverage. Sequence quality: (e) 
Number of chimeric reads per layer of coverage. (f) Number of SNPs per layer of coverage. 
Improvements in DNA quality and quantity were also obtained for mammalian DNA 
(4T1), where a 21% decrease in the amount of SNPs per layer of genome coverage 
and a 65% increase in the breadth of genome coverage was observed in the DNA 
treated with the described method, although not supported by statistical significance.  
 





To our knowledge, this is the first such study in prokaryotic DNA, where an 
understanding of effects of FFPE on DNA, and impact on downstream analyses is 
arguably even more important. Our results show bacterial FFPE DNA to be a poor 
PCR template, with a log-fold reduction in the recovery of DNA fragments. This can 
be at least partially attributed to DNA fragmentation, since an inverse correlation 
between fragment size and PCR readability was shown (Figure 1a), culminating in a 
log fold reduction in recovery between 200 bp and 500 bp fragments.  
Crosslinks were found to be ubiquitous in FFPE bacterial DNA (Figure 1b), and 
potentially more prevalent than in FFPE human DNA, based on previous research [12, 
24]. Current decrosslinking protocols have been found to induce sequence alterations 
[21], and reducing heat-exposure has been proposed to prevent this damage [21, 24]. 
Our results are in agreement with these hypothesis, as a reduction from 90 oC (current 
protocols) to 80 oC, showed a significant reduction in off-target effects, without 
compromising the decrosslinking efficiency. Here, we hypothesise that TB1 
(containing 50 mM Tris-HCL (pH 8.0), 30 mM EDTA, 800 mM GuHCL, 0.5% Triton-
X, 0.5% Tween-20) established reaction conditions that promoted decrosslinking at a 
lower temperature. This could be explained by a higher protein denaturing capability 
of GuHCL (facilitated by a higher Proteinase K activity) [55-57], but also because 
GuHCL reduces the Tm of DNA (while maintaining high hybridisation stringency) 
[58, 59]. This would facilitate the exposure and hydrolysis of ubiquitous DNA-Protein 
crosslinks [51, 60] and DNA-DNA complexes [61-63] at lower temperature [64], 
reduce potential straining of the DNA structure, and maintain a high base paring 
fidelity. Although this could have also been assisted by other reaction conditions (such 
as pH and ionic strength) [61, 65-67], Tris-HCl formaldehyde scavenger activity [50, 
51] or possibly Guanidium-formaldehyde interactions, this requires further 
investigation.  
Treatment with glycosylases significantly reduces the appearance of sequence 
artefacts in FFPE DNA. Glycosylases generate blocked ends that are in most cases, 
unsuitable for amplification. This effect was confirmed in all glycosylases tested. 
Studies performed in human DNA have shown that cytosine deamination to uracil is 
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the main source of sequence artefacts in FFPE DNA [12]. However, this has been 
found controversial [14, 21, 24, 68]. Our data suggest that DNA damage found in 
bacterial FFPE DNA is primarily driven by oxidation and subsequent cytosine 
deamination, as evident in higher activity observed for FPG and Endo VIII. It is-
known that oxidised products of cytosine can trigger deamination [69]. While UDG is 
able to repair some of the oxidised deaminated lesions (5-OH dU), Endo VIII has a 
broader spectrum of target products of oxidation and deamination. Quantitative and 
qualitative analysis by qPCR (Figure 5a, sFigure 4) and sequencing (Figure 5c) of 
samples treated with Endo VIII BER consistently yielded better results than UDG 
BER did, in terms of template readability and sequence fidelity. Interestingly, samples 
treated with Endo VIII alone showed an improved sequence quality. Given that 
damage targeted by Endo VIII is PCR inhibitory, this might be indicative of activity 
in non-blocking lesions (Fapy-A), reflect PCR errors triggered by blocking lesions 
(jumping PCR), or be due to a reduction of Taq Polymerase fidelity (A rule and/or 
deletions) [70, 71]. While the HRM melting curve analysis provided a valuable guide, 
confirmation was provided by qPCR and sequencing data. After exhaustive 
comparisons, the strategy found to be most effective involves decrosslinking using a 
chaotrophic agent at 80 oC, followed by DNA repair using a combination of 
Formamidopyrimidine DNA glycosylase and Endonuclease VIII.  
CONCLUSION 
To conclude, the information generated here provides a better understating of FFPE-
derived DNA damage, informing strategies for its repair. Here is also presented a 
thoroughly characterised method to address this damage. Given the increased activity 
in, and controversy surrounding, the field of low-biomass microbiome analysis, 
methods that improve the quality of microbiome studies (through sensitivity 
improvement or access to increased sample size) such as described here, are necessary. 
Given the paucity of published information on mammalian FFPE DNA repair, and 
none on bacterial repair, the strategy devised here provides compelling evidence to 
further pursue BER strategies to improve the sequencing quality of bacterial FFPE 






Supplementary Figure 1. Evaluating the effect of DNA glycosylases on bacterial 
FFPE DNA.  
DNA purified from FFPE blocks loaded with E. coli fixed for 24h or 48h was pooled and 
equal quantities subjected to treatment with DNA glycosylases shown in plots.  Tm analysis 
of 4 ( 100 bp) DNA sequences was performed on normalised quantities of amplifiable DNA. 
Shown here are the results for two sequences, wherein the melting temperature of fragments 
tested is compared between untreated DNA (grey, n = 12), NF DNA (orange, for each box n 






Supplementary Figure 2. DNA repair by BER system: Optimising a buffer.  
A universal buffer (blue) allowing the reconstitution of the system was prepared and its 
influence on enzyme activity assessed by comparing its activity with the  buffer provided by 
supplier(grey). This was analysed by: a) Tm analysis (each box n = 6), b) Recovery of 
amplifiable DNA (each box n = 6), c) Sanger sequencing readability (each box n = 3), d) 
HRM (each box n = 6). In all analysis the outputs of the enzyme activity using both buffers 













Supplementary Figure 3. Quantitative analysis of treatment with glycosylases.  







Supplementary Figure 4. Quantitative analysis of treatment with single glycosylases 
BER mixes (a) Amplification with Taq Polymerase (b) Amplification with Q5. 
 
 










Supplementary Table 1. Specifications of primers used for qPCR assays 




E coli MG1655 
[CP032667] 





5’TCA TTT GGT CCG CCC GAA AC F 
525 
5’CCA CCA TCA TTG AGG CAC CC R 
5’GCC GAA CTG TCG CTT GAT GA F 
217 
5’ATT TGT CTC AGC CGA TGC CG R 
5’TCG GCT GAG ACA AAT TGC TC F 
110 
5’GAT GCC AAG AGT GGC CTG R 
5’ATG CCA AAG TGC CAC TGA T F 
100 
5’CCA CCA TCA TTG AGG CAC C R 
5’CCC CTT GTA TCT GGC TTT CA F 
116 
5’AGA ACA AAA CGG CCA TCA AC R 
Staphylococcus 
aureus subsp. 







5’ACG CCA GAA ACG GTG AAA C F 
533 5’GAC GTA TTA TTA GCG AAG CCA TAG 
AGC 
R 
5’CGC CTG TAC AAC CAT TTG GC F 
182 
5’TCT AGC AAG TCC CTT TTC CAC T R 
*F= Forward primer, R = Reverse primer 
 
Supplementary Table 2. Genomic data from E. coli used to calculate DNA 
glycosylases input. 
Genome size  4,636,831 bp 
Copy number per ng of DNA  2.102 x 105 
Moles per ng of DNA  3.49 X 10 -19 




Supplementary Table 3. Description of DNA glycosylases tested 
* P = phosphates; dT: deoxy-thymine; dA: deoxy-adenine; dC: deoxy-cytosine; dU: deoxy-
uracil; dI: deoxy-Inosine; OH: Hydroxy; diOH: dihydroxyl me: methyl, dH: dihydroxyl  
1 8-oxodeoxypurines: 8-oxo-dG, 8-oxo-dA, 8-oxo-dNebularine, and 8-oxo-dInosine 
2Formamidopyrimidines: fapy-dG, fapy-dA, and me-fapy-dG  









Enzyme Damage targeted Activity Product 
Units per 










Deaminated cytosines  
(dU, 5-OH-dU) [73] 
Glycosyl
ase 













AP sites [74, 75] 
Glycosyl
ase, β, δ 
- 
APlyase 





Endonuclease VIII  
(Endo VIII) 
Oxidised Pyrimidines  
(dT and dU-Glycol, 
5,6-dH-dT and dU, 
5,6-diOH-dU and dC, 
5-OH-6-H-dT and dU, 
5-OH-dU and 
methylhydantoin)   
Oxidised purine  
(Fapy-dA) [76] 
Glycosyl
ase, β, δ 
- 
APlyase 























Supplementary Table 4. Description of downstream lesion repair enzymes. 
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E coli DNA 
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All 
Gap sealing  
[41, 78] 
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Development of a novel protocol for bacterial 








Background. The role of the microbiome in health status is an expanding research 
area. Recently, body sites previously considered sterile have been found to harbour an 
endogenous microbiome. One of the key rate limiting factors in progression of such 
research is difficulty in accessing sufficient tissue samples for statistically significant 
analysis to be carried out or to perform retrospective analyses. FFPE tissue represents 
the biggest repository of human tissue samples and could represent a vital resource for 
expanding microbiome research. Current methods for isolation of DNA from FFPE 
samples are not suitable for bacterial microbiome studies as they have been developed 
for human DNA.  As such, we sought to develop a method for processing of FFPE 
samples to yield a higher quantity and genus range of bacterial DNA than currently 
available methods, of the quality required for 16S sequencing and whole genome 
sequencing.  
The method consists of: 1) Dewaxing and rehydration with ethanol; 2) Host depletion 
with Saponin and Benzonase nuclease; 3) Bacterial lysis with Metapolyzyme; 4) 
Protein digestion with Proteinase K; 5) Decrosslinking with a GuHCL based lysis 
buffer; 6) a silica column based DNA isolation; 7) DNA repair using the BER 
pathway. The method was validated using Protoblocks, FFPE murine models, and 
clinical human tissue samples. DNA quantity and quality in terms of fragment length 
and sequence fidelity was assessed by qPCR and16S sequencing. The method 
developed shows clear and significant improvement over the current gold standard in 
both mock communities and murine samples, this was seen particularly in terms of 
consistent bacterial lysis across a number of species, and effective host depletion. The 
tissue dissociation step requires optimisation, and additional measures must be 
implemented to limit the effect of environmental contamination.  Future work to 
remedy these issues is discussed in the main text.  This novel method opens the door 
for reliable use of standard clinical FFPE tissue samples for modern bacterial 





The use of formalin-fixed, paraffin-embedded (FFPE) tissues in microbial surveys has 
the potential to revolutionise the field of human microbiome research with 
unprecedented access to samples. It is well established that a DNA isolation method, 
prior to sequencing, should be based upon specific study aims, target organisms and 
sample types [1]. However, at present, no such method exists for bacterial DNA in 
FFPE samples, although several groups have carried out metabarcoding surveys of 
bacterial communities within these tissues [2]. There is a plethora confounding 
features present when carrying out sequence-based analysis of bacterial communities 
[3], and when coupled with the criticisms levelled at recent sequencing experiments 
targeting similarly challenging sample types [4] it is unlikely that large scale 
microbiome studies using FFPE samples will remain tenable without the development 
of bespoke methodologies and biological standards. The key characteristics of FFPE 
samples that impair effective microbial analysis are: (i) Formalin-derived crosslinks 
and damages to DNA present in the sample[5]. (ii) A high ratio of host to bacterial 
DNA[6]. (iii) DNA extraction methods for FFPE DNA to date are optimised for 
human cells. (iv) The extent of processing necessary leaves samples vulnerable to 
contamination. (v) No standards exist to validate the effects of the above on 
downstream analysis.  
Previous work presented here was has sought to address some of the above issues, 
namely the design of an effective DNA repair strategy (Chapter 3) and a FFPE-based 
biological standard to validate the effectiveness of any developed methodology 
(Chapter 2). This study draws on these tools, and combines them with effective and 
validated host depletion and bacterial lysis strategies, to present a final method for the 
analysis of bacterial communities within FFPE tissues.  
Host Cell Depletion. In low bacterial biomass samples, such as many human tissue 
scenarios, host DNA can constitute > 90 % of total DNA, severely limiting 
metagenomic studies, as the vast majority of sequencing reads are taken up by this 
background human DNA. This is critical, particularly for whole genome shotgun 
(WGS) methods [7]. It has been also shown to affect the outputs of 16S rRNA 
amplicon sequencing, since in reactions of low bacterial to human DNA ratios, human 
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DNA can be annealed and amplified during 16S PCR [8]. Furthermore, a reduction in 
bacterial range and rare bacteria taxa can occur during dilutions made to avoid 
overloading DNA in PCR reactions [9]. Therefore, any reduction in the ratio of 
background mammalian to target bacterial DNA would improve readout. DNAse 
treatment can reduce the quantity of intact background DNA, if it’s activity can be 
targeted to mammalian cells, e.g. by restricting access of the DNAse enzyme to only 
mammalian cells. Mammalian specific-membrane permeabilisation may achieve this. 
For differential membrane permeabilisation, structural differences between 
mammalian and bacterial cells can guide the choice of permeabilisation agents [10]. 
In principle, both mammalian membranes and the outer membrane (OM) of Gram-
negative (G-) bacteria are composed of a phospholipid bilayer [11, 12]. However, in 
the OM of G- bacteria, the phospholipid bilayer is surrounded by an outer envelope of 
lipopolysaccharide (LPS) with polysaccharide chains facing the hydrophilic end [13]. 
LPS are densely and tightly packed highly hydrophobic structures that seal the inner-
membrane from action of detergents [14]. The lipid bilayer of mammalian cells is 
made mainly of phospholipids, with variable contents of glycosphingolipids and 
cholesterol rafts [11, 15].  
Several host depletion strategies for microbiome analysis have been published [16]. 
However, the principles by which mammalian membranes are lysed in these cases, do 
not apply for FFPE samples, where dead cells have no membrane potential or active 
homeostatic mechanisms to ensure tonicity. FFPE tissue is also hardened by the nature 
of the processing, such that methods that lyse membranes with soft-tissue lysis beads 
are not suitable for this sample type [17]. Chaotrophic agents are capable of disrupting 
hydrophobic interactions [18, 19], such as those maintaining the tightly packed LPS 
structure in G- bacteria, annulling the protection of the phospholipid bilayer [14], as 
in the case of mammalian membranes [20], exposing intermembrane proteins that are 
easily denatured by these agents, and the peptidoglycan layer [21]. The state of the 
interpeptide bridges enforcing the structure of the peptidoglycan layer could be 
severed by formalin fixation [22]. Finally, methods developed to capture host DNA 
by binding CpG islands in mammalian DNA [18, 23] were deemed unsuitable for 
FFPE DNA, for which CpG sites represent hotspots for sequence alterations, with 
higher number of degraded cytosines than in NF samples observed in multiple studies. 
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Non-ionic, mild detergents, are known to solubilise membrane lipids, without 
significantly disrupting the integrity membrane proteins [10]. Among these, Triton-X 
and Tween-20 preferentially solubilise membrane phospholipids [24]. Alternatively, 
Saponin and Digitonin target cholesterol, present in high ratios in the mammalian 
cellular membrane [25]. It has been shown that these detergents have virtually no 
activity in solubilising membranes without cholesterol (nuclear envelope, vacuoles 
and mitochondria) [25, 26], making them selective for mammalian cell membranes. 
All of these detergents have been shown to temporarily permeabilise membranes, 
inducing pores 4 – 5 nm of diameter in live cells at low concentrations and completely 
solubilising membranes it at higher concentrations [24, 27]. The efficacy of these 
detergents upon FF mammalian cells is well described and has been found variable 
[28]. While live bacteria are tolerant to these detergents [29, 30] their effect on FF 
bacteria is still unexplored. 
Bacterial Lysis. Bacterial lysis is a critical step in sample processing for 
microbiome analysis. It can be major source of bias in community composition, as 
lysis methods that favour particular taxa will cause overrepresentation in the final 
analysis [8, 31-35]. Many methods for unbiased bacterial lysis of non-fixed samples 
have been proposed and applied, including bead-beating, enzymatic lysis, detergents 
and denaturing agents [32, 33, 36]. Recently, several studies have agreed that bead-
beating is the lysis method that yields higher uniformity of bacterial lysis and have 
shown that combining bead-beating with other methods shows further improvements 
in uniformity [36, 37]. Furthermore, it has been found that properties inherent to the 
type of sample influence the efficiency of the sample prep [34]. 
FFPE samples are characterised by DNA damage that includes high levels of 
fragmentation and DNA damage reducing the recovery of PCR/sequencing readable 
DNA [38, 39]. Additionally, FFPE samples typically have low bacterial biomass 
concealed by large quantities of DNA from the larger human genome. Bead-beating 
decreases DNA yields by causing DNA fragmentation leading to the formation of 
chimeras during PCR [1, 40, 41], which would be detrimental for FFPE samples. For 
this sample type, lysis must be performed under conditions that do not negatively 
affect the integrity of DNA, such as enzymatic lysis. Accordingly, the Association of 
Biomolecular Resource Facilities Metagenomics Research Group developed a mix of 
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6 lytic enzymes (achromopeptidase, chitinase, lyticase, lysostaphin, lysozyme, and 
mutanolysin) that target the cell wall of bacteria, yeast, and fungi, and is able to lyse 
recalcitrant endospores [42]. The incorporation of this enzyme, known as 
Metapolyzyme (Sigma-Aldrich), in sample preparation has been shown to increase the 
recovery sphearoplasts or protoplasts, and improve the overall DNA recovery across 
taxa in multiple sample types [1, 42]. Recently, a microbiome study was performed 
on ancient DNA specimens (with similar levels of DNA damage as FFPE), validating 
the efficacy of Metapolyzyme over traditional bead beating methods in this sample 
type [43].  
Study Aims. In this study, host DNA depletion, cross-taxa bacterial lysis, were 
optimised and combined with DNA repair as a single protocol as per Figure 1. 
Differential cell lysis strategies were investigated and individually validated before a 
final validation of the method as a whole was performed, using a cancer line and 
multiple bacterial genera. The combined methodology was assessed using the 
“Protoblock” biological standard, and by formalin fixed mouse faeces as a high 
biomass sample. The bespoke protocol was compared with the current gold standard, 
the Qiagen QIAmp FFPE kit. Lastly, low biomass samples of malignant formalin fixed 
patient breast tissue were processed using the novel method, and compared with paired 




Figure 1. Full Protocol for bacterial DNA isolation from FFPE samples – describing steps 





The models used to test the different steps of this protocol, were, a) ex vitro: i) 
Formalin fixed (FF) cells, ii) Protoblocks, and; b) ex vivo models: i) mice tumours and 
normal gut tissue and ii) mice faeces.  
A. Cellular models 
For this type of model, bacterial and mammalian cells were grown, harvested, formalin 
fixed and counted, as follows: 
Cell culture. Mus musculus mammary gland cancer cells (4T1) were grown at 37oC 
5% CO2, in RPMI media supplemented with 10% FBS, 100 U/mL penicillin and 100 
μg/mL of streptomycin (ThermoFisher) to a final count of 108 cells. The cells were 
harvested with 0.5 ml/10cm2 trypsin, washed with PBS, pooled and counted with a 
NucleoCounter® NC-100™ (chemometect, Copenhagen) following manufacturer’s 
instructions.  The cells were fixed in 40 ml of 4% buffered formalin for 48h at RT, 
unless specified. 
Bacterial growth conditions.  E. coli K12 MG1655 carrying a P16Lux plasmid 
[44] or E coli Nissle 1917, was grown aerobically at 37oC to an OD600 of 0.8 in LB 
medium supplemented with 300 µg/ml Erythromycin. Staphylococcus aureus newman 
(ATCC 25904) was grown aerobically at 37oC to an OD600 of 0.8 in Tod-Hewwit 
broth. Bifidobacterium longum 35624 was anaerobically grown at 37oC for 24 h in 
MRS medium. Lactobacillus amylophilus (ATCC® 49845™) was grown at 30oC in 
an atmosphere of 5% CO2 for 24 h. Bacteroides thetaiotaomicron (ATCC®29741™) 
was grown anaerobically at 37oC for 24 h in FAB medium (NEOGEN, Lancashire, 
UK). Bacterial cultures were harvested by centrifugation at 3000 x g, for 10 min at 
4oC, and suspended to 2X with PBS. A one ml aliquot of the suspension was kept for 
obtaining the viable CFU by retrospectively counting plated dilutions (10-5, 10-6, 10-
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7), the rest of the suspension was pelleted and suspended to a 2X concentration with 
buffered formalin and fixed as specified for each model or experiment. 
Counting total fixed bacterial cells.  The cell suspension was counted using a 
bacterial counting kit for flow cytometry (Invitrogen), following manufacturer’s 
instructions. In brief, after fixation, bacterial suspensions were harvested and 
suspended in 4% Neutral Buffered formalin to a suspension of an approximate density 
of 106 cells/µl (100X concentration). The final suspension volume was measured, to 
account for the displacement created by the cells in the solution. Displacement volume 
was calculated by subtracting the volume of formalin added from the final suspension 
volume. This was 4 x 106 µl/cell for 4T1 cells, 1.04 x 107 µl/cell for E. coli, 1.38 x 107 
µl/cell for S. aureus, 1.26 x 106 µl/cell for B. longum, 4.32 x 107 µl/cell for B. 
thetaiotaomicron and 1.37 x 107 µl/cell for L. amylophilus. A 10% aliquot was taken 
from this suspension and serially diluted (100X) with filtered sterilised 0.15M NaCl 
solution to obtain a cell density of approximately 1x 106 cells in 989 µl of NaCl. 
Bacterial cells were stained with 1 µl of SytoBC and 10 µl (1X 106) of counting beads 
were added to the suspension. Cells were counted in an LSR II Flow Cytometer (BD 
Biosciences, NJ, USA). The acquisition trigger was set to side scatter and regulated 
for each bacterial strain to filter out electronic noise without missing bacterial cells. 
This value was approximately 800.   
Protoblocks.  Protoblocks with the bacterial and 4T1 cell content specified 
per experiment were made following the same protocols described in Chapter 2. 
Briefly, cells formalin fixed in formalin for 18 h were suspended to a density of 2 – 6 
x 106 bacterial cells per µl and 1.2 x 105 4T1 cells per µl. The volume corresponding 
to 2 x 107 CFU for each bacterial strain and 2.2 x 107 4T1 cells were aliquoted to create 
a mixed cell suspension. These suspension was mixed thoroughly with an equal 
volume of sterile agar (1.5X concentration) and the mix pipetted to a cylindrical mould 
made from a 54 x 11 mm adapter tube (SARSTEDT, Cat No. 55.1570), with a flat end 
sealed with a double layer of parafilm, and let solidify for 3 minutes. The parafilm was 
removed from the bottom and the disk shaped cell matrix dropped into a 15 ml tube 
filled with 8 ml of formalin, using a sterile bacterial loop. The protoblocks were fixed 
for an extra 24 h for 48 h fixation time point or processed immediately for 24h fixation 
time point. After fixation, the cassettes containing the guts were dehydrated and 
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paraffin embedded automatically with a LOGOS J (Milestone Medical, Bergamo). 
Following this protocol: Dehydration for 4 hours with increasing concentrations of 
ethanol at 37oC. Clearing with 2 x xylene washes for 2 h and 20 min each, at 37 oC, 
2 x washes of isopropanol for 1 h and 40 min at 37oC and 1 x wash with isopropanol 
for 50 min at 60 oC. Paraffin embedding for 8 h and 32 min at 62 oC. Once dehydrated 
and paraffinised, the protoblocks’ volume, diameter and height were measured with a 
calliper and by volume displacement.  
Sectioning. The blocks were sectioned keeping an aseptic technique either at 4 µm 
for imaging or at 10-20 µm for DNA purification. The cell load of each slide was 
calculated by multiplying the total bacterial load by the volume of each slide, using 
the volume of a cylinder.  
Microscopy. Following protocols from Chapter 2, cell integrity was evaluate by 
H&E staining with Mayer’s haematoxylin (Sigma, MHS16) and Gram-staining 
(Sigma, 77730).  To confirm the bacterial content of each protoblock sections and 
three immunofluorescent stained with DAPI, α-S. aureus or α- E. coli sections were 
used to label bacteria and 4T1 cells. 25 fields of view were counted for each slide and 
the average plotted against the slide volume to obtain cell density per µl of block.    
B. Murine models 
Mice. BALB/c mice were housed in a conventional environment (temperature 21 °C, 
12 h light: 12 h darkness, humidity 50%). They were fed a standard non-sterile pellet 
diet and tap water ad libitum. Mice were allowed 2 weeks to acclimatise before 
entering the study. All animal procedures were performed according to national ethical 
guidelines following approval by the University College Cork Animal 
Experimentation Ethics Committee. 
Mice gut tissue processing. Distal guts from 2 mice were dissected using an aseptic 
technique. The gut tissue was opened longitudinally, excess faecal matter removed 
and the tissue was rolled and placed into a processing cassette, where it was formalin 
fixed for 24 h.  After fixation, the cassettes containing the guts were dehydrated and 
paraffin embedded using the same protocol described for protoblocks. Processed 
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tissues were placed in 2 x 2 cm embedding mould and mounted to a processing 
cassette, using standard histology procedures.   
Mice faeces blocks. 6 mice were samples for this model. From each mouse, 3 pellets 
were collected into a 2 ml Eppendorf tube filled with 1.5 ml of formalin. The tube 
closed and the pellets fixed for 18 h. After fixation, using a sterile bacterial loop, the 
3 pellets were placed in the same cylindrical mould as specified for protoblocks. 350 
µl of sterile, molten agar, kept in aliquots at 65oC was poured onto the pellets and let 
solidify for 3 minutes. Just as with protoblocks, the disk shaped matrix containing the 
pellets were dropped into a 15 ml tube filled with 8 ml of formalin. The disks were 
either processed immediately or further fixed for 24 h (for 48 h fixation) and processed 
(dehydrated and paraffinised) as specified for protoblocks. The resulting paraffinated 
disk was placed into 1.5 x 1.5 cm embedding mould and mounted into a cassette using 
standard histology procedures. 
Sectioning. The blocks were sectioned keeping an aseptic technique either at 4 µm 
for imaging or at 10-20 µm for DNA purification.  
Microscopy. The presence of bacterial cells in gut tissue and mouse pellets was 
evaluated in three Gram-stained sections and the integrity of the tissue cells with H&E. 
2. DNA analysis 
Conventional PCR. 25 µl reactions were setup using Taq 2X Master Mix (NEB, 
Ipswich, MA, USA) and 0.25 µM of each primer.  Cycling conditions included: an 
initial denaturation for 30 sec at 95oC. 25 – 35 cycles of denaturation at 95oC for 10 
sec, annealing for 15 sec at the primers’ optimal temperature [54-56oC] (specified by 
NEB’s calculator for Taq DNA polymerase), 20-40 sec of extension at 68oC (20 sec 
for 200bp amplicons and 40 sec for 400-500 bp amplicons), and a 5 min final extension 
at 68oC. 10 µl of amplified products were loaded to a 1.5% agarose gel, run at 200V 
for 20 min, and imaged with Gel Doc EZ System (Bio-Rad) 
Quantitative PCR. For dye-based qPCR, reactions were prepared using LUNA 
Universal qPCR (NEB, USA) and 0.25 µM of each primer and 0.25 µM of probe. 
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Multiplex qPCR, reactions were prepared using LUNA Universal Probe qPCR (NEB, 
USA) and 0.5 µM of each primer and 0.25 µM of probe for each strain. Reactions for 
simultaneously quantifying three bacterial strains, were set using fluorochromes: 
FAM, HEX, CY3. Amplification was performed in an AriaMx (Agilent Technologies, 
USA) using fluorescence probe or DNA binding dye absolute quantitation experiment 
type.  
The thermal profile included an initial denaturation of 1 min at 95oC, and 40 cycles of 
denaturation at 95oC for 10 sec, annealing for 15 sec at the primers’ optimal 
temperature [54-56oC] (specified by NEB’s calculator for Hot Start Taq) and 20-40 
sec of extension at 68 oC (20 sec for 200bp amplicons and 40 sec for 400-500 bp 
amplicons).  
Each assay included triplicates of 5 points standards using log-dilutions of gene blocks 
(750 bp), which were designed based upon species-specific genetic regions. Primers 
and/or probes targeting these regions and maintaining a similar Tm (+/-2oC) were 
designed using the NCBI primer design tool and their parameters (ΔG, hairpins and 
dimers) verified using IDT’s Oligo analyser tool. Primers and gene-blocks were 
acquired from IDT (Coralville, USA) (see Table 1). qPCR efficiencies between 95% 
and 105% and R-square values higher than 0.995 were deemed as acceptable, all 
samples were ran in triplicate. 
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5’TCA TTT GGT CCG CCC GAA AC F 525 
 5’CCA CCA TCA TTG AGG CAC CC R 
5’GCC GAA CTG TCG CTT GAT GA F 
217 
5’ATT TGT CTC AGC CGA TGC CG R 







5’GAA CAT ACA GAC CGC TAT CC F 
460 















5’CGC CTG TAC AAC CATT TGG C F 
182 
5’TCT AGC AAG TCC CTT TTC CAC T R 
5’TGC TAT GAT TGT GGT AGC CAT C F 
425 
5’ACT TCT CTC TAG CAA GTC CCT R 












5’CCC TTG GAA CGT GGT TAT G F 
474 
5’ACG GGT TCC TTC GACT T R 














5’CAT TCT TCT TCT TGT GGC TAA AC F 
480 
5’TGG GAA ATG TAC AAC CTG AAA R 











5’GTC GGA CTT GCT GCG TTT ATC GTT G F 
125 
5’ CGG GGC GCT TGA TAG AGA ACA ATG R 
5’CGT CGT CGT CTG ATT CGT AAG F 
440 
5’GGG CGC TTG ATA GAG AAC AA R 












5’GCG TGT CAG ACG TTT TTC CC F 
156 
5’ AGA AAA GAG CGG AGG TTC GG R 
5’GAT TAC TGC TCT GGC TCC TAG F 
147 
5’GAC TCA TCG TAC TCC TGC TTG R 






region of 16S 
rRNA gene 
5’TCG TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG 
CCT ACG GGN GGC WGC AG 
F 
460 
5’GTC TCG TGG GCT CGG AGA TGT GTA TAA GAG ACA 




16S library Preparation. Genomic DNA was amplified using 16S rRNA gene 
amplicon polymerase chain reaction (PCR) primers targeting the hypervariable V3-
V4 region of the 16S rRNA gene (see Table 1) using the Illumina 16S rRNA gene 
Sequencing Protocol (Illumina, CA, USA). The amplification reaction was performed 
in a final volume of 50 µl, containing 1X concentration of NEBNext High Fidelity 2X 
PCR Master Mix (NEB, USA), 0.5 µM of each primer, 8 µl template (5-15 ng/µl) and 
12 µl nuclease free water.  
Thermal cycling was performed in an Eppendorf Mastercycler, with a thermal profile 
that included a 98 oC denaturation for 30 sec and 25 cycles of 98 oC for 10 sec, 
annealing at 55 oC for 30 sec and extension at 72 oC for 30 sec. A final extension step 
was performed at 72 oC for 5 min.  Amplification was confirmed by running 5 µl PCR 
product on a 1.5 % agarose followed by imaging on a Gel Doc EZ System. The product 
was approximately 450 base pairs (bp) in size.  
PCR-positive products were cleaned per the ‘PCR Clean-Up’ section of the Illumina 
protocol. Sequencing libraries were then prepared using the Nextera XT Index Kit 
(Illumina) and cleaned per the Illumina protocol. Libraries were quantified using a 
Qubit fluorometer (Invitrogen) using the ‘High Sensitivity’ assay, normalised to 10 
ng/µl and pooled into a single reaction tube. Further processing was performed by 
GENEWIZ (Leipzig, Germany) where samples underwent a paired-end 450 bp run on 
the Illumina MiSeq platform. 
3. Host depletion strategy 
Experiments to develop a host depletion were performed with flow cytometry and 
confirmed by qPCR. First, the effect of permeabilisation agents was investigated and 
later the internalisation and effect of DNAse enzymes. 
Membrane permeabilisation assay. For mammalian cells, 8 x 107 4T1 cells were 
fixed in 40 ml of formalin for 48 h, pelleted at 250 x g for 10 min, washed once with 
TBS (50 mM Tris, 150 mM NaCl, pH 7.6), and suspended to a final density of 2.5 x 
106 cells per ml in TBS. For bacterial cells, 5 x 109 E. coli cells, were fixed in 50 ml 
of formalin for 48 h, pelleted at 300 x g for 10 min, washed once with 20 ml of TBS 
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and suspended to a final density of 2.5 x 107 cell per ml in TBS. 500 µl of the cell 
suspensions were aliquoted into 1.5 ml tubes and treated with a permeabilisation agent 
(see Table 2).  
The cells were permeabilised for 25 min, at 25oC, in a thermomixer, shaking at 500 
rpm. Permeabilised cells were washed once with TBS and blocked on ice with TBS + 
1% BSA. Blocked cells were exposed to 0.75 µg of Cy5 labelled Streptavidin (SAv-
Cy5, MW = 60 KDa, globular structure) (Biolegend, CA, USA) for 30 min at 25oC, 
shaking at 280 rpm. Cells were washed with 1 ml of 0.15 M NaCl solution and 
resuspended in 350 µl of the same solution for analysis. Bacterial cells were labelled 
with 1 µl of SytoBC (Invitrogen) for 5 min and analysed by flow cytometry in a BD 
LSRII.  
4T1 Cells were identified and gated based on their Forward/Side scatter and E. coli 
cells were detected using the 488-1 (FITC) 525/50 filter for SytoBC and gated using 
the side scatter. Cy5+ cells were detected with the red 670/14 filter.  10,000 events 
were recorded for 4T1 cells and 100,000 for bacteria. 
 
Table 2. Permeabilisation agents tested and concentrations (Sigma-Aldrich) 
Permeabilisation agent Concentration[50] 
Triton X-100 0.1% v/v 
Tween-20 0.2% v/v 
Saponin 0.1% w/v 
Digitonin 0.5 µg/ml 
 
DNAse screening. A screen for selecting the DNAse that had highest activity in 
depleting DNA in a reaction buffer containing Saponin. DNAses tested: Recombinant 
DNAse I [1-2U, 1 µl] (Sigma-Aldrich), Turbo DNAse [2U, 1 µl] (Thermo-Fisher), 
Molysis DNase [2 µl] (Molzym GmbH & Co, Bremen, Germany), RQ1 DNAse [20U, 
20 µl] (Promega), Benzonase [75 U, 0.3 µl] (Sigma-Aldrich). 5 x 106 4T1 cells, FF for 
48h were treated with 0.1% Saponin and the DNAse tested. Reactions were set in 
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reaction buffers provided or suggested by supplier, supplemented with 0.2% Saponin, 
for 20 min at 37oC. The reaction was stopped by either: the addition of EDTA 
(Benzonase), the supplied reaction Stop Buffer, or by incubating at 75oC (DNAse I). 
After which, cells were subject to DNA purification with the QIAGEN DNA mini kit. 
After which DNA yield was measured by QUBIT. All reactions were performed in 
triplicate. A no-DNAse control was included with incubated under the same conditions 
with buffer supplied for DNAse I. 
Saponin Titration.  Different w/v saponin concentration (0.1%, 0.25%, 0.5%, 1%) 
were tested in 1 x 106 E. coli cells that were fixed, washed, permeabilised, blocked 
and imaged as described for membrane permeabilisation assay.  
DNA depletion assay.  Cells were fixed, washed and permeabilised as described for the 
membrane permeabilisation assay. 2.5 x 105 4T1 or 2.5 x 106 E. coli cells were 
permeabilised, blocked with 500 µl of 1% BSA in TBS+ MgCl2 (20mM Tris-HCL, 20 
mM NaCl, 2mM MgCl2, pH 8) for 30 min on ice. Blocked cells were treated with 1.5 
µl (≥ 375 units) of Benzonase nuclease (Sigma-Aldrich) for 30 min at 37oC, shaking 
at 360 rpm. Treatment was stopped by the addition of 100 µl of 100 mM EDTA.  The 
cells were washed once with TBS and suspended in 0.15M NaCl, where they were 
stained with 10µM CytoPhase Violet (Biolegend) for 1.5 h at 25oC, shaking at 200 rpm 
in the dark. Bacterial cells were labelled with 100 µM of BacLight red (Invitrogen) for 
15 min at 25oC, shaking at 200 rpm and analysed by flow cytometry. 4T1 Cells were 
identified and gated based on their Forward/Side scatter and E. coli cells were detected 
using the 561 laser (Yellow/Green) 660/20 filter for BacLight red and gated using the 
side scatter. CytoPhase+ cells were detected with the 355 (UV) laser and 450/50 filter.  
Confirmation of host depletion (HD) strategy.  The efficacy of the combined 
treatment was verified by qPCR in DNA purified from a mixed cell suspension, 
consisting of 1 x 107 E. coli cells and 1 x 104 4T1 cells. Cells were incubated for 30 
min at 37oC, shaking at 360 rpm in TBS or the optimised HD buffer (0.2% Saponin, 
0.2% Tween-20, in TBS + MgCl2 (20mM Tris-HCL, 20 mM NaCl, 2mM MgCl2), pH 
8) with or without 500 U of Benzonase. The treated cells were then processed for DNA 




4. Bacterial lysis strategy 
Membrane/Cell wall Disruption. FFPE bacterial cells, fixed for 48h, to numbers 
specified in results, the deparaffinised contents off FFPE slides were treated with 200 
µl of PBS +/- 150 µg of Metapolyzyme (Sigma-Aldrich, MAC4L) for 4h.  After which 
cells were either processed for qPCR using the QIAGEN FFPE DNA kit (Qiagen Inc., 
Valencia, CA, USA). B. longum cells FF for 48h were treated with 200 µl of PBS +/- 
150 µg of Metapolyzyme (Sigma-Aldrich, MAC4L) for 1, 4 or 24h.  After this, 
contents from each reaction were split in 2. Half the contents were DNA purified for 
qPCR and   the other half was stained with BacLight and SytoBC for flow cytometry 
analysis. BacLight stains the bacterial cell wall, so BacLight+ bacteria were Wall+. 
These were detected with 561 laser (Yellow/Green) 660/20 filter. SytoBC stains 
bacterial DNA, and SytoBC+ cells were DNA+ cells. These were detected with the 
488-1 (FITC) 525/50 filter. Cells were gated using the side scatter, and only cells 
positive for both dyes were considered to be integral.  100,000 events were recorded 
per replicate analysed. Cells were counted using counting beads as described for in 
methods section I.a. Counting bacterial cells. 
 
Sample digestion. Optimisation of sample digestion was performed using 8 x 12 
µm slides from FFPE blocks loaded with 1x 108 E. coli cells. The slides were 
deparaffinised using Zymo deparaffinization solution and resuspended in 200 µl of 
Lysis Buffer, supplemented with 20 µg of Proteinase K (Qiagen), a top-up of 
Proteinase K was done every 18 h until reaching the incubation time-point. After tested 
incubations, DNA was purified using the QIAGEN FFPE DNA kit. 5 µl of purified 
DNA were loaded to a qPCR reaction for quantitative analysis. 
5. Integration of the protocol 
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Filtering columns. Sterile filtering columns were sought as means to perform the 
several treatments and washes required for processing the samples. The membrane 
material for the columns for which results are shown here are either Hydrophilic 
Polyvinylidene Fluoride (PVDF) (Ultrafree-MC Centrifugal Filters, Merck Millipore) 
or a Cellulose Acetate (CA) (Corning Costar Spin-X Centrifuge tube filters, Sigma-
Aldrich), with pore sizes of 0.1 µm or 0.2 µm.  Corning Costar 2 ml microcentrifuge 
tubes (Sigma-Aldrich, CLS3213) fit CA columns and were used as collection tubes 
for these columns. Sarstedt 2 ml PP tubes (Sarstedt, 72.689) were found to fit PVDF 
membranes, and were used as collection tubes for these columns. 
Deparaffination. FFPE slides loaded to a filtering column (0.2 µm, CA filter) 
were deparaffinated by heating the suspension for 2 min at 56oC with 500 µl of Zymo 
deparaffination solution (Zymo Research, Irvine, CA, USA). The solution was 
removed by centrifuging the column for 1 min at 1,000 x g. 
Testing the removal of enzymes from samples. The ability of filtering columns 
to allow the removal of proteins > 60 KDa was tested in 0.1 µm PVDF filters. Bovine 
Serum Albumin (BSA) was selected as a model protein. 200 µl of bacteria suspension 
with 250 µg/ml BSA in TBS (pH 7.6) were passed through a filtering membrane by 
centrifuging at 2,000 x g for 1 min, the filtrate (FT) collected and 200 µl of TBS were 
added to the column, mixed thoroughly and saved as elute fraction (E). This process 
was repeated twice, until 3 FT were collected. 15 µl of each fraction were loaded to a 
4-12% graduated SDS-PAGE gel (Invitrogen) and run for 45 min at 200V. The gel 
was resolved using EZ Blue (Sigma-Aldrich) and imaged and quantified with a Gel 
Doc EZ System (Bio-Rad).  
Testing adaptation & integration of strategies. Experiments for integrating and 
adapting the steps of the protocol were performed using 8 x 12 µm slides from FFPE 
blocks loaded with 1x 108 E. coli and S. aureus cells.  Sections were loaded into a 0.2 
µm CA filter column (unless specified), deparaffinated as described in section b, and 
subjected to experimental conditions. Unless specified, the wash buffer is TBS buffer 
(50 mM Tris, 150 mM NaCl, pH 7.6). All solutions were filtered by a 1 min 
centrifugation at the specified speed. 100 µl of eluates were collected after each 
treatment from each replicate and were pooled into one tube that was processed for 
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DNA purification. Filtrates were collected at the end of the protocol, resuspended in 
200 µl. DNA purification was performed using the QIAGEN FFPE DNA kit. Purified 
DNA was eluted in 40 µl of 10 mM Tris-HCl. A 5 µl aliquot was amplified and 
resolved using methods described in conventional PCR and run on an agarose gel as 
described in Methods section II. 
Impact of all process and filter pore size on bacteria. The loss of bacterial cells 
in filter columns was evaluated on 0.1µm PVDF and 0.2 µm CA filters. FFPE slides, 
rehydrated and deparaffinated, were washed twice in a PBS solution. Aliquots of 
filtrates and eluates DNA purified and analysed through conventional PCR.  
Incorporating tissue rehydration.  Deparaffinated slides were rehydrated with 3 
washes: 1 x 400 µl wash of 100%, 1 x 400 µl of 80% ethanol and 1 x 400 µl of TBS. 
Once the solutions were loaded, the mixture was briefly mixed by vortexing and 
removed by centrifugation at 800 x g for 100% ethanol, 1,200 x g for 80% ethanol and 
1,400 x g for TBS.  Rehydrated slides, were then treated with HD solution (without 
DNAse) for 30 min at 37oC, after which they were washed with PBS. Slides that were 
not rehydrated were directly resuspended in the HD solution, and all other downstream 
procedures were the same as rehydrated slides. 
Adapting the HD strategy to filtering columns. A time-point incubation with 300 
µl of HD solution (without DNAse) for 10, 20 or 30 min, was performed on 
deparaffinated and rehydrated sections. The reaction was stopped by the addition of 
50 mM EDTA and the solution removed by centrifuging at 1,800 x g. The cells washed 
with 300 µl of TBS, filtered by centrifugation at 1,800 x g for 1 min and the final 
eluate resuspended in 200 µl of TBS.  
Incorporating a tissue dissociation strategy. The effect of tissue dissociation 
solutions on bacteria was explored with Proteinase K (Qiagen) and 
Collagenase/Dispase (Sigma-Aldrich). Deparaffinised sections were incubated with 
300 µl with 20 µg of Proteinase K for 10 min at 56oC or 5 µg/µl of Collagenase 
/Dispase for 1 h at 37oC. The solution was filtered by centrifuging at 1,600 x g, 
contents washed with 300 µl of TBS, centrifuged at 1,600 x g, and then incubated with 
HD solution (without DNAse) for 30 min at 37 oC. This was removed by centrifuging 






6. Validation of the protocol 
A. Protocol for bacterial DNA isolation from FFPE samples 
1. Tissue sectioning:  
Materials:  
- Corning Costar 0.2 µm CA filter columns [1 per experimental replicate] 
- DISTEL disinfecting wipes (Tristel Solutions Ltd., Cambridge, UK) 
- DNA decontamination solution (Sigma-Aldrich) 
- Milli-Q water 
- Microtome blades  [1 per FFPE block] 
- Sterile Petri-dishes 
- Sterile forceps, individually wrapped [1 per FFPE block] 
- Sterile scalpel, individually wrapped [1 per FFPE block] 
- Sterile gloves [1 pair per FFPE block] 
- Mask 
 
Before starting:  the microtome and cold plate are thoroughly cleaned with DISTEL 
microbial/DNA/RNA disinfectant wipes and a DNA decontaminating solution 
(Sigma). FFPE blocks are wiped with DISTEL wipes and placed in a cold plate. 
 
Notes:  
(i) This protocol was validating using 0.2 µm CA sterile filtering columns. 
(ii) To maintain an aseptic technique a mask and sterile gloves, are worn at all times.  
(iii) Use a new microtome blade per block sectioned, to avoid cross-contamination. 
(iv) Slides a handled with individually wrapped, sterile forceps, only. Use a new pair 
of forceps per block. 
(v) Sterile gloves were changed for handling different blocks. 
(vi) Wiping was performed using DISTEL disinfecting wipes. 
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(vii) If sections from the same block will be taken for staining, cut the sections for 
staining after cutting the sections for DNA purification have been cut and sterilize 
probes and brushes to be used by autoclaving and wiping them with a DNAse 
decontaminating solution. 
(viii) If working with difficult to cut tissue that requires rehydrating. Aliquot 20 ml of 
Milli-Q water in a sterile petri dish (per block), keep it covered until used.  
 
Procedure:   
Slides are cut when the equipment is disinfected, the blocks were cooled and all 
material to be used per-block (sterile forceps, sterile-scalpel, labelled filtering 
columns, blades, wipes, gloves and mask) placed at hand to avoid touching other 
surfaces.  
(1)  A new disinfected blade is placed in the microtome.  
(2) An FFPE block is taken and with a new sterile scalpel a small amount of wax 
from a corner scraped and placed in a filtering-column labelled as wax control.  
(3) The FFPE block is placed in the microtome and carefully aligned to the knife’s 
edge. 
(4) The microtome trimming thickness is set to 10 µm and 30 –50 µm of the block 
are trimmed to achieve a full face. 
(5) With the block still held in the microtome, any residual wax is wiped off the 
microtome, and the cutting surface and blade carefully wiped. The blade is 
repositioned so that a new part of the blade cuts the sections for DNA purification.   
(6) The microtome thickness is set to 10 – 12 µm. 
(7) Sections are cut slowly, letting them roll and grabbed with forceps before falling 
from blade/cutting area. 
(8) 3 – 5 sections are placed into each replicate sterile 0.2 µm CA membrane filtering 
column.    
(9) After sectioning each block, used blades are removed, residual wax material in 
microtome disposed and the surface of the microtome disinfected.   




1. Dewaxing and tissue rehydration:  
Consumables & Solutions (per reaction): 
- 4 collection tubes  
- 450 µl of Zymo deparaffination solution 
- 450 µl of 100% Ethanol  
- 450 µl of 80% Ethanol 
- 300 µl of TBS (50 mM Tris, 150 mM NaCl, pH 7.6) 
 
Notes:  
(i) All present and downstream procedures must be performed in a laminar flow 
hood.  
(ii) All present and downstream material must be UV sterilised before.    




(1) Add 450 µl of deparaffination solution into each column.  
(2) Incubate at 56oC for 2 min. 
(3) Centrifuge for 1 min at 1,000 x g.  [Note: If there is remaining wax – repeat step 
1 -3] 
(4) Discard the collection tube and place the filtering column in a new collection tube. 
(5) Add 450 µl of 100% ethanol, briefly mix by vortexing. 
(6) Centrifuge at 1,000 x g for 1 min, discard the collection tube and place the filtering 
column in a new collection tube. 
(7) Add 450 µl of 80% ethanol, briefly mix by vortexing. 
(8) Centrifuge at 1,200 x g for 1 min, discard the collection tube and place the filtering 
column in a new collection tube. 
(9) Add 300 µl of TBS,  mix thoroughly by vortexing 




(11) Discard the collection tube and place the filtering column in a new collection tube. 
2. Tissue dissociation and host depletion:  
Consumables & Solutions (per reaction): 
- 5 Collection tubes  
- Tissue dissociation solution (TDS):  250 µl of TBS (50 mM Tris, 150 mM NaCl, 
pH 7.6) supplemented with 20 µg of Proteinase K (Qiagen)  
- Host Depletion Buffer (HDB): 300 µl of TBS + MgCl2 buffer (20mM Tris-HCL, 
20 mM NaCl, 2mM MgCl2, pH 8) 
- Host Depletion Solution (HDS): 300 µl of a solution with 375 U Benzonase, 
0.2% Saponin, 0.1% Tween-20, in TBS + MgCl2 (20mM Tris-HCL, 20 mM 
NaCl, 2mM MgCl2), pH 8) 
- Stop Solution: 20 µl of EDTA (500 mM) for a final  33 mM EDTA 
concentration. 




(1) Add 250 µl of TDS, mix thoroughly by pipetting. Incubate at 56oC for 5 - 8 min 
(tissue is noticeably dissociated), shaking at 800 rpm. 
(2) Centrifuge at 1,500 x g for 1 min, or until the solution has completely flowed 
through. 
(3) Discard the collection tube and place the filtering column in a new collection tube. 
(4) Wash off any remaining Proteinase K with 300 µl of TDB, mix thoroughly by 
pipetting to achieve a uniform suspension. 
(5) Centrifuge at 1,500 x g for 1 min, or until the solution has completely flowed 
through. 
(6) Discard the collection tube and place the filtering column in a new collection tube. 
(7) Add 300 µl of HDS, mix thoroughly by pipetting to achieve a uniform suspension 
and incubate at 37oC for 15 – 20 min, shaking at 650 rpm.  
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(8) Stop Benzonase activity by adding 20 µl of stop solution. Mix thoroughly by 
pipetting. 
(9) Centrifuge at 1,800 x g for 1 min, or until the solution has completely flowed 
through.  
(10) Discard the collection tube and place the filtering column in a new collection tube. 
(11) Wash contents with 400 µl of 1X PBS, mix thoroughly by pipetting to make a 
uniform suspension. 
(12) Centrifuge at 2,000 x g for 1 min, or until the solution has completely flowed 
through. 
(13) Discard the collection tube and place the filtering column in a new collection tube. 
4. Bacterial and protein lysis:  
Consumables & Solutions (per reaction): 
- 1 x 2 ml centrifuge tube (labelled) 
- 70 µl of  Proteinase K (20 mg/ml) 
- 200 µl of Bacterial Lysis solution (BLS) = 1X PBS supplemented with 150 – 
200 µg of Metapolyzyme. 
- 160 µl of Decrosslinking solution (DCL) =  (2 M GuHCL, 1.25% Triton X-100, 
1.25% Tween-20, 75 mM EDTA (pH 8.0), 100 mM Tris-HCl (pH 8.0)), for a 
final solution of (800 mM GuHCL, 0.5% Triton X-100, 0. 5% Tween-20, 30 




(1) Resuspend contents in 200 µL of BLS, mix contents thoroughly by pipetting 
slowly several times until achieving a uniform suspension. Incubate for 4h at 
35oC, shaking at 460 rpm. 
(2) While incubating, add 30 µl of Proteinase K (20 mg/ml) to the bottom of a 2 ml 
centrifuge tube and label the tube.  
(3) Spin the columns briefly to avoid aerosols 
(4) Add to the column 160 µl of DCL, and mix thoroughly by pipetting.  
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(5) Transfer all the contents of the column to the 2 ml tube with Proteinase K. 
(6) Incubate for 18 h at 56oC, shaking at 700 rpm 
(7) After 18h, spin the tube briefly to avoid aerosols, and top up the mix with 20 µl 
of Proteinase K. Incubate for another 18 h at 56oC, shaking at 700 rpm. 
(8) Repeat Proteinase K top up (20 µl) and incubate for further 6 – 12 hours if the 
lysate is not completely clear.   
 
5. Decrosslinking and DNA purification: 
Notes: The procedures described in for this step includes adapted procedures from the 
QIAGEN FFPE DNA kit protocol  
 
Consumables & Solutions (per reaction): 
- 1 x 1.5 ml centrifuge tube (labelled) 
- 1 QIAGEN FFPE DNA purification silica based column  
- 5 QIAGEN collection tubes 
- 700 µL of  column binding buffer made with a 1:1 mixture of 100% ethanol 
and Buffer AL(Qiagen) 
- 600 µl of Buffer AW1 (Qiagen) 
- 600 µl of Buffer AW2 (Qiagen) 




(1) Set a thermoblock at 80oC, when the block has reached the temperature, transfer 
the lysed samples into the block and incubate for 1 h. 
(2) After incubation, remove tubes form block and let them cool for 5 min.  
(3) Spin briefly to avoid aerosols. 
(4) Add 700 µl of Column binding buffer to the sample and mix by inverting 3-4 
times. 
(5) Spin briefly to avoid aerosols  
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(6) Transfer 650 µl of the tube contents to a Qiagen column, centrifuge at 8,000 x g 
for 1 min, and change collection tube 
(7) Transfer remaining sample content into the column and centrifuge at 8,000 x g for 
1 min, and change collection tube.  
(8) Wash bound DNA with 600 µl of AW1 wash buffer. Centrifuge at 8,000 x g for 
1 min, and change collection tube. 
(9) Wash bound DNA with 600 µl of AW2 wash buffer. Centrifuge at 8,000 x g for 
1 min, and change collection tube. 
(10) Centrifuge at 18,000 x g  for 3 min, and place column in a 1.5 ml centrifuge tube 
(11) Add 50 µl of Tris-HCl (warm at 50oC) and incubate for 5 min at rt 
(12) Centrifuge at 18,000 x g for 1 min, remove column and store eluted DNA at 4oC 
for next steps. 
 
6. DNA repair: 
Notes: The procedures described in for this step includes adapted procedures from 
AMPURE XP magnetic beads DNA clean-up protocol 
Consumables & Solutions (per reaction): 
- 2 x 1.5 ml tube or 1 well in a 96-well plate 
- Reaction buffer to the following concentrations: 1X NEB CutSmart buffer, 
supplemented with 100 µM of dNTPs, 50 µM of NAD+ and 2 mM of DTT.  
- Enzymes per ng of DNA in the reaction, mix:  0.004 U Formamidopyrimidine DNA 
glycosylase (FPG), 0.010 U of Endonuclease VIII (Endo VIII), 0.016 U of T4 – 
Polynucleotide DNA Kinase (T4-PNK), 0.014 U of DNA polymerase I (Pol I) and 
0.024 U of E. coli DNA ligase (Ligase). All enzymes are acquired from NEB. 
- For a 40 µl reaction, with 25 µl of template DNA with a total content of  1,000 ng,  
add: 4 µl of NEB CutSmart Buffer, 0.10 µl of 40 mM dNTPs (NEB), 0.5 µl of 50 
mM NAD+ (NEB), 0.08 µl of 1M DTT (Sigma-Aldrich) and 3.42 µl of nuclease-
free water. 0.48 µl of FPG, 0.96 µl of Endo VIII, 1.54 µl of T4-PNK, 1.34 µL of 
Pol I and 2.3 µl of  Ligase.  
- Agencourt AMPure XP magnetic beads (Beckman Coulter, IN, USA) 
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- 80% Ethanol (recently prepared) 
- Magnetic rack  
- Elution buffer (EB): Tris-HCl (10 mM) 
-  1,000 ng of template DNA 
 
Procedure: 
(1) Measure DNA concentration using a QUBIT and aliquot 1,000 ng from each 
sample to the reaction tube. If concentration of samples is between 10 – 30 ng, 
proceed as follow, for higher or lower DNA concentrations, adjust reaction 
volumes 
(2) Prepare a master mix of the buffer by multiplying the number of samples to be 
treated by the amount of reagent required.  
(3) Dispense the volume of master mix (8.10 µl) into each reaction tube or well  
(4) Dispense 25 µl of DNA (20 ng/µl)  into the reactions tube 
(5) Dispense the enzyme mix [Keep on ice or cooled block until all reactions are 
ready]  
(6) Transfer to a thermoblock and incubate at 37oC for 30 min.  
(7) Stop the reactions by adding 2 volumes of Agencourt AMPure XP magnetic 
beads, and mix beads and DNA by pipetting at least 10 times 
(8) Incubate for 5 minutes , place in magnetic rack and incubate for 2-3 min, until 
beads are bound to walls and solution is clear 
(9) Remove supernatant without removing any beads (remove 110 µl). 
(10) With tube/ plate in the rack, wash beads with 200 µl of 80% ethanol, incubate for 
1 min 
(11) Remove ethanol and again wash beads with 200 µl of 80% ethanol, incubating for 
1 min 
(12)  Remove all ethanol contents and let the beads dry for 3 minutes, until no residual 
ethanol is observable, but without over-drying beads. 
(13) Remove tube/plate from rack  
(14) Add 35 µl of EB and mix with beads by pipetting 10 times. 
(15) Incubate beads with EB for 5 min. 
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(16) Place tube/plate in magnetic rack and incubate for 2-3 min, until beads are bound 
to walls and solution becomes clear. 




B. Bacterial DNA isolation from flash frozen samples  
Breast tumour core-biopsies were aseptically resected using an Achieve 14G Breast 
Biopsy System (Iskus Health, UT, USA). The specimens were transported in sterile 
PBS to the lab, where they were flash-frozen and kept at -80oC until further processing. 
DNA from the specimens was purified following the protocol and reagents provided 
in the Ultra Deep Microbiome Prep (Molzym, GmbH & Co. KG., Bremen, 
Germany) and eluted in 100 µl of Tris-HCl.  
7. Bioinformatics  
The quality of the paired-end sequence data was initially visualised using FastQC 
v0.11.6, and then filtered and trimmed using Trimmomatic v0.36 to ensure a minimum 
average quality of 25. The remaining high-quality reads were then imported into the R 
environment v3.4.4 for analysis with the DADA2 package v1.8.0. After further quality 
filtering, error correction and chimera removal, the raw reads generated by the 
sequencing process were refined into a table of Amplicon Sequence Variants (ASVs) 
and their distribution among the samples. It is recommended that ASVs (formerly 
called ‘Ribosomal Sequence Variants’) be used in place of ‘operational taxonomic 
units’ (OTU), in part because ASVs give better resolution than OTUs, which are 
clustered based on similarity. ASVs were then exported back into Linux and a second 
stage of chimera removal was carried out using USEARCH v9 in conjunction with the 
ChimeraSlayer Gold database v6 as a relatively high number of cycles was used during 
PCR amplification.  
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The following statistical analyses were carried out in R: Shannon alpha diversity and 
Chao1 species richness metrics, and Bray-Curtis distances, for analysis of beta 
diversity, were calculated using the PhyloSeq package v1.24, and the Vegan package 
v2.52. Beta diversity calculations produce distance matrices with as many columns 
and rows as there are samples; thus, beta diversity is often represented using some 
form of dimensionality reduction, in this case, using principal co-ordinates analysis 
(PCoA) with the Ape package v5.1. Hierarchical clustering, an unsupervised method 
that can reveal key taxa that distinguish their respective environments, was performed 
with the heatplot function in the made4 package v1.54. Differential abundance 
analysis was carried out using Deseq2 v1.2.0, which identifies differentially abundant 
features between two groups within the data. Tests of means were performed using the 
Mann-Whitney U test unless otherwise stated, and correlations were calculated using 
Spearman’s rank correlation coefficient. Where applicable, false positive rates were 
controlled below 5% using the FDR procedure. Random forest classification trees 
were run using the RandomForest (v4.6.15) and pROC (v1.15.3) packages in R.  
Bioinformatics contamination control. Despite not identifying the contaminant 
taxa themselves, the source tracker utility is invaluable in estimating the proportion of 
a sample (“Sink”) that may have originated in a negative control (“Source”) Decontam 
can remove taxa, based on presence or absence in negative controls, or inverse 
correlations with input DNA. Requires a threshold to be set, which can be dictated by 




1. Strategy for host DNA depletion 
Host membrane permeabilisation. The state of membrane permeabilisation in both, 
Gram negative bacteria and mammalian cells was evaluated and a permeabilisation 
agent able to induce pores in mammalian, but not in bacterial cells was investigated. 
For this, a cell internalisation marker with similar dimensions to that of DNAse was 
exploited to report on the degree of permeabilisation of mammalian or bacterial cells. 
DNAse I is a compact monomer with a MW of  30 KDa and dimensions of 4.6 x 4 x 
3.5 nm, and most DNAses commercially available have similar dimensions [51]. SAv 
is a globular tetramer, with a MW of   52 KDa dimension of 5 nm [52]. SAv strongly 
binds biotin (Kd ~ 10
-15 M) [53], an intrinsic and essential co-factor for many enzymes 
in all domains of life, including prokaryotes and eukaryotes [54]. The highly specific, 
rapid and resistant nature of this interaction has been exploited for many purposes 
[55]. This includes the detection of naturally biotinylated intracellular molecules, such 
as proteins [56-59]. With this information, the marker for internalisation used was SAv 
conjugated with Cy5 (60 KDa) to target any naturally available biotinylated proteins 
that would be crosslinked due to formalin fixation and therefore would not be lost 
during cell permeabilisation.   
The internalisation of proteins was by flow cytometry in 4T1 cells (mouse breast 
carcinoma) and E. coli as a model organism for G- bacteria. Cell suspensions with 
1.25 x 106 4T1 cells and 1.25 x 107 were exposed to either Triton-X, Tween-20, 
Saponin, Digitonin or none. Treated cells were then labelled with Streptavidin-Cy5 
(SAv-Cy5), as a fluorescent marker for protein internalisation. As seen in Figure 2, 
impermeabilised 4T1 cells show much less fluorescence than those exposed to a 
detergent (Top) and only E. coli cells treated with Triton-X were permeabilised, as 
evident from the 363 X (p <0.001) increase in fluorescence. This indicates that pores 
induced by fixation are not large enough to internalise SAv-CY5, and thus require 
permeabilisation for allowing its introduction to the cell. From the detergents tested, 
Saponin showed the highest capacity of permeabilising 4T1 cells, as measured with 
205 
 
the 186 X (p <0.001) increase in fluorescence, without any effects observed in E. coli 
(p >0.05). A further exploration in the concentration of Saponin that can be used 
without significantly permeabilising E. coli cells, allowed for an adjustment in 
Saponin concentrations used, which was increased from 0.1% to 0.20% (sFigure 1a).  
 
Figure 2. Membrane permeabilisation.  
Cell permeabilisation is measured by the internalisation of Cy5 labelled streptavidin (SAv-
Cy5 was measured in (a) 4T1 cells and (b) E. coli. (Left) Histograms showing the maximum 
fluorescence intensity (Cy5+) after treatment with permeabilisation agents (grey, 
impermeabilised cells, n = x̅ 6). (Right) Box plot showing median fluorescence intensity of 
treated and untreated cells (n = 6 for each box). Saponin-treated (green) 4T1 cells show 185 
X (p <0.001) increase in SAv-Cy5 intake, while no effect is seen E. coli (p > 0.05). n.s. = p 
<0.05    
Host DNA depletion. Among 6 DNAses screened for activity under the conditions set 
by this sample type and permeabilisation agent, the highest levels of activity was 
observed for Benzonase (sFigure 1b). Host depletion was tested here by measuring the 
fluorescence emitted by a DNA intercalating dye (CytoPhase Violet), after treatment 
with a permeabilisation agent and Benzonase. To ensure that the pore sizes created by 
permeabilisation agents allowed for the internalisation of Benzonase in 4T1 cells, the 
4 permeabilisation agents were tested. For Bacteria, only Saponin was tested and 
Triton-X was used as a permeabilisation+ control. Here, a reduction in CytoPhase 
fluorescence of the cell population tested is indicative of a reduction in the DNA 
available for binding CytoPhase, suggesting a higher activity of DNAse. Results 
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shown in Figure 3 reflect those in Figure 2. Again, Saponin was the most effective 
permeabilisation agent for 4T1 cells (top), where a 30.8% (p <0.001) reduction in 
fluorescence is observed. The opposite was observed in E. coli (bottom), where 
treatment with Saponin did not show any significant change in fluorescence (4.5% 
decrease, p >0.05)) from the Impermeabilised + DNAse or Impermeabilised – DNAse 
controls. The analysis of bacterial cells was validated with Triton-X where a 43.7% (p 
<0.001) reduction in fluorescence was observed. Therefore, Saponin + Benzonase 
were chosen as the reagents for host depletion strategy. An enzyme dose optimisation 
was performed, where units ranged from 75 U to 375 U (data not shown). Therefore, 
from this point onward the active components of the Host Depletion (HD) solution 
were 0.20% Saponin and 375 U of Benzonase.  
 
Figure 3. DNA depletion.   
DNA depletion is measured here by a reduction in fluorescence of CytoPhase (intercalating 
DNA dye), after treatment with a permeabilisation agent and Benzonase measured in (a) 4T1 
cells and (b) E. coli. (Left) Histograms showing the maximum fluorescence intensity for 
CytoPhase+ cells. In grey = impermeabilised, DNAse negative controls, pink = 
impermeabilised, DNAse+ controls, for each line, n = x̅ 6. (Right) Box plot showing median 
fluorescence intensity of treated and untreated cells (for each box, n = 6). Saponin treated 
(green) 4T1 cells show 30.8% (p <0.001) decrease in CytoPhase fluorescence, while no effect 
is seen in E. coli exposed to Saponin and DNAse (p >0.05). Triton-X (Purple) as a 
Permeabilisation + DNAse treatment control for bacteria, shows a 43.7% (p <0.001) 
decrease in E. coli cells. 
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Quantifying Host DNA depletion.  The effect of the HD strategy in terms of DNA 
depletion was quantified by qPCR, in a mixed FF cell population with 1 x 107 E. coli 
and 1 x 106 4T1 cells. Here, FF cells exposed to the HD strategy were harvested and 
DNA purified and eluted DNA analysed by qPCR. As it can be seen in Figure 4, results 
are concordant with the previous experiments, where the quantity of genomes 
retrieved is a log-fold (p <0.01) reduced by treatment with the HD strategy. On the 
other hand, that allows for a higher representation of bacterial DNA, which after 
treatment with the HD strategy, exhibits a 3X (p <0.01) increase in the number of 
genomes recovered. Finally, the impact of incubation time was also assessed and 
confirmed optimal at 20 min (sFigure 2c).  
 
Figure 4. Quantifying Host Depletion.   
DNA depletion is measured by a reduction of genomes recovered by qPCR. A mixed cells 
suspension of (a) 1 x 105 4T1 cells and (b) 1 x 106 E. coli was treated or not with Saponin and 
Benzonase, DNA purified and quantified by absolute quantitation. Here, P+D+ = Saponin + 
DNAse + (orange), P-D+ = Saponin – DNAse + (cyan), P+D- = Saponin + DNAse – (purple) 
and P-D- = Saponin – DNAse – (green). For each box, n = 6. As seen here P+D+ treated cells 
show a log fold reduction in the recovery of DNA for 4T1 cells (b), and the effect of reduction 
of host DNA, enriches bacterial DNA in the template, as seen in (a) A 3X increase of E. coli 







2. Bacterial lysis strategy 
Bacterial lysis in FFPE blocks was examined with a combination of treatments, known 
to be ‘safe’ in maintaining the integrity of nucleic acids. These include 1) 
Membrane/wall disruption with lytic enzymes, and 2) Sample Digestion with 
chaotrophic agents and Proteinase K.  
Membrane/Cell wall disruption. Given the intrinsic DNA damage present in 
FFPE samples, membrane/cell wall disruption was attempted through a mix of lytic 
enzymes known to disrupt the walls of gram positive (G+) bacteria and capsids of 
gram negative bacteria. This was first evaluated by qPCR in FFPE blocks loaded with 
1x 108 of each:  E. coli, S. aureus and B. longum cells, formalin-fixed for 48 h. 
Deparaffinised contents were incubated in PBS +/- Metapolyzyme for 4 h before DNA 
purification. qPCR reactions were loaded with the equivalent of 1 x 107 bacterial cells 
of each strain and set to amplify a 200 bp fragment. A marked increase in DNA 
recovery is evident for all three bacterial strains, indicating that Metapolyzyme lyses 
both G+ and G- FFPE bacteria (Figure 5a). The effect of Metapolyzyme was more 
pronounced in S. aureus, where treatment with Metapolyzyme increased its recovery 
by 2-log fold (p <0.001), followed by a 1-log-fold (p <0.001) increase shown for B. 
longum and a 0.5-log-fold (p <0.001) increase observed for E. coli. Given the log-fold 
decrease in the recovery of PCR readable 200 bp long DNA fragments, and that G- 
cells are more liable to lyse by treatments (centrifugation, exposure to solvents), it can 
be implied that by incubating these samples with Metapolyzyme more than 70% of 
the available PCR readable bacterial DNA was recovered. These results were 
confirmed by a time-point incubation of B. longum cells FF for 48 h. 1x 109 cells were 
treated with Metapolyzyme for 1, 4, or 24 h. Half the contents were analysed by flow 
cytometry (Figure 5bi) and half were analysed by qPCR (Figure 5bii). Results from 
both analyses are in agreement. The optimal incubation time to recover ‘difficult to 
lyse’ Bifidobacterium is 4 h at 35oC, shaking at 550 rpm. As can be seen in Figure 5bi, 
at this point, only 0.25% (p < 0.01) of the cells loaded in the reaction were 
DNA+/Wall+. These results were confirmed by qPCR (5bii), where the highest DNA 
recovery (71%, p < 0.001) of a 121 bp fragment (single genome copy) was observed. 
On the other hand, 83% of the Bifidobacterium cells not treated with Metapolyzyme 
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after 24 h incubation were still integral (Wall+/DNA+) and from this bacterial 
population, DNA accessible for purification from only 4.4% of cells. Lastly, upon O/N 
incubations (24 h) with Metapolyzyme, cells were lysed at the same level as observed 
for 4 h - however, the DNA contents were reduced by half. This could be an effect of 
nucleases or DNA denaturing agents released from the crosslinked matrix. 
Sample digestion. After membrane rupturing with Metapolyzyme, the complete 
digestion of the peptidoglycans and other cellular proteins crosslinked to DNA need 
to be digested. Sample digestion is essential for DNA purification and is included in 
all DNA purification protocols. However, the choice of denaturing agent is guided by 
the cell type and macromolecule content of cells. The buffer choice here (chaotrophic), 
was informed by previous experiments indicating that this buffer has a higher 
capability of decrosslinking DNA at lower temperatures (see Ch. 3 - FFPE DNA 
damage & repair). Interestingly, Proteinase K is known to have a higher activity in a 
buffer with similar composition. Sample digestion in FFPE tissue is usually performed 
with Proteinase K. It has been suggested that longer digestion incubations lead to 
increase yield of amplifiable DNA [60]. This was confirmed here, where a time point 
incubation with Proteinase K was performed to inform the incubation length that will 
lead to the highest yield of amplifiable DNA in FFPE bacteria. Deparaffinised contents 
of FFPE blocks loaded with E. coli were digestested for 1 h, 24 h or 48 h. As can be 
seen in Figure 5C, longer digestions lead to a higher recovery of long and short DNA 
fragments, with 1.6X and 2X increase in the recovery of short and long fragments, 
respectively, after increasing digestion from 1 h to 24 h (p < 0.001). A mild 6 % (Short) 
and 0.5 % (long) increase is observed after increasing the length of incubation from 
24 h to 48 h, indicating that after 24 h of incubation with Proteinase K, almost all the 





Figure 5. Bacterial Membrane/Cell wall disruption   
 (a) Metapolyzyme lyses FFPE bacteria. Bar Plot showing qPCR DNA recovery of a 200 bp, 
single copy DNA fragment after lysis (blue) /no lysis (grey) with Metapolyzyme. Recovery 
(black) was estimated from a 1 x 107 genome load. For each bar, n = 6. For the 3 strains 
tested, treatment with Metapolyzyme markedly increased the recovery of DNA (p <0.01). This 
was more noticeable for S. aureus, which without treatment with Metapolyzyme, only 1 % of 
the bacterial DNA was detected. 
(b) Optimising lysis with Metapolyzyme in ‘difficult to lyse bacteria’. 1 x 109 Bifidobacterium 
cells incubated with Metapolyzyme at 1 h, 4 h, and 24 h and without Metapolyzyme for 24 h. 
(i) Box plot showing average cell counts (n = 6) of integral cells (Wall+, as measured by 
fluorescence of BacLight and DNA+, as measured by fluorescence by SytoBC) after 
incubation with/without Metapolyzyme. (ii) qPCR recovered genomes recovered from an 
equal fraction of populations treated (for each box, n = 6). For cells not treated with 
Metapolyzyme after 24 h (green), the cell count was almost the same as the initial population. 
Higher lysis levels / DNA recovery was achieved after 4 h incubation (cyan), with only 0.25 
% (p<0.001) maintaining integrity and genomes corresponding to 71 % qPCR recovered.  
(c) Optimising protein lysis. Deparaffinised contents from 8 x 12 µm slides from FFPE blocks 
loaded with 1 x 109 E. coli cells were digested for 1 h, 24 h or 48 h. Genomes recovered by 
qPCR measuring amplification of a 200 (blue) or 500 (cyan) bp fragment is shown. Increasing 
digestion time from 1 h to 24 h increases the yield of amplifiable fragments in both short (1.6X) 




3. Integration of a Protocol for microbiome analysis of FFPE tissues 
As a means to integrate this protocol without the significant loss of bacterial cells / 
DNA, the use of filtering columns with filter pores sizes allowing a rapid flow (less 
centrifugation), while retaining bacterial contents, was examined. Several 
commercially available columns were examined to identify the columns that perform 
best in terms of parameters required for this protocol (high flow-rate, resistance to 
solvents, low retention, no bacterial loss, and availability of collection tubes).  
To evaluate the choice of columns, first the flow-capacity of a lower flow-rate column 
(PVDF 0.1 µm) was tested in its ability to filter BSA (64 KDa) from a bacterial 
suspension. As can be seen in the protein gel in sFigure 2a, after a single centrifugation 
at 2,000 x g for 1 min, 99.6% of the 250 µg /ml BSA was in the eluate and the 
remaining 0.4% was completely filtered after a second wash. No protein was detected 
in a third eluate. On the other hand, filtrates were also subjected to flow cytometry and 
no bacteria were found in the solution (data not shown), thus confirming that filtering 
units are a good strategy to remove enzymes from a sample without the need of high 
speed centrifugation.  
After this, the effect of filter pore size of 0.2 µm Cellulose Acetate (CA) filters on 
bacterial loss was evaluated by PCR of eluates and filtrates of FFPE slides washed 
twice with PBS. As seen in the gel in sFigure 2b, amplification products for E. coli 
and S. aureus were only detected in the filtrate of both 0.1 µm PVDF membranes and 
0.2 µm CA filters. The use of 0.2 µm pore CA filter membrane (Corning Costar Spin-
X) columns  allowed for the entire workflow to be carried out at centrifugation speeds 
lower than 2,500 x g, for 1 min (see Methods – Protocol). 
Once the filters to be used were confirmed, the effect of rehydration and wash of traces 
of organic residues was assessed. As seen in the gels in sFigure 2c, only in the filtrates 
of tissues that were rehydrated and washed was there a consistent band for both E. coli 
and S. aureus. Conversely, on dehydrated tissues, not all samples amplified, and off-
target effects were observed for Saponin. These data mirrored the incubation 
conditions for host depletion (sFigure 2d), for which an off-target effect that did not 
affect the output of the assay, was observed for E. coli across all incubation time-
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points, with lower effects observed in 10 min incubation. Given that, in the models 
used, bacteria are more readily exposed to the treatment and that during the process of 
making the model some bacterial membranes can be damaged, it was decided to 
maintain the host depletion incubation at 20 min.  
Finally, two tissue dissociation strategies were evaluated. As can be seen in sFigure 
2E, both strategies have an effect in G- bacteria, with higher loss of E. coli DNA 
observed for Collagenase/Dispase, which clearly lysed a portion of the bacteria. For 
Proteinase K, a band was found after permeabilisation, indicating that Proteinase K 
debilitates the OM, exposing the phospholipid bilayer, which can be then accessed by 
Saponin. Since -dissociation of a tightly packed and hardened FFPE tissue is necessary 
for enzyme access, it was opted for the Proteinase K alternative.   
4. Validation of the protocol by 16S sequencing 
Assessment of contamination introduced.  The level of processing required when 
creating a sequencing library from FFPE samples, coupled with the anticipated low 
biomass of the samples, makes them highly susceptible to contamination. Figure 6 
shows a representative sample from each sample group, and each library preparation 
method. The “In House methods” are consistently more susceptible to contamination 
than the gold standard Qiagen method, and a controllable level of contamination is 
present in all sample types with the exception of FFPE breast samples, which are 
overwhelmingly contaminated. The output of the SourceTracker algorithm also 
indicates which negative controls were implicated in the contamination, and Figure 
6a, shows the composition of these samples at the family level.   
The use of Protoblocks with known bacterial composition allowed for accurate 
quantification of the number of sequencing reads lost due to contamination between 
the three different treatment groups. As seen in Figure 7, in both the Qiagen FFPE 
protocol (Q) and the In house with host depletion (IHP) protocols, the proportion of 
reads removed as part of the contamination control workflow was less than 5%. With 
the in house without host depletion (IHN) protocol, almost a quarter of all reads 




Figure 6. Inherent contamination present in method.   
(a) Shows the sample composition of the three negative controls implicated by the 
SourceTracker algorithm.  
(b) Shows the output of the SourceTracker algorithm, with one representative pie chart per 
sample type indicating the degree of contamination present.  
Data indicate that although contamination is present in most samples only FFPE breast 
samples are overwhelmingly affected by environmental contaminants. In addition, only 3 of 










Figure 7. Proportion of reads lost due to environmental contamination introduced 
during processing.   
The data indicates that while only a marginal percentage of reads are consumed by 
environmental contaminant DNA in the Qiagen and IHP samples, just under 30% of reads on 
average are lost in IHN samples.  
 
Assessment of method in protoblocks  Samples labelled as IHP went through 
the DNA protocol (bacterial lysis, sample digestion, DNA purification and repair) plus 
a host depletion step, and IHN samples, did not include a host depletion step. The 
precise quantities of bacteria added to the FFPE mock communities can be seen in 
Supplementary Table 1. This information allowed a robust analysis of methodological 
bias in terms of under or over-representation of different bacteria.  
As shown in Figure 8, the Q protocol, which is not optimised for bacterial DNA, 
showed statistically significant under or overrepresentations in all 5 genera present in 
the Protoblock, particularly in the case of Bacteroides and Lactobacillus, which were 
over and underrepresented by more than 20% respectively. In the IHN method, no 
significant bias was observed with lactobacillus, the deviation in Bacteroides was 
marginally significant, while all other genera were significantly under or 
overrepresented. The IHP method was the least susceptible to bias, with only the 
proportion of E. coli presenting as significantly different from what was theoretically 
present in the Protoblock. These findings are supported by qPCR recovery analysis of 





Figure 8. Assessment of bias in terms of bacterial community composition between 
methods.  
(a) Shows the percentage deviation of bacterial composition per genera, per extraction 
method, from the original quantities input into the protoblock.  
(b) Shows sample composition of all samples merged by extraction kit, with the right most 
column representing the ideal proportions as dictated by the input quantities.  
Visually IHP has the least degree of bias over the five bacterial genera. This is confirmed 
statistically in (a).  
 
Assessment of method in murine models. The comparisons facilitated by the 





and paraffin embedded as described in methods (murine models) and their protocol 
included bacterial lysis, sample digestion, DNA purification and DNA repair, with 
host depletion + tissue dissociation (DT-P) or without any of these 2 treatments (DT-
N). The community structure in these samples was considerably more complex than 
in the Protoblock. 
Beta diversity analysis using Bray-Curtis dissimilarity shows no significant difference 
between the IHN and Qiagen methods. This can be seen visually as the samples cluster 
together, and is confirmed by PERMANOVA analysis, (p = 0.231). Both Qiagen and 
DT-N are significantly dissimilar to DT-P as per PERMANOVA, (p = <0.001) (Figure 
9).  
The driving factors behind the distinct clustering were assessed by searching for 
correlations between the dominant bacterial families seen in the samples, and either of 
the two principal coordinate axes. The correlations were carried out using Spearman’s 
method, and multiple testing was controlled for using the FDR method. This was 
expanded upon in Figure 10, with a direct comparison of sample composition between 
FFPE vs Flash-frozen samples in the three treatment groups. Figure 10a compares Q 
and DT-P paired samples. In this instance, the Gram positive Coriobacteriaceae and 
Lactobacillaceae were significantly elevated in terms of mean proportion in the DT-
P samples, while the Gram negative Porphyromonadaceae, Rickenellaceae, 
Prevotellaceae and Bacteroidacaeae were elevated in samples treated with Q. Figure 
10b compares the paired samples prepared using the Q and DT-N methods 
respectively. In this instance, the there was no significant difference in the Gram 
positive families, while the two previously indicated Gram negative families 
Coriobacteriaceae and Lactobacillaceae were elevated in the DT-N group. Also 
elevated were the Pseudomonadaceae and Promicromonosporaceae families, which 
are likely to be residual environmental contaminants missed by the retrospective 
bioinformatic contamination removal. Figure 10c compares the in house method with 
and without host depletion + tissue dissociation, where the difference was in the Gram 





Figure 9. Principal Coordinate analysis of matched murine samples.  
Points coloured by extraction method, and shaped by host depletion status. PcOA plot 
supported by correlations of major bacterial families present in dataset with PC1 and PC2 
values used to generate plot. Only significantly correlating families show, with significance 
tested for using Spearman’s method. False discovery rate controlled for using FDR method. 





Figure 10. Mouse faecal sample composition comparison between methods.  
Mean abundance of major families between groups tested using Wilcox signed rank test, with 
false discovery rate controlled for using the FDR method. The arrow indicates the direction 
if increase in cases of significant difference.  (a) Compares Qiagen with IHP. (b) Compares 






Assessment of protocol in Patient samples. The final assessment of the method was 
the analysis of FFPE malignant breast tissue samples. The accuracy was verified by 
comparing the FFPE samples with their matched freshly frozen samples. As was 
suggested by the representative pie chart of the FFPE breast samples in Figure 6b, the 
quantity of environmental contamination was overwhelming, this was unsurprising 
given the low level of microbial biomass present in the samples. Even after 
contamination removal, leaving all other sample types with little to no contamination, 
the FFPE breast samples in Figure 11b are dominated by the Pseudomonadaceae and 
Xanthomonadaceae families seen in the negative control samples and bear little 
resemblance to their fresh frozen counterparts in Figure 11C. However, when Figure 
11b is recreated in 11d, with all Pseudomonadaceae and Xanthomonadaceae 
associated sequences manually removed, there is resemblance between the two groups 
that begins to justify what the Venn diagram in Figure 11a indicates in terms of shared 
bacterial families. In total 24.6% of the total bacterial abundance in Figure 11d is 
accounted for by bacterial families also found in the fresh samples shown in Figure 




Figure 11. Sample composition comparison between matched patient samples. 4 
(a) Venn diagram visualising the observed families in (b) FFPE breast tissue and (c) Matched 
fresh frozen breast samples processed using Molzym Ultra-Deep Microbiome kit. (d) FFPE 
samples with the two obvious contaminant families, Xanthomonadaceae and 







Given the potentials that FFPE material could bring to the field of the human 
microbiome, a method that allows access to this material is essential. Currently, there 
are no methods available to process this sample type for microbiome studies. This 
research presents foundational strategies to treat these samples in order to guarantee a 
truthful representation of the bacterial communities inhabiting tissues.    
Bias generated by host DNA was confirmed for FFPE samples by qPCR (sFigure 3A), 
it was therefore relevant to this project to devise a host DNA depletion assay for FFPE 
samples. It is well established that fixatives permeabilise eukaryotic cell membranes, 
allowing the passage of small molecules. Although the exact size of pores induced by 
fixation has not been investigated, several protocols include permeabilisation steps to 
enhance the internalisation of larger molecules, such as antibodies. In this study, we 
explored whether the size of pores induced by fixation allows the entrance of proteins 
the size of DNAse into cells. Data shown in figure 2, confirms that formalin fixation 
does not induce pores that are large enough to introduce molecules of 4-5 nm of 
diameter, while all permeabilisation agents tested here were proven to induce pores 
>5 nm of diameter in mammalian cells, thus, allowing the internalisation of proteins 
of the size of DNAse I and Streptavidin. Among the permeabilisation agents tested, 
the best mammalian cell selective permeabilising agent was Saponin, which exhibited 
high Cy5+ internalisation in mammalian cells, without having any effect in bacterial 
cells. Of note, in experiments performed at early stages of this project (sFigu1c), the 
use of chaotrophes was found detrimental for this sample type. 
After confirming permeabilisation, a screen of DNAses, informed the choice for 
Benzonase as the nuclease to use in this host depletion strategy. While most of the 
DNAses tested here, are monomers with an average MW of 30 KDa, Benzonase, is a 
dimeric nuclease, each monomer with a MW of 30 KDa, similar to the size of SAv-
Cy5. [61]. Its activity was confirmed by DNA depletion experiments. The results from 
these experiments were in agreement with results from cell permeabilisation. A 
marked reduction in DNA quantity, as analysed by flow cytometry and qPCR, was 
observed after treatment with the complete HD strategy (Saponin + Benzonase) was 
observed for host (4T1) cells only (Figure 3 & 4). These results are supported by 
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experiments performed on protoblocks (sFigure 3B) and recently-published (during 
the course of this project) evidence on non-fixed samples, showing that Saponin 
outperforms other permeabilisation agents trialled for host-depletion strategies [62, 
63]. Similarly, 4other authors have found on non-fixed samples that Benzonase is the 
most effective DNAse for host depletion strategies [16, 17]. It must be noted that 
during tissue dehydration, a fraction of cell membrane lipids is lost (up to 40%) [64], 
it is therefore expected to observe a reduction in the permeabilisation efficacy once 
applied to FFPE tissues. 
Results presented here indicate that FFPE processing does not severely debilitate 
bacterial cell walls, meaning a bacterial lysis mechanism must be included in sample 
processing for microbiome analysis. Without this, the results will be biased towards 
easier to lyse G- bacteria. Bacterial FFPE DNA is inherently damaged and harsh lysis 
methods would be detrimental, reducing already low yields and further fragmenting 
an already severely fragmented DNA. Due to time constrains and the complexity of 
integrating bead beating or other mechanical lysis strategies to the workflow, these 
were not tested here to set a reference. However, numerous reports have confirmed 
this effect in different NF sample types and in archaic samples. The later having a 
DNA damage profile resembling that of FFPE DNA [40, 65-68]. Thus, a targeted lytic 
reaction, such as those catalysed by enzymes, is essential to maintain DNA integrity. 
It was proven here that despite morphological or chemical changes that might occur 
in the bacterial cell wall during FFPE processing, enzymes in the Metapolyzyme mix 
are still effective at targeting and lysing FFPE bacteria (Figure 5), and that lysis with 
Metapolyzyme led to more uniform DNA recovery that more closely resembled the 
bacterial contents of a mock FFPE community. This is supported by evidence in 
archaic samples, where lysis with Metapolyzyme was found to yield a community 
composition that resembles that obtained by bead beating [43].  
In addition to the two previously discussed sample treatments, there are other 
parameters to take into account when working with FFPE tissue. (i) FFPE tissues are 
paraffin embedded, dehydrated and carry traces of organic solutions (formalin, 
ethanol, and xylene) that can be toxic for enzymes. (ii) In FFPE samples, the tissues 
are tightly packed and hardened. This will limit access of enzymes to the target cells. 
(iii) All these processes require rapid changes of solution that establish the reaction 
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conditions required for the enzymes or active principles to take place. Therefore, 
integration of this protocol without the significant loss of bacterial cells / DNA is also 
a parameter to consider. For example, it has been noted that exposing G- bacteria to 
centrifugation speeds higher than 6,000-x g can damage the bacterial envelop, which 
will translate into the loss of bacterial DNA during processing [69]. Thus, repeatedly 
centrifuging samples at high speed for solution exchange could lead to bacterial cell 
wall damage, before treatment with DNase. Here the integration of the protocol was 
achieved by using sterile 0.2 µm CA filtering columns, which allowed a rapid flow 
rate with the lowest retention or losses. In addition, the inclusion of rehydration steps 
to the protocol was found to significantly increase amplifiable DNA yields. Lastly, a 
tissue dissociation step with the lowest off-target effects was adopted (Proteinase K).   
During the assessment of the host depletion strategy, an off-target effect was observed 
in a qualitative analysis. This is unsurprising as most if not all host depletion strategies 
report some off target effects on bacteria [6]. To fully explore the effects that this 
would have on downstream sequence analysis, paired protoblock samples treated with 
(IHP) and without (IHN) host depletion were analysed by 16S sequencing and 
compared to the gold standard Qiagen QIAMP FFPE kit (Q). The results from this 
analysis indicate, that while there might be a loss of Gram negative bacteria, this does 
not significantly affect the outputs of 16S sequencing. This is supported by qPCR 
evidence showing higher recovery of the 16S gene by QUBIT and qPCR, in addition 
to an increase in the bacterial to host DNA ratio (sFigures 4). In addition to a better 
cross taxa representation of bacterial DNA recovered by qPCR (sFigure 5). 
Furthermore, in this analysis the QIAGEN method, which is not optimised for 
bacterial lysis, showed statistically significant deviation from the input proportions 
across all five bacterial species present in the Protoblock. The IHN method showed 
improvement on the Q method, with the IHP method being the best performing 
approach in this instance. This improvement in performance is related to incorporation 
of a host depletion step, since it is the only variable tested here. It can be hypothesised 
that this may be due to (1) a reduction of a good portion of the contaminants (as shown 
in Figure 7) that improves the ratio of bacteria present in the samples being sequenced 
and (2) the reduction of mammalian DNA positively affects the PCR reaction, by 
improving the access to target sequences.  
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This was further explored in mouse FFPE faecal samples were exposed or not to a 
combined treatment with tissue dissociation and host depletion. Based on the evidence 
from the Protoblock-based comparison of the three methods, the expectation would be 
for the DT-P (in house with host depletion and tissue dissociation) and DT-N (in house 
without host depletion and tissue dissociation) to cluster together on a PcOA. 
However, in this instance, it was the DT-N and Q methods that clustered, showing no 
statistically significant difference in terms of their Bray-Curtis dissimilarity. Both are 
significantly different to the samples processed using the DT-P method. Subsequent 
spearman correlation of the dominant bacterial families identified across the samples 
with the PC1 and PC2 axis reveals that this separation on the PcOA plot is driven by 
Gram status. Gram positive bacteria correlate significantly with the direction of the 
DT-P samples, and Gram negative samples correlate significantly with the two other 
groups (Figure 9). These findings are corroborated by results in Figure 10. Altogether, 
these results confirm a significant loss of G- bacteria after the combined treatment 
with tissue dissociation and host depletion strategies, indicating that Proteinase K 
debilitates the OM of G- bacteria, exposing the phospholipid bilayer, which can be 
then accessed by Saponin, leading to G- bacteria loss. However, this is a necessary 
step in processing tissues, and thus a further optimisation of this step is necessary. This 
could be addressed by incorporating a short decrosslinking step that will allow tissue 
dissociation enzymes to be more effective, leading to a reduction on incubation times 
or enzyme units used in the reaction. This could lead to less off-target effects in G- 
bacteria.  
By a process of elimination, the best net performing method in this instance appears 
to be the DT-N method. The DT-P method shows significantly increased Gram 
positive bacterial family abundance such as Lactobacillaceae and Coriobacteriaceae 
when compared with the Qiagen method; conversely the Qiagen method shows 
significantly more Gram negative bacteria such as Prevotellaceae and 
Bacteroidaceae. The DT-N method shows significantly more Gram negative bacterial 
families vs DT-P (Figure 10c), and significantly more Gram positive families such as 
Coriobacteriaceae vs Q, with no families significantly reduced in abundance vs either 
group. Thus confirming that the tissue dissociation strategy needs to be optimised. 
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Despite mayor efforts on maintaining an aseptic technique, there are still numerous 
potential sources of contamination, ranging from the wax used to embed samples, 
through all the DNA purification solutions and enzymes, which are unsuitable for 
sterilisation or could not be gamma irradiated at our facilities. Thus, it is unsurprising 
that there was a considerable amount of contamination present in the samples. The 
biomass in the Protoblock and Mouse Faeces samples is sufficient to ensure that the 
majority of the reads are of sample origin according to the SourceTracker algorithm, 
but the FFPE breast samples appeared to consist almost entirely of bacterial reads 
attributed to one or more of the negative controls. The SourceTracker output in Figure 
6b indicates that all contamination is attributable to three negative control samples, 
namely the Wax control, taken from the edges of the blocks of patient samples, the “In 
House method” negative control, and the non-bacterial control, which is an empty 
Protoblock FFPE processed at our facilities.  The first two negative controls are 
dominated by the genera Stenotrophomonas, Pseudomonas and Clostridium, all of 
which count among the most abundant genera in the dataset. The presence of both high 
and low abundance environmental contaminants presents a problem for most 
bioinformatic contamination removal methods, and highlights the value of using both 
positive and negative controls to assist in contamination removal [70]. In this instance, 
we are provided with a much clearer picture of the contamination induced during the 
process by the use of the Protoblock in conjunction with negative controls. Figure 6 
also provided us with evidence of a phenomenon that is gaining more attention in 
Microbiome research, cross contamination, originating within the pool of samples[71]. 
This phenomenon is known to affect lower biomass samples, and can be clearly seen 
in the non-bacterial control where five of the common bacterial families across the 
dataset also appear in the negative controls. This is particularly dangerous when 
undertaking established, but conservative contamination removal by subtraction 
approaches.  
Validation in FFPE breast tissue Non-tract biopsies are notoriously low in 
microbial biomass [72], a fact that is further compounded in analysis of FFPE biopsies 
by the fact that the formalin fixation process accounts for a log fold reduction in the 
quantity of recoverable DNA [73]. These challenges clearly manifest in the 
comparison of paired fresh and FFPE breast samples. Once the major contaminant 
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ASV’s and those suspected of aligning to the human genome are removed, the FFPE 
breast samples are still dominated by known contaminant families, seen in the negative 
controls in Figure 6. Encouragingly, there are some common families to both the FFPE 
breast samples shown in Figure 11b and the fresh frozen breast sample shown in 
Figure 11c. As mentioned in the results, manual removal of the Pseudomonadaceae 
and Xanthomonadaceae families reveals a sample composition plot where 24.6% of 
the total bacterial abundance in FFPE breast tissue is accounted for by the bacterial 
families also present in the fresh frozen breast samples (Figure 11a).  
The reason for Figure 11d is that it is a crude retrospective imitation of a potential 
improvement to make this method a viable option for low biomass FFPE studies. With 
the main contaminants inherent to the In House FFPE protocol now identified, these 
can be biologically removed from the sample by blocking their amplification from the 
16S PCR pool. Numerous methods have been developed to achieve an asymmetric 
PCR reaction that will favour the amplification of certain target regions and avoid the 
amplification of other, which have been used extensively for SNP detection or to 
reduce off-target capture during sequencing library enrichment. This is achieved by: 
(1) Blocking extension with DNA probe/oligo that has high affinity towards a specific 
DNA sequence (on either DNA strand) that includes a 3’ end (i.e. phosphate, inverted 
dNTP). (2) Inhibiting primer annealing with a homologous peptide nucleic acid 
(PMA) or locked nucleic acids (LNAs), which have increased thermal or base stacking 
stability, respectively and will inhibit PCR [74-76].  
CONCLUSION 
Strategies for the unbiased treatment of FFPE samples for microbiome analysis are 
presented in this work, as summarised in Figure 1. Each step validated by flow 
cytometry, qPCR and 16S sequencing on mock bacterial communities, murine models 
and human breast tissue samples. The results shown here confirm that most of these 
strategies would have a positive effect in the treatment for microbiome analysis. 
However, key areas that need to be addressed are the optimisation of a tissue 
dissociation strategy that does not lead to G- bacterial loss and the biological 
decontamination of samples previous to the analysis. Alternatives to achieve this are 





Supplementary Figure 1. Optimising host depletion.  
(a) Saponin titration. Histogram showing fluorescence intensity for Cy5. As a marker for 
protein internalisation, hence, membrane permeabilisation. E. coli cells were permeabilised 
with increasing concentrations of Saponin (n = 6, for each line). Unlike Triton-X (Pink), 
Saponin treated E. coli cells showed no increase in fluorescence intensity even after treatment 
with high (1%) saponin concentrations.   
(b) DNAse screen. 5 commercially available DNAses were tested for their capacity of 
depleting DNA from 5 x 106 FF 4T1 cells in 20 min at 37oC. In bar plot is the resulting DNA 
yield obtained after DNA purification. From here, Benzonase was take as the most cost-
effective strategy.  
(c) Trial with Molysis Host Depletion strategy. Slides from FFPE blocks loaded with 4T1, E. 
coli and S. aureus cells were treated with the protocol, including (blue) or excluding (grey) 
DNA depletion.  A decrease in quantity of recoverable DNA was observed in the 3 cell types. 




Supplementary Figure 2. Integration of the protocol 
For all figures: L = ladder. Red arrows = indicate the 500 bp mark in ladder. PCR targets a 
 500 bp DNA fragment. Eluates = a total of 300 µl were DNA purified, 100 µl were aliquoted 
from each experimental replicate (x̅ n = 3). Filtrates correspond to final filtrate, obtained at 
the end of the protocol. (A-B) were performed with an E. coli cell suspension. (C-E) were 
performed in slides from protoblocks with 1 x 10 8 E. coli and S. aureus cells fixed for 48 h.  
(A) Are proteins removed by filtering columns? Protein gel confirming the removal of BSA 
(64 KDa) from a cell suspension.  
(B) Are bacteria lost when using a 0.2 µm filter? Agarose gel of eluate and filtrates performed 
on a bacterial cell suspension washed twice with PBS. No DNA is seen for the eluates.  
(C) Does rehydrating the samples have any effect? DNA gel showing eluate/filtrates after 
treatments. Only for rehydrated samples was there a band in all elutes. E1 = Host depletion, 
E2 = Wash after host depletion.  
(D) Is bacterial DNA lost by HD strategy? What is the optimal incubation time? Gel showing 
that there is a loss of E. coli DNA during the HD strategy and this increase with longer 
incubations. Shorter incubation times (10m) reduces the loss of G - bacteria, but also reduces 
the quantity of host DNA depleted seen in the table below gels. Quantity as the difference from 
DNA concentration measured for non-depleted and the average DNA concentration (n = 3) 
obtained after host depletion for each time point. 
(E) Do tissue dissociation strategies affect bacteria? Which is the most adequate tissue 
dissociation strategy?  Gel showing that there is loss of G- bacteria during tissue dissociation. 






Supplementary Figure 3. Investigating Host DNA influence and host DNA 
depletion 
(A) Measuring bias introduced by host DNA. i) Box plot comparing DNA recovery of bacteria 
in Protoblocks loaded with (cyan) and without 4T1 cells (orange). Quantitative PCR recovery 
was normalised to a sample input of 106 cells. For each box, n = 6. Protoblocks without 4T1 
cells had a higher recovery of all bacteria taxa. Difference of means between tests was 
measured using a Wilcoxon Signed Rank test, for all bacterial taxa. ii) Immunofluorescence 
microscopy images of Protoblocks with and without mammalian cells, stained with α-E.coli 
(green) and DAPI (Blue) for 4T1 cells. 
(B) Testing host DNA depletion strategies. DNA recovery of 4T1 cells (orange), Escherichia 
(cyan) and Staphylococcus (green) after 10 min treatment with either Triton-X (0.1%), 
Saponin (0.1%) or Molysis CM buffer. For each bar, n = 3. % increase or decrease in recovery 
from untreated is shown above each bar. Dotted lines indicate the PCR recovery of samples 




Supplementary Figure 4. QPCR percent recovery of bacterial DNA from 
protoblocks. In red In house method + Host Depletion. 
 In blue: QIAGEN FFPE kit. The qPCR reaction was set in a multiplex format, using primers 
and probes described in methods. A recovery of 1% is a normal recovery, lower % recovery 
is considered a reduction and higher % an overestimation. 
 
 
Supplementary Figure 5. Measuring the recovery of 16S amplicons.  
a) DNA concentration of amplicons recovered after 16S rRNA gene PCR for protoblocks  
processed with QIAGEN FFPE DNA kit, Molzym, and the in house method. b) QPCR recovery 
of B-actin or the 16S gene from protoblocks processed with the in house method or QIAGEN 
FFPE DNA. It is clear from this figure that with the in house method a higher recovery of 
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bacterial DNA (16S gene) is achieved, at the same time an improvement in the bacterial to 
host DNA ratio is achieved. 
 
 
Supplementary Table 1. Bacterial load of protoblocks used for 16S sequencing  
 Counts in microscope  /   volume measured for each 
type of FFPE block [single strain to mixed strain] 
Calculations for DNA  purified from blocks 
Cell type 
Microscope 
Counts in block 
Cells/µl in 
mixed block 









4T1 2.20E+07 8.85E+04 1.06E+06 1.28E+07 2.55E+05 3.83E+06  
Escherichia coli 3.10E+07 1.25E+05 1.46E+06 1.75E+07 3.50E+05 5.25E+06 0.17 
S. aureus 9.01E+06 3.63E+04 4.22E+05 5.06E+06 1.01E+05 1.52E+06 0.05 
B. longum 8.50E+06 3.43E+04 4.01E+05 4.81E+06 9.62E+04 1.44E+06 0.05 
L. amylophilus 8.12E+07 3.28E+05 3.74E+06 4.48E+07 8.97E+05 1.35E+07 0.43 
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In this manuscript are presented the foundations for to pursuing microbiome analysis 
on FFPE samples. FFPE samples represent a huge potential repertoire of material for 
microbiome studies yet to be accessed. Finding of bacterial profiling in FFPE samples 
have encouraged the use of this samples as source material by providing evidence that 
bacteria remain in tissues after FFPE samples and that the communities are still 
somehow representative of what has been previously observed in fresh samples. 
However, the lack of evidence describing the state of bacteria in FFPE tissues is a 
mayor limitation, which might even lead to doubt findings from projects using them.  
Pursuing microbiome studies in human tissues has been proven challenging in non-
fixed samples, as many obstacles such as low bacterial biomass, high human DNA 
background, high levels of contamination from surgical processing and the lack of a 
standardised protocol for these sample-type constrain the scope and extent of the 
analysis. Now, in FFPE samples, it can be assumed that these would be more 
accentuated by the unsterile nature of the FFPE process and the detrimental effects 
that formalin exerts on biomolecules.  Nevertheless, giving its huge potential as 
resource, exploring this sample-type and optimising methods for their use as source 
material could be a corner-stone for microbiome research. This will allow for 
retrospective research, provide access to tissues from inaccessible body sites and study 
the microbiome of numerous diseases for which FFPE samples have been catalogued. 
It will also facilitate current clinical studies, by avoiding interference during surgical 
processes.  
Now, to address the gap of knowledge of the state of bacteria in FFPE samples it was 
first required to bridge several research areas: histology, microbiology, cancer biology 
and genomics. State of the art knowledge was gathered to raise the questions needed 
testing and to challenge assumptions that could be carried in translation from one field 
to the other. For example: Is formalin-fixation the same in bacteria then in human? Is 
DNA damage in bacteria the same as in human DNA? Are bacterial cells 
permeabilised/lysed by processing and hence do not necessitate further lysis? Which 
are the best models to study these?   
The first issue that needed to be addressed was a model suitable to describe FFPE 
bacteria. The first attempts were done in mouse tissue loaded with bacterial cells, 
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however when using this model sample to sample variability was too high, impeding 
the attribution of results to experimental treatments. This could be due to differences 
in the distribution of bacterial cells within the tissue and the morphological differences 
of each layer of tissue included in each sample. Therefore, a simplified model that 
allowed for a reduction in variability and more uniform results was sought and 
developed by embedding fixed bacteria with or without mammalian cells in an agar 
mould that was processed using standard histology procedures.  This model exhibited 
uniform results and allowed for a better description of molecular and cellular changes 
that can be attributed exclusively to the fixation process, and enabled the measurement 
of treatment effects that could lead to improvements in the yields and quality of DNA. 
This allowed for a description of the state of FFPE DNA in bacteria. It was confirmed 
here that bacterial FFPE DNA is highly fragmented, crosslinked and bears sequence 
artefacts that reflect oxidative damage, uracil and methylation. The information 
gathered here and that found for human FFPE samples, leads to hypothesize that these 
damages are more pervasive in bacteria. This, given that FFPE blocks studied here 
were not stored for more than one year and that damage in human DNA to the extent 
found here is usually found in blocks stored for more than three years. Among 
differences found between bacterial and human DNA damage, is a higher rate of 
oxidative damage than reported for humans, with uracil lesions being less pervasive. 
However, the ratio at which these occur in human FFPE DNA is still a topic of 
controversy, as different ratios are found on different samples. As an off-topic 
conclusion, it is suggested that an evaluation of human FFPE DNA damage is 
performed in a simplified model, such as the protoblock (but with only mammalian 
cells). This will allow for an assessment without conflicting results that derive from 
inter-sample variability.    
The information gathered by the evaluation of DNA integrity in FFPE bacterial 
allowed the development of strategies that reduce this damage or improves its quality. 
This was achieve by reducing DNA denaturation and its associated breaking, with a 
combination of decrosslinking at lower temperatures in the presence of chaotrophic 




In addition, the state of the bacterial envelop/wall was investigated. Results from this 
study suggest that the FFPE bacterial cell envelop and wall are not permeable to large 
molecules, such as DNAses or Proteinase k. Thus, allowing for the development of 
differential lysis strategies that allow for host depletion. Here, a cholesterol targeting 
detergent, saponin, proved effective for differential lysis. Furthermore, this also 
informed of the necessity to incorporate a bacterial lysis strategy, which was proven 
effective here with a mix of bacterial lytic enzymes, Metapolyzyme, followed by a 
prolonged protein digestion with Proteinase K.  
Evidence gathered by flow cytometry, qPCR and 16S analysis after treatment with the 
combined strategies for host depletion, bacterial lysis, protein digestion, 
decrosslinking and DNA repair indicate that the quantity and quality of bacterial FFPE 
DNA yielded outperforms those gold-standard kits for either FFPE human DNA. 
Furthermore, the bacterial community composition obtained is more resembling to 
that of the input, again outperforming the FFPE human DNA kit or non-fixed 
microbiome kit. Therefore, these strategies can be readily optimised for adoption in 
the microbiome analysis workflow, in FFPE samples.  
On the other hand, it is suggested from the results obtained that new strategies for 
tissue dissociation, should be tested, as the strategies tested here debilitate the gram-
negative bacterial envelop, which is detrimental to the downstream workflow. In this 
study, no other strategies that would not be detrimental for bacteria, were found, thus 
tested, however, this search was not done exhaustively. It can be hypothesised that 
with a mild, short period decrosslinking incubation before tissue dissociation would 
allow a faster digestion of tissue fibres, thus lower enzyme concentrations or 
incubation times would be used. Thus, limiting off-target activity in bacteria. 
Besides, it was decided here to use filtering columns to allow rapid solution exchange 
and reduce the probabilities of damaging the bacterial cell walls or losing bacteria 
during washes by centrifugation. However, these proved more difficult to handle when 
testing them with tissue specimens, as they will clot and delay buffer exchange. It is 
advisable that when working with large tissue sections the tissue input is limited to 2 
-3 slide. Otherwise, alternatives for carrying out this process should be sought.    
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Furthermore, despite made efforts in maintaining aseptic procedures along the process, 
a large amount of contamination in low-biomass samples obscured their analysis. 
These contaminants were traced to: (1) Reagent prepared in the lab: All solutions were 
prepared aseptically in a laminar hood, filter-sterilised, autoclaved (if allowed by the 
solution) or UV sterilised for 20 min. Despite all of these efforts, unless reagents are 
prepared in clean-room environment and gamma-irradiated, bacterial DNA will be 
present and present a mayor problem for low biomass samples. (2) FFPE processing: 
It was clear from the processing controls that some contaminant bacterial DNA was 
sourced from processing of FFPE samples. The identification of these contaminants is 
vital to proceed with FFPE-microbiome workflows, as they inform strategies for 
bioinformatic or biological removal. It was shown here that the bioinformatic 
decontamination of samples is in cases not sufficient to obtain a valid sequencing 
analysis. As such, it is important to include in the workflow strategies that allow for 
the biological removal of contaminating sequences from the PCR pool. This can be 
easily achieved through PCR enrichment methods, such as blocking DNA 
probe/oligos, peptide nucleic acid (PMA) or locked nucleic acids (LNAs) [1-3].     
Lastly, there are variables in the tissue processing and storage conditions of FFPE 
samples that were not in the scope of this project and need to be addressed before 
adopting a protocol for microbiome analysis. While the models used here were 
representative of long fixation periods, as a mean of keeping a ‘worse fixation 
scenario’, due to time constraints in the duration of this project the maximum storage 
time assessed was 1 year. Therefore, a study characterisation the damage with age 
would be needed as a comparison for older FFPE samples.  
Altogether, it is concluded from this work that to unlock the huge potential that FFPE 
specimens could provide to the field of microbiome research, it is essential that 
dedicated workflows designed for this sample type need to be in place. While sample 
prep was shown here as fundamental, this workflow should not be restricted to the 
sample-prep, and must include a robust QC system that allows for the screening of 
DNA quality in a sample and directs the workflow to either reject the sample, perform 
a DNA repair strategy or directs the amplification strategies. . In addition, a database 
for known FFPE derived contaminants should be in place to inform future potential 
strategies for their biological removal. Such workflow should include a dedicated 16S 
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sequencing workflow optimal for low-biomass FFPE samples, which might require 
longer PCR cycles, the use of shorter 16S sequences (e.g. V1-V2), or the use of more 
amplicon template for the sequencing runs. All sequencing workflow available to date 
are optimised for the analysis of high-biomass faecal samples, which differ 
significantly to FFPE specimens. As shown in this work, both sample types cannot be 
analysed with the same workflows.   
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